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Of all the organs in the human body, the brain is often considered as the most mysterious 
and least understood, yet most indispensable organ. Both the development in early years 
and degeneration in late life are poorly understood. Neuro-degeneration in late life often 
causes clinical disorders, such as dementia, cognitive decline, stroke, and depression. From 
a public health perspective, these neurodegenerative disorders put a massive burden on 
health resources and health care: not only are these disorders already highly frequent, but 
with the increasingly older population their prevalence and incidence are only expected 
to further increase in prevalence and incidence.1 In order to prevent these diseases knowl-
edge of their etiology is an essential first step. Research using neuro-imaging and genetics 
has played a central role in finding etiologic markers of neurodegenerative disease.
Using MRI various studies have identified in vivo imaging markers of neurodegenerative 
diseases.2-15 Such markers include focal structural brain changes, such as hippocampal 
atrophy, white matter lesions and lacunar infarcts, and are usually rated visually on MRI 
scans. Hippocampal atrophy is considered a marker of Alzheimer pathology and indicates 
an increased risk of dementia, even in cognitively normal persons. White matter lesions and 
lacunar infarcts are markers of vascular brain disease and have been implicated in the etiol-
ogy of dementia, stroke, and depression. However, apart from these focal brain changes, 
generalized brain changes are also frequently seen. It has been suggested that brain atrophy 
may be an important marker of neurodegenerative diseases. However, research on whole 
brain atrophy has been limited, partly because appropriate quantification methods were 
lacking. The difficulty lay not only in obtaining an accurate and reproducible measure for 
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brain atrophy, but also in distinguishing gray matter atrophy from white matter atrophy and 
in separating the different cerebral lobes. Advances in MRI technology and image process-
ing have recently led to the ability to automatically quantify volumes of various brain tis-
sues and structures. As a result, we are now able to investigate generalized structural brain 
changes, such as whole brain atrophy and lobar atrophy. Moreover, exact quantification of 
focal brain changes increases the power to detect more subtle associations, which could 
not be detected previously using qualitative or semi-quantitative rating scales.
Until recently, the quest for finding genes and genetic markers of neurological diseases 
has been disappointing. Although linkage studies and candidate gene studies implicated 
various genetic markers in the etiology of neurodegenerative diseases, replication studies 
usually failed to confirm these associations. Only the APOE gene in the etiology of late-onset 
Alzheimer’s disease can be considered as a robust finding.16-18 One reason for this dearth 
of genetic markers for neurodegenerative diseases is that thus far genetic research was 
restricted to investigating single or few markers. These markers had to be selected a priori 
from certain genomic loci based on available (and often incomplete) biological knowledge 
of the disease. Only recently has it become possible to investigate genetic markers on 
a large scale across the whole genome. These hypothesis-free ‘genome-wide association 
studies’ have uncovered several previously unknown genes for various complex diseases, 
such as diabetes, heart disease, and auto-immune disorders.19 Likewise, identifying novel 
genes involved in neurological disorders using the genome-wide approach is now possible 
and its results eagerly anticipated.
The aim of this thesis is to investigate determinants – both non-genetic and genetic – and 
clinical outcomes of structural brain changes on MRI. The focus will be on markers across 
the whole brain and whole genome and their relationship with neurodegenerative diseases. 
The research is embedded within the epidemiological framework of the Rotterdam Study 
and Rotterdam Scan Study, both large prospective population-based cohort studies with 
more than a decade of continuous follow-up. The aim of these studies is to investigate 
genetic and non-genetic determinants of chronic diseases in the elderly, including neu-
rological diseases. In the Rotterdam Scan Study an additional focus is on structural brain 
changes as seen on MRI.
In the following two parts of this thesis I investigate determinants and outcomes of brain 
changes on MRI. Part 2 embarks by presenting descriptives of structural brain changes: in 
chapter 2.1.1 normative, expected values of brain tissue volumes in the elderly popula-
tion are presented together with their association with known cardiovascular risk factors. 
Chapter 2.1.2 describes pathologic changes in the brain that are unexpected and therefore 
can be considered as incidental findings. Part 2 continues by investigating novel risk fac-
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tors and risk indicators and their association with brain changes. These novel determinants 
are kidney function (chapter 2.2), unrecognized myocardial infarction (chapter 2.3), 
cerebral blood flow (chapter 2.4) and retinal vessels (chapter 2.5). Part 3 of this thesis 
is dedicated to the relationship of brain changes with cognition and dementia (chapter 
3.1), depression (chapter 3.2), and all-cause and cardiovascular mortality (chapter 3.3). 
In Part 4 of the thesis, two genetic studies are presented that apply the novel genome-wide 
association approach. Chapter 4.1 presents results from genome-wide association studies 
on clinical stroke and subclinical stroke, respectively. The following chapter (4.2) is a rep-
lication study of a gene that was previously identified in a genome-wide association study. 
In Part 5, I round up the main findings and reflect on these from a broader perspective 
regarding brain research. I also tentatively give directions for future research.
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Chapter 
2.1
Structural Brain Changes

Chapter 
2.1.1
Brain tissue Volumes in the general elderly 
Population. the rotterdam Scan Study
M. Arfan Ikram, Henri A. Vrooman, Meike W. Vernooij, Fedde van der Lijn, 
Albert Hofman, Aad van der Lugt, Wiro J. Niessen, Monique M.B. Breteler
ABStrACt
We investigated how volumes of cerebrospinal fluid (CSF), grey matter (GM) and white 
matter (WM) varied with age, sex, small vessel disease and cardiovascular risk factors in 
the Rotterdam Scan Study. Participants (n=490; 60-90 years) were non-demented and 51.0% 
had hypertension, 4.9% had diabetes mellitus, 17.8% were current smoker and 54.0% were 
former smoker. We segmented brain MR-images into GM, normal WM, white matter lesion 
(WML) and CSF. Brain infarcts were rated visually. Volumes were expressed as percentage of 
intra-cranial volume. With increasing age, volumes of total brain, normal WM and total WM 
decreased; that of GM remained unchanged; and that of WML increased, in both men and 
women. Excluding persons with infarcts did not alter these results. Persons with larger load 
of small vessel disease had smaller brain volume, especially normal WM volume. Diastolic 
blood pressure, diabetes mellitus and current smoking were also related to smaller brain 
volume. In the elderly, higher age, small vessel disease and cardiovascular risk factors are 
associated with smaller brain volume, especially WM volume.
Chapter 2.1.1
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intrODuCtiOn
During lifespan the human brain undergoes structural changes. Using quantification of 
brain structures on magnetic resonance imaging (MRI) several studies have investigated 
changes in the volumes of cerebrospinal fluid (CSF), grey matter (GM) and white matter 
(WM) over age ranges from childhood to early senescence.1-9 GM is thought to decrease 
steadily after adolescence, whereas WM shows a peak around age 40 and decreases there-
after. Linear extrapolation to older age remains tentative, because of possible nonlinear 
and non-monotonous effects.10 Moreover, in the elderly cerebral small vessel disease and 
neurodegenerative processes are often present11 and can affect brain tissue volumes,12 
which is not always taken into account. Only a few studies have reported the effects of 
cerebral small vessel disease on brain tissues in the elderly: DeCarli et al. showed that pres-
ence of lacunar brain infarcts was associated with smaller whole brain volume.13 Guttman 
et al. and Jernigan et al. reported that a decrease in normal WM not only coincides with 
an increase in white matter lesions (WML), but also reflects atrophy of total WM.12, 14 These 
studies either did not investigate the various brain tissues separately or were performed in 
selected participants.
Therefore, there is need for a large population-based study in elderly persons investi-
gating various brain tissues separately. Using automated image analysis of MRI data, we 
quantified brain tissue volumes in a population-based study of elderly and investigated how 
these volumes were related to age, sex, markers of small vessel disease, and cardiovascular 
risk factors.
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Descriptives of structural brain changes
methODS
Participants
This study is based on the Rotterdam Scan Study, a large population-based cohort study 
in the Netherlands that aims to study the etiology and natural history of age-related brain 
changes in the elderly.11 The study was approved by the medical ethics committee of the 
Erasmus Medical Center, Rotterdam. In 1995-1996, we randomly invited participants, aged 
60 to 90 years, stratified by sex and 5-year age strata from two on-going population-based 
studies to participate in the Rotterdam Scan Study.15, 16 Participants who were demented, 
were excluded based on a stepwise approach as used in the Rotterdam Study.17 Briefly, 
participants were screened with the Mini-Mental State Examination (MMSE) and Geriatric 
Mental State Schedule (GMS). Screen-positives (MMSE < 26 or GMS > 0) underwent further 
testing using the Cambridge examination for mental disorders in the elderly (CAMDEX). 
Finally, a panel consisting of a neurologist, neuropsychologist and research physician made 
the diagnosis based on internationally accepted criteria. After exclusion of individuals who 
were demented or had MRI contraindications 1,077 participants gave their written in-
formed consent to participate in the study, which included MR brain imaging. The present 
study is restricted to persons (n=563), who underwent an additional high-resolution MR 
sequence.
MRI acquisition
MR brain imaging was performed on a 1.5-Tesla MRI System (VISION MR, Siemens AG, 
Erlangen, Germany). The protocol included three axial scans, i.e. T1-weighted (TR=700, 
TE=14, NEX=1, matrix 192x256, FOV=256x256, flip angle=80°, 20 slices), proton-density 
(PD) weighted (TR=2200, TE=20, NEX=1, matrix=192x256, FOV=256x256, flip angle=80°, 
20 slices) and T2-weighted (TR=2200, TE=80, NEX=1, matrix=192x256, FOV=256x256, flip 
angle=80°, 20 slices). Slice thickness was 5 mm with an interslice gap of 20%. Further-
more, a high-resolution, Inversion-Recovery double contrast, 3-D half-Fourier acquisition 
single-shot turbo spin echo (HASTE) sequence was included (inversion time=4400ms, 
TR=2800, matrix=192x256, FOV=256x256, 128 contiguous sagittal slices of 1.25 mm). The 
interpolated voxel dimensions were 1x1x1.25mm3. Two HASTE modules were sequentially 
acquired after the inversion pulse (effective TE of 29 ms and 440 ms). Each HASTE module 
combined nonselective radio frequency excitations to provide a short interecho spacing 
of 3.9 ms. We used the PD-weighted, T2-weighted and first HASTE module (HASTE-Odd) for 
automated brain tissue classification.
Among the 563 participants, 52 developed claustrophobia during MRI acquisition. 
Complete data were available in 511 persons. Twenty-one datasets were unusable due to 
excessive ghosting artifacts (n=5), scanning outside the range of coil sensitivity (n=10), or 
other reasons (n=6), leaving a total of 490 participants in our present study.
Chapter 2.1.1
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MRI analysis
Data were transferred and stored onto a Linux Workstation. Preprocessing steps and the 
tissue classification algorithm have been described previously.18 In summary, preprocessing 
included registration of the T2 and PD scans to the HASTE-Odd scan, non-uniformity cor-
rection and scaling of the intensities to zero mean and unit variance (tools obtained from 
the Brain Imaging Center, Montreal; www.bic.mni.mcgill.ca). Two trained neuro-imagers 
independently performed manual labeling of twelve scans into five tissue classes (GM, 
normal WM, CSF, WML and background) to create a three-dimensional training feature-
space. Using these training data we subsequently classified scans with k-nearest-neighbor 
(kNN) tissue classification. kNN has been successfully applied in neuroimaging studies.2, 19 
In order to minimize any misclassification of partial volume voxels as WML around cortical 
GM, we registered to each brain a manually created mask, within which voxels could be 
classified as WML.
To remove non-brain tissue, we used a validated, non-rigid transformation based on free-
form deformations.20 A fast implementation of this algorithm (Elastix) was used to transform 
one template scan to each brain.21 In this template all non-cerebral tissues, including e.g. 
eyes, skull and skin, were manually masked. Because the PD and T2 scans comprised only 
20 slices, the cerebellum and brainstem were not always completely covered. Therefore, 
we also masked all infratentorial tissue (including the cerebellum) from our template scan. 
To control for potential sex differences we used a different template for men and women. 
The templates were chosen from our cohort as the scans nearest to the sex-specific mean, 
which was obtained based on previously conducted visual rating of all scans for cortical 
atrophy, subcortical atrophy and hippocampal volume.11 Figure 1 shows a typical classifica-
tion result.
Finally, two trained neuro-imagers, blinded for clinical information, independently went 
through all scans on a slice-by-slice basis to verify the classification result. If needed, voxels 
that were misclassified were manually reclassified appropriately. This was needed in only 
45 scans, mostly due to misclassification because of slight motion artifacts.
We validated the classification and transformation algorithms using a leave-one-out 
strategy within the twelve manual classifications.18 We used similarity indices and intra-
class correlation coefficients (ICC) as validation measures. The similarity index is a measure 
ranging from 0 to 1 indicating the amount of overlap between two segmentations.22 Values 
above 0.7 indicate excellent overlap.22 The averaged similarity indices between the auto-
mated classification and manual labeling were 0.91 for CSF, 0.92 for GM, 0.93 for normal 
WM and 0.63 for WML. The similarity indices between the two neuro-imagers were 0.91 
for CSF, 0.90 for GM, 0.91 for normal WM and 0.79 for WML. The averaged ICC between the 
automated classification and manual labeling was 0.89 for CSF, 0.94 for GM, 0.80 for normal 
WM and 0.84 for WML. The ICCs between the two neuro-imagers were slightly higher 
(range 0.84-0.96). These numbers indicate very good to excellent agreement and overlap.
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For the brain templates used to remove non-brain tissue, the ICCs compared to manual 
tracings were 0.97 for the male mask and 0.99 for the female mask. To assess the impact 
of different brain masks for men and women we applied the male template to 100 women 
and the female template to 100 men. This had only marginal effect on our results (ICC>0.98 
for all tissue classes).
Brain infarcts were rated visually as focal hyperintensities on T2-weighted images, 3 mm 
in size or larger. Hyperintensities in WM also had to have corresponding prominent hypoin-
tensities on T1-weighted images. Proton-density scans were used to distinguish infarcts 
from dilated perivascular spaces. Infarcts were scored as lacunar or cortical. Persons with 
both lacunar and cortical infarcts were included in the group with cortical infarcts. Intra-
rater agreement for detection of infarcts was good (κ=0.80).11
Other measures
Information on current health status was collected by interview and physical examination.11 
Level of education was assessed during the interview and we classified persons into those 
with primary education only or those with education beyond primary level. Participants 
were also asked about their smoking habits and they were classified into one of three 
categories: current smoker, former smoker, or never smoker. At the research center, sitting 
blood pressure was measured twice at the right arm with a random-zero sphygmomanom-
eter. The average of the two values measured at one occasion was used. Hypertension was 
defined as one of the following: a systolic blood pressure of 160 mm Hg or higher, or a 
diastolic blood pressure of 100 mm Hg or higher, or current use of blood pressure lowering 
drugs. This corresponds to grades 2 and 3 according to the 1999 World Health Organization 
guidelines.23 Diabetes mellitus was defined as non-fasting serum glucose level exceeding 
Figure 1. From left to right: HASTE-Odd scan, Proton-density weighted scan, T2 weighted scan, and result after tissue classification and 
removal of non-brain tissues (no manual reclassification performed; blue: cerebrospinal fluid; green: grey matter; red: white matter; 
white: white matter lesion). See this figure in color in the Appendix. 
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11.1 mmol/l or the use of oral blood glucose lowering drugs or insulin. All persons with 
diabetes mellitus had diabetes type 2.
Statistical analysis
Summing all voxels (1 voxel = 1.25mm3) of a certain tissue across the whole brain yielded 
volumes in milliliters. To correct for individual head size, we expressed all volumes as per-
centages of intra-cranial volume, which was the sum of GM, total WM and CSF. We defined 
total WM volume as the sum of normal WM and WML. Brain volume (BV) was the sum 
of GM and total WM. WML volume was further natural log (ln) transformed because of 
leftward skewness of the untransformed measure.
We investigated differences between men and women with AN(C)OVA and the relation-
ship between age and tissue volumes with linear regression. We also assessed differences be-
tween sexes in the effect of age. For WM, a non-linear relation with age has been reported.10 
Therefore, we also added a quadratic term of age to the linear model. To assess whether our 
results could be confounded by tissue loss due to infarcts, we repeated the same analyses 
excluding persons with any brain infarct. Differences in tissue volumes in persons without 
brain infarcts, with lacunar infarcts and with cortical infarcts were investigated using AN(C)
OVA. With linear regression models we investigated the relationship between WML (per 
standard deviation (SD)) and brain tissues. All analyses were performed adjusting for age, 
sex (if applicable), and additionally for education, and cardiovascular risk factors.
Finally, with linear regression models we investigated how education, current smoking, 
former smoking, hypertension, systolic blood pressure, diastolic blood pressure, and diabetes 
mellitus were related to brain tissue volumes and whether their effects were different between 
men and women. Initially, we investigated the effect of a risk factor only adjusting for age and 
Table 1. Characteristics of the study population, stratified by sex.
total
n=490
men
n=241
women
n=249
p-value*
Age, yr a 73.4 ± 7.9 73.7 ± 7.7 73.1 ± 8.0 0.368
Height, cm 168 ± 9 174 ± 6 162 ± 7 <0.001
Intra-cranial volume, ml 1128 ± 116 1201 ± 97 1057 ± 84 <0.001
Cortical brain infarct b 25 (5.1) 17 (7.1) 8 (3.2) 0.12
Lacunar brain infarct 112 (22.9) 50 (20.7) 62 (24.9) 0.24
Hypertension 250 (51.0) 128 (53.1) 122 (49.0) 0.47
Diabetes mellitus 24 (4.9) 18 (7.5) 6 (2.4) 0.01
Current smoker 87 (17.8) 48 (20.0) 39 (15.7) <0.001
Former smoker 264 (54.0) 194 (72.5) 90 (36.1) <0.001
Primary education only 149 (30) 54 (22) 95 (38) <0.001
a values are means ± standard deviation for continuous variables
b values are numbers (percentages) for dichotomous variables
* p-value for age-adjusted differences between men and women.
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sex. Then, using multivariable modeling we also 
adjusted for the other risk factors. Subsequently, 
we investigated any interaction of education with 
the cardiovascular risk factors and interactions 
between cardiovascular risk factors.
Results are presented with 95% confidence 
intervals (CI).
reSultS
Table 1 shows the characteristics of the study 
population. We did not find a significant as-
sociation between age and intra-cranial volume 
(sex-adjusted difference per year increase: -0.76 
(95%CI -1.79;0.26)). This relation was further at-
tenuated after adjusting for height (-0.15 (95%CI 
-1.19;0.89)), suggesting that this may reflect 
a secular trend. Brain infarcts were present in 
137 persons (28%), of whom 112 had lacunar 
infarcts only.
When expressed as percentages of intra-
cranial volume, men had a significantly smaller 
BV and larger volume of total and normal WM 
than women, whereas women had more GM 
and WML than men (table 2). Table 2 also shows 
the effect of age on the various brain tissues, in 
strata of sex. Figure 2 shows corresponding scat-
terplots for these relationships. BV and volumes 
of both normal WM and total WM were smaller 
with increasing age. No association with age 
was found for GM. WML showed a significant in-
crease with age. Effect of age on tissue volumes 
was not different between men and women 
(table 2). Adding a quadratic term of age did not 
improve the linear model for total WM (p=0.22 
for men and p=0.19 for women). These results 
did not change after additional adjustment for 
education, diabetes mellitus, hypertension, T
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systolic and diastolic blood pressure, and 
smoking or when persons with any infarct on 
MRI were excluded (data not shown).
Figure 3 shows mean tissue volumes in 
persons grouped according to presence of 
infarcts. Persons with a lacunar brain infarct 
had smaller BV and smaller volumes of normal 
and total WM. No significant differences were 
found for GM. Similarly, persons with more 
WML had smaller BV (age and sex adjusted 
difference in BV per SD increase in ln WML 
was -0.40% (95%CI -0.66;-0.13)). The smaller 
BV was particularly caused by smaller total 
WM volume (age and sex-adjusted difference 
per SD increase in ln WML was -0.98% (95%CI 
-1.47;-0.49)). GM did not decrease with in-
creasing WML (age and sex-adjusted difference 
per SD increase in ln WML was 0.58% (95%CI 
0.19;0.98)). The associations between markers 
of small vessel disease and brain tissue volumes 
did not change after we additionally adjusted 
for education and cardiovascular risk factors.
Finally, table 3 shows how education and 
cardiovascular risk factors were related to 
brain tissue volumes, adjusting for age and sex. 
Higher education was related to larger ICV, but 
not to BV. Diastolic blood pressure, current 
smoking and diabetes mellitus were all related 
to smaller BV. Furthermore, diabetes mellitus 
was more associated with GM than total WM, 
although not significantly, whereas diastolic 
blood pressure and current smoking were 
more related to total WM than GM. Investigat-
ing the effects of cardiovascular risk factors, 
while additionally adjusting for the other risk 
factors, yielded similar results. These effects 
did not differ between sexes. Also, we did not 
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find any significant interaction of education with age, sex or these cardiovascular risk fac-
tors nor between cardiovascular risk factors.
Figure 2. Scatterplots of tissue volumes against age, segregated by sex.
A. brain volume; B. grey matter; C. normal white matter; D. total white matter; E. white matter lesions (natural log transformed). 
Regression lines for linear fit are shown. Volumes are expressed as percentage of intra-cranial volume. Women: open triangles and 
dotted line. Men: closed circles and solid line.
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DiSCuSSiOn
Our study shows that in people aged 60 years and older, men had proportionally smaller 
BV, but more total WM than women, whereas women had more GM. Women also had 
more WML than men. Furthermore, increasing age was associated with smaller BV. This 
was particularly due to smaller volume of total WM and not GM. We found no difference 
between the sexes in the effect of age on brain tissue volumes. Finally, cerebral small vessel 
disease, current but not past smoking, diastolic blood pressure and diabetes mellitus were 
all related to smaller BV.
A major strength of our study is the population-based setting. This approach gives a 
good indication of brain changes in the general population, and with follow-up will allow 
for investigating determinants and consequences of brain changes related to cognitive 
impairment and dementia. Other strengths are the large sample size of elderly persons and 
the quantification of all brain tissues, as well as WML. Moreover, we used highly reliable 
Figure 3. Age- and sex-adjusted mean tissue volumes in persons without brain infarcts (n=353), with lacunar infarcts 
(n=112) and cortical infarcts (n=25).
A. brain volume; B. grey matter; C. normal white matter; D. total white matter; E. white matter lesions.
Volumes are expressed as percentage of intra-cranial volume. Bars represent means; lines represent standard errors. * Significantly 
different from persons without any infarct (p<0.05).
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automated quantification methods. Limitations of our study include the cross-sectional 
study-design, which limits our understanding of intra-individual brain changes. However, 
comparable effects of age on brain tissue volumes have been shown between cross-section-
al and longitudinal data.1 Another possible limitation could be the relatively low similarity 
index for classification of WML. This was particularly due to low similarity index for small 
WML. The underlying reason is that the same amount of partial-volume voxels being classi-
fied differently will have a larger effect on the similarity index of smaller WML than on the 
similarity index of larger WML.24 Indeed, if we excluded two persons with smallest WML 
from our validation set, the similarity index for WML increased to 0.71. Furthermore, the 
high ICC for WML indicates that despite any potential misclassification, the relative ranking 
of our participants was very good.
Before interpreting our results in light of published literature, two considerations need to 
be addressed. Firstly, we included only non-demented persons in our study, whereas various 
other neuroimaging studies in elderly persons also included demented and cognitively im-
paired persons.1, 25 Therefore, because of different study populations, comparison with other 
studies needs to be done with caution. Secondly, we used a 3D Inversion-Recovery sequence, 
whereas other studies usually base their classification on a T1-weighted or T2-weighted 
sequence.1, 6 We did not use our T1-weighted sequence, because of inter-leaved scanning, 
which would complicate image processing. Differences in sequences used for tissue clas-
sification may influence comparison between studies. However, Anbeek et al. showed that 
inclusion of an Inversion-Recovery sequence in k-nearest-neighbor classification yielded 
results that were at least as good as with inclusion of the T1-weighted sequence.19
Studies have consistently shown smaller whole brain volumes with aging in persons 
above 55 years of age.1, 13, 26 We found similar effects in our study of elderly persons. How-
ever, studies further investigating GM and WM separately have not yielded uniform results. 
Differences in study population, study design and - most importantly - age range under 
investigation might explain most discrepancies. We did not find an association between age 
and GM. This is in contrast to studies reporting a decline in GM volume from early adult-
hood onwards.1, 4, 6, 8, 9, 12, 27 However, these studies investigated GM volume over a broad age 
range, whereas we focused on elderly persons specifically. Moreover, our data are supported 
by a recent neuroimaging study by Greenberg et al.28 and various post-mortem studies29-31 
showing that GM decline is minimal in healthy older human and non-human primates.
We found that the volume of total WM not only decreases with age, but also in the pres-
ence of small vessel disease. DeCarli et al. reported a similar association between lacunar 
infarcts and whole brain volume, but did not analyze GM and total WM separately.13 Fur-
thermore, our data confirm results by Jernigan et al. that a larger volume of WML coincides 
with smaller volumes of both normal and total WM.12 We propose two mechanisms that 
may influence normal WM. Firstly, normal WM transforms into WML and lacunar infarcts. 
Secondly, normal WM atrophies, leading to a smaller volume of total WM. The question 
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remains whether these are sequential processes or whether WM undergoes atrophy con-
comitant with lesion formation and infarction.  Longitudinal studies that distinguish total 
WM in normal WM and WML are required to elucidate this issue.
In contrast to previous reports,8, 9 adding a quadratic term did not improve our WM 
volume model. Because whole brain WM volume peaks at age 40 years, the age range of 
our study population (60 years and over) might explain this finding.10, 32 Once again, this 
emphasizes the importance of the age range under investigation.10
Although we found that men had proportionally smaller BV and larger volume of total 
WM than women, whereas women had more GM and WML, no differences were seen 
between the sexes in the effect of age. This is in line with findings from two previous 
studies and might reflect genetic effects of sex on mean tissue volumes.33, 34 However, data 
on sex differences in mean tissue volumes or in the effect of age have not always yielded 
consistent results.1, 4
Finally, we showed that current smoking, higher diastolic blood pressure and diabetes 
mellitus were all related to smaller brain volume. This is in line with previous studies, which 
reported more neurodegenerative changes in persons with more vascular damage.35-37 We 
found that the effect of these determinants on brain tissue volumes was independent of 
each other. Previously, we found that these vascular risk factors are also related to lacunar 
infarcts and WML.38, 39 Several studies reported that ischemic damage, arteriolosclerosis and 
hypoperfusion may underlie this relationship between vascular factors and lacunar infarcts 
and WML.40 Our data suggest that similar mechanisms may also underlie brain atrophy. It 
is unclear whether various cardiovascular risk factors also affect GM and WM differently. 
We found that diabetes mellitus was more related to GM than to total WM, which is in 
line with two previous studies showing that diabetes mellitus is associated with corti-
cal atrophy41 and hippocampal atrophy,42 but not with subcortical atrophy.41 In contrast, 
current smoking and diastolic blood pressure were more related to total WM than to GM. 
However, these associations with GM and total WM separately need to be replicated in 
other population-based studies.
In conclusion, our study shows that in the elderly higher age, presence of small vessel 
disease, and cardiovascular risk factors are associated with a smaller whole brain volume. 
This is particularly due to a smaller volume of WM. 
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ABStrACt
Background: Magnetic resonance imaging (MRI) of the brain is increasingly used both in 
research and in clinical medicine, and scanner hardware and MRI sequences are continually 
being improved. These advances are likely to result in the detection of unexpected, as-
ymptomatic brain abnormalities, such as brain tumors, aneurysms, and subclinical vascular 
pathologic changes. We conducted a study to determine the prevalence of such incidental 
brain findings in the general population. 
Methods: The subjects were 2000 persons (mean age, 63.3 years; range, 45.7 to 96.7) from 
the population-based Rotterdam Study in whom high-resolution, structural brain MRI (1.5 
T) was performed according to a standardized protocol. Two trained reviewers recorded 
all brain abnormalities, including asymptomatic brain infarcts. The volume of white matter 
lesions was quantified in milliliters with the use of automated postprocessing techniques. 
Two experienced neuroradiologists reviewed all incidental findings. All diagnoses were 
based on MRI findings, and additional histologic confirmation was not obtained. 
Results: Asymptomatic brain infarcts were present in 145 persons (7.2%). Among findings 
other than infarcts, cerebral aneurysms (1.8%) and benign primary tumors (1.6%), mainly 
meningiomas, were the most frequent. The prevalence of asymptomatic brain infarcts and 
meningiomas increased with age, as did the volume of white matter lesions, whereas aneu-
rysms showed no age-related increase in prevalence. 
Conclusions: Incidental brain findings on MRI, including subclinical vascular pathologic 
changes, are common in the general population. The most frequent are brain infarcts, fol-
lowed by cerebral aneurysms and benign primary tumors. Information on the natural 
course of these lesions is needed to inform clinical management.
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intrODuCtiOn
Magnetic resonance imaging (MRI) of the brain is increasingly used both in research and 
in clinical medicine, and scanner hardware and MRI sequences are improving. Performing 
MRI at higher resolution and field strength and with more sensitive sequences may lead to 
the detection of subtle or small brain abnormalities that would not have been detected pre-
viously. In combination with the increasing number of brain MRI scans obtained each year, 
these advances in MRI technology will probably result in more persons being confronted 
with incidental brain findings. Incidental findings are previously undetected abnormali-
ties of potential clinical relevance that are unexpectedly discovered and unrelated to the 
purpose of the examination.1 The detection of incidental findings poses various practi-
cal and ethical issues, particularly when the participants in a research study are healthy 
volunteers.2 The clinical relevance and natural course of these unexpected asymptomatic 
findings are largely unknown and may differ markedly from those of similar symptomatic 
abnormalities.
Previous studies investigated incidental findings, such as brain tumors and vascular 
abnormalities, in healthy research volunteers or in populations of patients who underwent 
MRI examinations for various reasons.3-8 Katzman et al. reported a prevalence of 1.1% for 
clinically serious abnormalities, such as brain tumors, in a retrospective study of a hetero-
geneous population of volunteers, 3 to 83 years old, who were participating in a variety of 
research studies.9 To date, only one population-based study has reported the occurrence of 
incidental brain findings; this study showed a prevalence of 1.7%.10, 11 
Not generally classified as incidental findings are subclinical vascular pathologic changes 
such as asymptomatic brain infarcts and white matter lesions, the prevalence of which 
is known to be high in elderly persons and to increase with age.12-17 These lesions are 
potentially clinically relevant because of the increased risk of adverse neurologic events as-
sociated with them.17-22 We report on the prevalence of incidental brain findings, including 
subclinical vascular pathologic changes, detected by high-resolution, state-of-the-art brain 
MRI in 2000 persons who participated in a population-based study.  
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methODS
Source population 
The subjects of this study were participants in the Rotterdam Study, a prospective, 
population-based cohort study initiated in 1990 among persons 55 years of age or older 
who were living in a suburb of Rotterdam, the Netherlands.23 The original cohort of the 
Rotterdam Study (7983 participants) was expanded in 2000 and again in 2006 to include 
participants who were 45 years of age or older. Every 2 to 3 years, participants are invited 
to the research center for interviews and extensive physical examinations. Since August 
2005, all participants without contraindications to MRI have been invited to undergo MRI 
examination as part of the Rotterdam Scan Study, a neuroimaging study embedded in the 
Rotterdam Study that aims to investigate the causes and consequences of age-related brain 
changes. 
The institutional review board at Erasmus MC University Medical Center approved the 
study, and all participants gave written informed consent; the consent form included a para-
graph on incidental findings and the option to refuse to be informed about any unexpected 
abnormality. All patients who had incidental findings that required follow-up evaluation 
or treatment had previously agreed to be informed of such findings and were referred to 
appropriate specialists. 
Between August 1st, 2005, and February 1st, 2007, 2027 of 2227 eligible subjects (91.0%) 
agreed to participate in the imaging study. In 27 subjects, imaging could not be performed 
because of physical constraints (in 21 subjects) or technical problems (in 6 subjects). Brain 
imaging results were thus available for 2000 participants. 
Brain MRI acquisition 
All scans were obtained with a 1.5-T scanner with an eight-channel head coil (GE Health-
care). Two trained technicians performed all examinations in a standardized way. The MRI 
protocol was identical for all participants and included four high-resolution axial sequences: 
a three-dimensional, T1-weighted sequence; a two-dimensional, proton-density– weighted 
sequence; a two-dimensional, fluid-attenuated inversion recovery (FLAIR) sequence; and a 
three-dimensional, T2*-weighted gradient-recalled echo (GRE) sequence. The slice thick-
ness was 1.6 mm for the T1-weighted, proton- density–weighted, and T2*-weighted GRE 
sequences (zero-padded to 0.8 mm for the T1-weighted and T2*-weighted GRE sequences) 
and 2.5 mm for the FLAIR sequence; all slices were contiguous. No contrast material was 
administered.
Assessment of incidental findings
All scans were read for incidental findings by one of two trained reviewers. The readings 
were usually performed within 1 day (over 90% of all scans) and at the latest 1 week after 
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acquisition. One reviewer was a resident in radiology, and the other a resident in neurology, 
with 4.5 and 2.0 years of experience in reading brain MRIs, respectively. Both reviewers 
were unaware of any clinical information on the subjects. The readings were performed 
with a digital picture archiving and communication system (PACS). Incidental findings of 
potential clinical relevance were defined as those requiring urgent or immediate referral, as 
previously described by others;9, 10, 24 examples include brain tumors, aneurysms, subdural 
fluid collections, and arachnoid cysts. The diagnoses were made on the basis of MRI findings 
characteristic of each lesion and were not confirmed by histologic studies. Case definitions 
for each incidental MRI finding are detailed in the Appendix. 
In addition, the presence of brain infarcts (both lacunar and cortical) was recorded. The 
distinction between symptomatic and asymptomatic infarcts was verified as follows. A 
history of stroke is obtained from each subject on entry into the Rotterdam Study.25 Sub-
sequently, participants are continuously monitored for incident stroke through automated 
linkage of the study database with files from general practitioners and hospital discharge 
information. All reported events are validated by an experienced neurologist.26 White 
matter lesion volumes (in milliliters) were quantified with a validated automated voxel 
classification technique, as described elsewhere.27 Brain findings that were not considered 
clinically relevant and were not recorded as incidental findings included simple sinus 
disease and variations from the norm, such as pineal cysts, ventricular asymmetry, and 
enlarged Virchow–Robin spaces. 
Two experienced neuroradiologists reviewed and reached a consensus on all initially 
reported abnormalities. To maximize sensitivity, the threshold for reporting abnormalities 
on initial review was kept low. To verify the sensitivity of the initial review for detecting 
incidental findings, an additional 230 scans (11.5% of the total of 2000) were also read by 
the neuroradiologists. No brain abnormalities were detected in addition to those already 
recorded by the initial reviewers. This result indicates that the initial review had a very high 
sensitivity for detection of brain abnormalities. 
The management of incidental findings was defined in a protocol that was agreed on 
before the start of the study. Depending on the detected abnormality and after consultation 
with clinicians, persons with incidental findings requiring additional clinical workup or 
medical treatment were referred to a relevant medical specialist (a neurosurgeon, neurolo-
gist, or internist). 
Statistical analysis
We calculated the prevalence of each incidental brain finding in the study population. 
Multiple similar findings within one participant (e.g., more than one aneurysm or multiple 
asymptomatic brain infarcts) were counted as a single finding. Next, we calculated the 
age-specific prevalence rates of the most frequent incidental findings. For white matter 
lesions, we calculated the age-specific median and interquartile range. 
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reSultS
The mean age of the study population was 63.3 years (range, 45.7 to 96.7), and 1049 of 
the subjects (52.4%) were women. Table 1 shows the prevalence of each incidental finding 
that was recorded. Asymptomatic brain infarcts were present in 145 persons (7.2%). Among 
findings other than brain infarcts, aneurysms (1.8%) were the most frequent. All aneurysms 
except two were located in the anterior circulation, and all except three were less than 7 
mm in diameter (the smallest was 2 mm). Four aneurysms had an intracavernous location. 
Benign tumors were also frequent (1.6%), with meningiomas being recorded most often 
(0.9%). The meningiomas ranged from 5 to 60 mm in diameter, and their prevalence was 
1.1% in women and 0.7% in men. Pituitary macroadenoma was present in six persons 
(0.3%). Vestibular schwannomas had a prevalence of 0.2%. We found one possibly malignant 
primary brain tumor (a low-grade glioma that was not histologically confirmed) and one 
case of multiple cerebral metastases in a person who in retrospect was found to have been 
Table 1. Incidental findings on 2000 MRI scans*
finding no. (%)
Asymptomatic brain infarct† 145 (7.2)
Lacunar infarcts 112 (5.6)
Cortical infarcts 41 (2.0)
Primary tumors, benign 31 (1.6)
Meningioma 18 (0.9)
Vestibular schwannoma 4 (0.2)
Intracranial lipoma‡ 2 (0.1) 
Trigeminal schwannoma 1 (<0.1)
Pituitary adenoma 6 (0.3)
Primary tumors, malignant§ 1 (<0.1)
Other findings
Aneurysm 35 (1.8)
Cavernous angioma 7 (0.4)
Metastases 1 (<0.1)
Subdural hematoma 1 (<0.1)
Arachnoid cyst¶ 22 (1.1)
Chiari I malformation|| 18 (0.9)
Major vessel stenosis** 9 (0.5)
Dermoid cyst of lateral orbital rim 1 (<0.1)
Fibrous dysplasia 1 (<0.1)
* The diagnoses were based on imaging only, without histologic confirmation. 
† Some subjects had both lacunar and cortical infarcts. 
‡ One person had quadrigeminal cistern lipoma, and one had intravestibular lipoma. 
§ This finding was a possible low-grade glioma. 
¶ There were 16 temporal cysts (left-to-right ratio, 3:1) and 6 infratentorial cysts. 
||Type I Chiari malformation is defined as tonsillar herniation extending more than 5 mm below the foramen magnum.28 The 
mean degree of herniation was 6.4 mm (range, 5.2 to 10.3). 
** Major-vessel stenosis is defined as lack of flow void in the cavernous internal carotid artery (in seven subjects) or the 
vertebral artery (in two subjects).
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treated for lung cancer. The finding that was medically most urgent was a large, chronic 
subdural hematoma in an otherwise asymptomatic person, who in retrospect was found to 
have had minor head trauma 4 weeks before the MRI scan. Figure 1 shows a selection of 
the abnormalities that were incidentally detected in this study.
None of the persons with incidental brain findings reported any symptoms, with the 
exception of two subjects. One person with vestibular schwannoma reported hearing 
loss that had been investigated 3 years earlier by computed tomography, which had not 
revealed any abnormalities. The other person, who had a right-sided intravestibular lipoma, 
had longstanding ipsilateral hearing loss that had never been evaluated.
None of the incidental findings in Table 1 were histologically or surgically confirmed, 
except for those in two persons for whom operative treatment was indicated. One had 
subdural hematoma, and the other had a 12-mm aneurysm of the medial cerebral artery.
Table 2 shows the age-specific distribution of the most frequent incidental findings. The 
prevalence of asymptomatic brain infarcts increased with age. The prevalence of menin-
giomas increased from 0.5% in 45- to 59-year-olds to 1.6% in persons 75 years of age or 
older. Aneurysms showed no change in prevalence with age.
Figure 1. Incidental findings on brain MRI. Arrows indicate the abnormalities in each image. An aneurysm of the anterior 
communicating artery (diameter, 6 mm) is shown on the proton-density–weighted axial image in Panel A. Panel B shows a tonsillar 
herniation (type I Chiari malformation) more than 5 mm below the level of the foramen magnum on a T1-weighted sagittal image. 
A typical vestibular schwannoma with extension into the right internal auditory canal is visible on the proton-density– weighted axial 
image in Panel C. A large meningioma is shown on the T1-weighted axial image in Panel D. Panel E shows a large, chronic subdural 
hematoma on a proton-density–weighted axial image. A trigeminal schwannoma of the left fifth cranial nerve, with cystic degeneration, 
is shown on the T1-weighted axial image in Panel F.
45
Incidental findings on brain MRI
The median volume of white matter lesions increased with increased age (Table 2). The 
distribution of white matter lesion volumes according to age category is shown in Figure 2. 
The proportion of persons without any white matter lesions decreased from 5.4% in 45- to 
59-year-olds to 2.0% in persons 75 years of age and older. Furthermore, with increasing age, 
there was a greater spread in the distribution of white matter lesion volumes (Figure 2).
Table 2. Distribution of incidental findings according to age
finding 45 to 59 Yr of Age 
(n= 750)
60 to 74 Yr of Age 
(n = 993)
75 to 97 Yr of Age 
(n = 257)
Asymptomatic brain infarct – no. (%) 30 (4.0) 68 (6.8) 47 (18.3)
Meningioma – no. (%) 4 (0.5) 10 (1.0) 4 (1.6)
Aneurysm – no. (%) 13 (1.7) 18 (1.8) 4 (1.6)
Volume of white matter lesions - ml
Median 1.80 3.05 7.74
Interquartile range 1.06-3.17 1.87-5.49 2.64-16.49
Figure 2. Age-specific distribution of white matter lesion volumes. Measured volumes of white matter lesions were rounded to 
the nearest milliliter before plotting. The proportion of persons with a specific volume of white matter lesions within each age category 
is shown on the y axis. Fourteen persons (<1%) had a white matter lesion volume of more than 50 ml. Of these persons, one was under 
59 years of age, four were 60 to 74 years of age, and nine were 75 years of age or older.
*The maximum white matter lesion volume measured was 95 ml.
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DiSCuSSiOn
In the general population of persons 45 to 97 years old, we found a high prevalence of 
potentially clinically relevant incidental brain abnormalities, including subclinical vascular 
pathologic changes. The prevalence of asymptomatic brain infarcts and meningiomas 
increased with age, as did the volume of white matter lesions, whereas aneurysms showed 
no age-related increase in prevalence. 
A major strength of our study is the large sample of persons 45 years of age or older. The 
MRI protocol was uniform for all subjects, and the reviewers were unaware of characteris-
tics of the subjects, making detection bias unlikely. We used high-resolution, state-of-the-art 
imaging sequences representing the advanced imaging techniques that are increasingly 
used in brain research.
A potential limitation with respect to the generalizability of our study results is the 
fairly homogeneous composition of our geographically defined study population, which 
consisted mainly of white, middle-class persons.29 Our results may not be generalizable to 
populations that include other ethnic or socioeconomic groups.
Another potential limitation of our study is that not all scans were read by neuroradi-
ologists. However, all scans with abnormalities detected on initial review were reviewed 
again by two neuroradiologists. In addition, a randomly chosen subgroup of all scans was 
reviewed by two neuroradiologists, who did not detect any incidental findings missed on 
initial review. Therefore, our initial review by physicians who were not neuroradiologists 
had a very high sensitivity for the detection of brain abnormalities, and we do not think the 
results would have been different if the scans had been read primarily by neuroradiologists. 
The sensitivity may be lower when scans are read by professionals who are not medically 
qualified, as is reportedly the case in many research centers in the United States.30
The incidental brain findings in our study were all diagnosed on the basis of imaging. 
Pathological confirmation of presumed brain tumors was not obtained, since none of these 
tumors required surgery after referral of the subject. However, the imaging characteristics 
of all lesions listed in Table 1 were typical and are usually considered diagnostic (see the 
Supplementary Appendix).
We did not use contrast-enhanced MRI. Because our study population consisted of volun-
teers without neurologic symptoms who were participating in a research study, the risks 
associated with the administration of contrast material were not considered warranted. 
However, the effect of the absence of contrast material, if any, would have been to leave 
some small lesions undetected, which would have resulted in an underestimate of the 
prevalence of incidental findings.
The prevalence of subclinical vascular pathologic changes in our population was high 
and increased with advancing age. This finding was not unexpected, since age-related 
changes, such as asymptomatic brain infarcts and white matter lesions, have been reported 
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to be very frequent in the general elderly population.12, 13, 15-17, 31 Although such changes 
have been shown to be associated with increased risks of stroke and cognitive decline,18, 
20, 32 preventive therapies for patients with these MRI findings have not been evaluated in 
randomized trials.
The prevalence of incidental brain findings other than subclinical vascular pathologic 
changes in our population was much higher than that reported in previous studies,8-10, 
24 even when the subjects were of similar age to the patients in our study.10 We found 
an especially high prevalence of small aneurysms.4, 9, 10, 24 This difference can partly be 
explained by differences among study populations, since aneurysms are very infrequent 
in children and young adults. However, the population- based study by Yue et al. showed 
aneurysms in only 0.11% of persons 65 years of age or older.10 We feel that a more likely 
explanation for the difference is that our scanning protocol, especially the high-resolution, 
proton-density–weighted sequence (Figure 1A), permitted very good visualization of the 
circle of Willis as compared with conventional T1-weighted and T2-weighted sequences. Of 
course, the use of even more sensitive sequences, such as magnetic resonance angiography, 
might have resulted in the detection of even smaller aneurysms. However, in a systematic 
review of autopsy and angiographic studies, Rinkel et al. concluded that aneurysms can be 
found in approximately 2% of adults without risk factors for subarachnoid hemorrhage,33 a 
proportion very close to the 1.8% detected by MRI in our study.
Meningiomas and small aneurysms were highly prevalent in our study population of 
persons 45 years of age or older. The rate of growth of meningiomas is typically slow,34, 
35 and most meningiomas remain asymptomatic throughout life, which explains why 50% 
of all meningiomas are discovered at autopsy.36 The prevalence of meningiomas found at 
autopsy in persons over 60 years of age is 3%, and the majority of the lesions are less than 
1 cm in diameter.37 Nevertheless, it is generally believed that asymptomatic meningiomas 
require close clinical and radiologic followup to rule out rapidly enlarging tumors.34, 38 
The current practice of many clinicians is to perform MRI yearly for at least 2 to 3 years 
to ascertain that rapid tumor growth does not occur. If this were done for all persons 
incidentally found to have meningiomas, many MRI examinations would be performed in 
otherwise healthy asymptomatic persons. In view of the resulting medical costs, as well as 
the psychological burden for those undergoing examination, it would be of great interest 
to review these guidelines on the basis of the natural course of meningiomas incidentally 
found on brain MRI.
Guidelines for the management of small aneurysms might also be reviewed. More than 
90% of unruptured, asymptomatic aneurysms found by means of autopsy or angiography 
are less than 10 mm in diameter.33, 39 In our study, all but three aneurysms were smaller than 
7 mm, and all but two were located in the anterior circulation. The reported risk of rupture 
for aneurysms of this size in the anterior circulation over a period of 4 years is 0%.40 This 
finding was based on follow- up of a group of patients who had no history of subarachnoid 
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hemorrhage. However, in this group there was an overrepresentation of persons with a 
family history of aneurysm and of persons with symptoms that had led to the detection of 
the unruptured aneurysm.40 The risk of rupture associated with asymptomatic aneurysms 
in the general population would be expected to be even lower than the reported risk in 
the described patient population.33 Preventive surgery or treatment of risk factors may thus 
not be indicated in the general population, and the benefit of longer follow-up has not yet 
been proven.41 Therefore, persons in our study with aneurysms of the anterior circulation 
that were under 7 mm in diameter were not referred for follow-up or medical treatment.
Several large, population-based MRI studies in the elderly are ongoing,11, 16, 42-45 and more 
will be conducted because of the increasing scientific interest in age-related brain diseases 
such as dementia. Moreover, imaging at higher MRI field strengths and with increased reso-
lution, as well as the use of new MRI sequences that are more sensitive to subtle structural 
changes, will probably increase the number of small brain abnormalities detected. Inciden-
tal findings from brain MRI in middle-aged and elderly persons will therefore become an 
important issue that should be considered in designing studies. The present study, as well as 
some previous studies,9,10 provides information on the prevalence of clinically asymptom-
atic brain abnormalities. This information is especially important in view of the ethical and 
practical issues involved in the management of incidental findings.1, 2
In conclusion, incidental findings on brain MRI in the general population are common. 
The most frequent findings are brain infarcts, followed by cerebral aneurysms and benign 
primary tumors. Such findings should be anticipated in the design of research protocols 
and the use of neuroimaging in clinical practice. Information on the natural course and 
prognosis of these lesions is needed to inform clinical management.
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Imaging diagnosis Case definition based on MRI characteristics
Asymptomatic brain infarct
Lacunar infarct Focal parenchymal lesion ≥ 3 mm and < 15 mm in size, with the same signal 
characteristics as cerebrospinal fluid on all sequences, and -when located 
supratentorially- with a hyperintense rim on the FLAIR images.1-3 No 
involvement of cortical grey matter. Commonly located in the basal ganglia, 
internal capsule, pons and corona radiata. Differentiation from Virchow-Robin 
(VR) spaces is based on signal intensity (absence of hyperintense rim on FLAIR 
images), shape (VR-spaces are more linear or lobulated in shape) and location 
(VR-spaces are often located around anterior commissure or near vertex of the 
brain).4, 5
Subcortical infarct Same MRI characteristics as lacunar infarct, but ≥ 15 mm in size.
Cortical infarct Focal parenchymal lesion with involvement of cortical grey matter, with the same 
signal characteristics as cerebrospinal fluid on all sequences, and -when located 
supratentorially- with a hyperintense rim on the FLAIR images.1-3 Tissue loss of 
variable magnitude present, visible as prominent adjacent sulci and ipsilateral 
ventricular enlargement.6
Primary tumors, benign
Meningioma Extra-axial lesion. Iso- or hypointense to grey matter on T1-weighted images, 
variable signal intensity on PD-weighted images. Calcifications (hypointense 
on T1-weighted and PD-weighted images) within lesion and/or hyperostosis of 
underlying bone may be present. Usually broad dural basis. When large, these 
lesions may cause moderate vasogenic edema in underlying brain tissue).6
Vestibular schwannoma Extra-axial lesion. Iso- or hypointense to grey matter on T1-weighted images. 
Located in the internal auditory canal, with variable extension into the 
cerebellopontine angle. Often with widening of the internal auditory canal when 
large. Typical ”ice cream cone” appearance.6 Can show cystic changes (visible as 
high signal intensity on PD-weighted images).7
Intracranial lipoma Lesion with the same signal characteristics as subcutaneous fat on all sequences. 
Sometimes with intralesional vessels seen as flow voids.8, 9
Trigeminal schwannoma Extra-axial lesion with signal characteristics similar to vestibular schwannoma 
except the course follows that of the 5th cranial nerve.6, 10
Pituitary macroadenoma Intrasellar mass, extending suprasellar and/or parasellar, frequently causing 
deviation of the pituitary stalk. May extend upward toward the optic chiasm. The 
normal pituitary gland may not be identified. Signal intensity usually isointense 
to grey matter on all sequences, but the lesion may show cystic changes (cystic 
macroadenoma; high signal intensity on PD-weighted images).6
Primary tumors, malignant
Low-grade glioma Diffuse lesion with mass effect and signal changes: hypointense relative to 
surrounding brain on T1-weighted images, hyperintense on PD-weighted and 
FLAIR images. No signs of necrosis or hemorrhage.6
Other findings
Aneurysm The presence of aneurysms is evaluated on PD-weighted images, on which 
arterial structures are visualized as flow voids (black). Aneurysms are defined as 
blind-ending, well delineated focal arterial out-pouchings with a saccular shape. 
Location usually in cavernous internal carotid artery or circle of Willis. Commonly 
located at vessel bifurcations.6
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Abbreviations: FLAIR fluid-attenuated inversion recovery; PD proton density; GRE gradient-
recalled echo.
Note that the PD-weighted sequence used in our MR protocol is a fast spin echo sequence 
with a long repetition time (12,300 ms), which results in hyperintense signal of (cerebro-
spinal) fluid, comparable to the tissue-fluid contrast seen in T2-weighted sequences.
Cavernous angioma ”Popcorn-like”, smoothly circumscribed, well-delineated parenchymal lesion. 
Complex reticulated core of mixed signal intensities, representing hemorrhage 
in various stages of evolution. Low-signal-intensity hemosiderin rim completely 
surrounding the lesion on both T1-weighted and PD-weighted images. On T2* 
GRE imaging, paramagnetic properties of hemosiderin cause a focus of signal loss. 
No feeding artery or draining vein demonstrated.6
Metastases Multifocal parenchymal round lesions with mass effect. Generally iso- to mildly 
hypointense on T1-weighted images, hyperintense on PD-weighted images. 
Variable amount of edema surrounding each lesion. Hemorrhage may be present 
in some lesions (causing susceptibility artifacts on T2* GRE images).6
Chronic subdural hematoma Crescent-shaped extra-axial fluid collection. Hyperintense signal intensity on 
PD-weighted images. Often not homogeneous in signal intensity due to presence 
of blood in different stages, with septae separating different blood products. 
The extra-axial fluid collection does not cross dural attachments, but does cross 
sutures.6
Arachnoid cyst Sharply-demarcated well-defined extra-axial cystic lesion exhibiting isointense 
signal to cerebrospinal fluid on all sequences (including on FLAIR images). 
No internal architecture. Typical locations are temporal or infratentorial 
(cerebellopontine angle, cisterna magna).6
Chiari I malformation Tonsillar herniation extending more than 5 mm below the foramen magnum. 
The plane of the foramen magnum is defined on sagittal T1-weighted images by 
a line connecting the basion and opisthion, and degree of tonsillar herniation 
is measured perpendicular from this line to the most inferior aspect of the 
cerebellar tonsils visible on all sections.11
Major vessel stenosis Absence of flow void on T1-weighted and PD-weighted images in carotid or 
vertebral artery.12
Extra-cranial dermoid cyst Extra-cranial lesion usually located around bony sutures (typical near 
superolateral orbital rim). Well-defined lesion, usually hypointense on T1-weighted 
and hyperintense on PD-weighted images. May exhibit a fat-fluid level. Shows 
bony remodelling without destruction.13
Fibrous dysplasia Bony expansion with intact but thickened cortex. Low signal intensity on both 
T1-weighted and PD-weighted images, as well as on FLAIR images.6, 14 No 
extension into soft tissue. Typical locations in the skull are frontal, sphenoid, 
maxillary, and ethmoidal bones.14
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Cerebral Small Vessel Disease
M. Arfan Ikram, Meike W. Vernooij, Albert Hofman, Wiro J. Niessen, Aad van der Lugt, 
Monique M.B. Breteler
ABStrACt
Background and purpose: Poor kidney function, as measured by glomerular filtration rate 
(GFR), is closely associated with presence of glomerular small vessel disease. Given the 
hemodynamic similarities between the vascular beds of the kidney and the brain, we 
hypothesized an association between kidney function and markers of cerebral small ves-
sel disease on magnetic resonance imaging (MRI). We investigated this association in a 
population-based study of elderly persons.
Methods: We measured GFR using the Cockcroft-Gault equation in 484 participants (60-90 
years) from the Rotterdam Scan Study. Using automated MRI-analysis we measured global 
as well as lobar and deep volumes of grey matter and white matter, and volume of WML. 
Lacunar infarcts were rated visually. Volumes of deep white matter and WML, and presence 
of lacunar infarcts reflected cerebral small vessel disease. We used linear and logistic regres-
sion models to investigate the association between GFR and brain imaging parameters. 
Analyses were adjusted for age, sex and additionally for cardiovascular risk factors.
Results: Persons with lower GFR had less deep white matter volume (difference in standard-
ized volume per SD decrease in GFR: -0.15 (95% CI -0.26 to -0.04)), more WML (difference 
per SD decrease in GFR: 0.14 (95% CI 0.03 to 0.25)), and more often lacunar infarcts, 
although the latter was not significant. GFR was not associated with grey matter volume 
or lobar white matter volume. Additional adjustment for cardiovascular risk factors yielded 
similar results.
Conclusion: Impaired kidney function is associated with markers of cerebral small vessel 
disease as assessed on MRI.
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intrODuCtiOn
Poor kidney function is highly prevalent in the general elderly population.1, 2 It often re-
mains subclinical and is then only identified by measuring a decreased glomerular filtration 
rate (GFR).3 Poor kidney function is associated with features of large vessel disease, such as 
hypertension, arterial stiffness, and ischemic heart disease.4-6 Moreover, kidney dysfunction 
is also characterized by glomerular endothelium dysfunction and lipohyalinosis, both of 
which are features of small vessel disease in the kidney.7
In the elderly, small vessel disease is also abundantly present in the brain.8, 9 White matter 
lesions (WML), lacunar infarcts, and subcortical atrophy are markers of cerebral small vessel 
disease that are visible on magnetic resonance imaging (MRI)10 and that increase the risk 
of stroke, cognitive decline and dementia.11-13 Given the hemodynamic similarities between 
the vascular beds of the kidney and the brain,14 small vessel disease in the kidney may be 
indicative of presence of small vessel disease in the brain. However, data on the relationship 
between kidney function and MRI-markers of cerebral small vessel disease are scarce. Two 
studies showed that decreased kidney function was associated with an increased preva-
lence of subclinical brain infarcts on MRI,15, 16 which are mostly lacunar infarcts.9 However, 
they did not investigate WML or subcortical atrophy. Recently, the Northern Manhattan 
Study presented data that showed an association between kidney function and WML.17
We hypothesized an association between kidney function, as measured by GFR, and MRI-
markers of cerebral small vessel disease and investigated this association in the population-
based Rotterdam Scan Study.
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mAteriAlS AnD methODS
Study population
The Rotterdam Study is a large population-base cohort study in the Netherlands that started 
in 1990 and investigates the prevalence, incidence and determinants of chronic diseases 
in the elderly.18 In 1995 to 1996 we randomly selected 965 living members (60-90 years of 
age) of the cohort in strata of sex and age (5 years) to participate in the Rotterdam Scan 
Study, designed to investigate age-related brain abnormalities on MRI.19 After excluding 
persons who were demented or had MRI contraindications, 832 persons were eligible and 
invited. Among these, 563 persons gave their written informed consent and participated 
in the study, which included physical examination, blood sampling and an MRI scan of the 
brain (response 68%). Participants were in general healthier than non-participants.20 Of the 
563 participants, 52 developed claustrophobia during MRI acquisition. Twenty-one datasets 
were unusable due to excessive ghosting artifacts (n=5), scanning outside the range of coil 
sensitivity (n=10), or other reasons (n=6), leaving a total of 490 participants with complete 
and usable MRI data.21 The study protocol was approved by the medical ethics committee 
of the Erasmus MC, Rotterdam, the Netherlands. The large majority of participants (>97%) 
were of Caucasian ethnicity.
Measurement of glomerular filtration rate
Non-fasting blood was collected and centrifuged within 30 minutes at 3000 rotations per 
minute for 10 minutes. Subsequently the serum was stored at -20°C for 1 week, until serum 
creatinine level was assessed by a nonkinetic alkaline picrate (Jaffe) method3 (Kone Autoana-
lyzer, Kone Corporation, Espoo, Finland and Elan, Merck, Darmstadt, Germany). The method 
was standardized against high performance liquid chromatography. The within-run precision 
was >98.5% and the day-by-day precision was >95.0%. Creatinine clearance was computed 
with the Cockcroft-Gault equation,22 corrected with a factor 0.9, and standardized for 1.73 
m2 body surface area using the Dubois23 formula: GFR = (140-age{years}) (weight{kg} x 1.23) 
(0.85 if female) (serum creatinine {μmol/l})-1 (0.9) (1.73) (weight{kg})-0.425 (height{cm})-0.725 
(0.007184)-1. Creatinine clearance generally exceeds GFR by 10-15% because of additional 
urinary creatinine excretion due to tubular secretion.24 The Cockroft Gault estimate of GFR 
was therefore additionally corrected with a factor of 0.9. Serum creatinine could not be 
assessed in 6 of the 490 persons due to technical difficulties, leaving 484 persons in our 
analysis.
MRI acquisition
MRI scans of the brain were performed on a 1.5-Tesla MRI System (VISION MR, Siemens 
AG, Erlangen, Germany). The protocol included T1-weighted, proton-density weighted and 
T2-weighted scans.20 Furthermore, a high-resolution, inversion-recovery double contrast, 
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3-D HASTE sequence was acquired.21 We used the proton-density, T2-weighted and the first 
HASTE module (HASTE-Odd) for our multi-spectral volumetry.
Multi-spectral brain tissue volumetry
Data were stored onto a Linux Workstation. Preprocessing steps and the classification 
algorithm have been described.21, 25 In summary, preprocessing included co-registration, 
non-uniformity correction and variance scaling. Afterwards, we used the k-nearest-neighbor 
(kNN) classifier to classify voxels into cerebrospinal fluid (CSF), grey matter (GM), normal 
white matter (WM), and WML.26 In order to minimize any misclassification of partial volume 
voxels as WML around cortical GM, we registered a manually created mask, within which 
voxels could be classified as WML. Using the kNN-classifier infarcts are classified as CSF and 
are not included in the volume of WML.
Using non-linear transformation, non-cerebral tissues (e.g. eyes, skull, dura) were 
stripped.27, 28 Volumes were calculated by summing all voxels of a single tissue class and 
multiplying by the voxel volume.
Validation methods and results have been described and showed very good to excellent 
agreement between automated classification and manual classification used as reference.21, 25
For differentiation between lobar and deep brain tissue volumes, we first created a 
template scan, in which the lobar and deep regions were labeled according to a slightly 
modified version of the segmentation protocol as described by Bokde et al.29, 30 Figure 1 
shows an example of this segmentation, which uses anatomical landmarks and cerebral 
fissures as boundaries and distinguishes the lobar regions from a deep central region (i.e. 
the area around the ventricles, which comprises the basal ganglia, insular cortex, corpus 
Figure 1. HASTE-Odd sequence, in which the boundary (red line) between the deep and lobar brain regions is delineated, according 
to the protocol by Bokde et al.29, 30 See this figure in color in the Appendix. 
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callosum and the white matter in this region). The volume of the deep region reflects 
subcortical atrophy. Subsequently, we used validated non-rigid transformation to transform 
this template to each brain.27, 28
Rating of lacunar infarcts
Lacunar infarcts were rated visually as focal hyperintensities on T2-weighted images, 3 mm 
in size or larger and with a corresponding prominent hypointensity on T1-weighted images. 
We used the linear aspect of dilated perivascular spaces and their characteristic location 
around the anterior commissure to distinguish these from lacunar infarcts. Intrarater agree-
ment for detection of infarcts was good (κ=0.80).31
Cardiovascular determinants
Blood pressure was measured twice in sitting position on the right arm with a random-
zero sphygmomanometer. We used the average of these 2 measurements in the analyses. 
Diabetes mellitus was defined as a random or post-load glucose level of 11.1 mmol/l or 
higher, or use of oral blood glucose lowering drugs or insulin. Total cholesterol, high-density 
lipoprotein cholesterol, and C-reactive protein were measured in non-fasting serum with 
an automated enzymatic procedure. Plasma homocysteine was determined by fluorescence 
polarization immunoassay in an IMx analyzer (Abbott Laboratories, Chicago, IL). History 
of myocardial infarction was positive if a participant had reported a myocardial infarction 
that was confirmed by ECG or medical records. Use of blood pressure-lowering medication 
and smoking history were assessed during a home interview. The number of pack years of 
smoking was calculated by multiplying the number of cigarette packs smoked per day by 
the number of years smoked.
Statistical analysis
All volumes were expressed as percentage of intra-cranial volume (= CSF + GM + normal WM + 
WML) to correct for individual head-size differences. Whole brain volume was defined as intra-
cranial volume minus CSF volume. Total WM was defined as the sum of normal WM and WML. 
WML were natural log transformed because of skewness of the untransformed measure.
Apart from global brain tissue volumes, we also assessed lobar and deep brain tissue 
volumes. To enable better comparison between the effects of kidney function on different 
tissue types we calculated z-scores for each participant for each tissue type separately 
(z-score = individual tissue volume minus mean tissue volume divided by the standard 
deviation).
With multiple linear regression we first investigated the association of quartiles of GFR 
with brain tissue volumes and WML volume. Persons in the highest quartile of GFR (indi-
cating best kidney function) were taken as reference category. We then investigated the 
association of GFR continuously per standard deviation (SD) decrease with brain tissue 
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volumes and WML volume. We first examined global brain tissue volumes and subsequently 
lobar and deep tissue volumes separately. With logistic regression we investigated the as-
sociation of GFR with lacunar infarcts. 
All analyses were adjusted for age and sex and additionally for systolic blood pressure, 
diastolic blood pressure, blood pressure-lowering medication, diabetes mellitus, pack years 
of smoking, previous myocardial infarction, homocysteine, total cholesterol, high-density 
lipoprotein cholesterol and C-reactive protein.
Finally, we repeated the analyses after adjusting for or excluding persons with a cortical 
infarct on MRI (n=25).
reSultS
Table 1 shows the characteristics of the study population. Figure 2 shows the associations 
between quartiles of kidney function and z-scores of global brain tissue volumes. Table 
2 shows these associations using GFR continuously per SD decrease. Persons with low 
GFR had a smaller brain volume (difference in brain volume, expressed as percentage of 
intra-cranial volume, per standard deviation (SD) decrease in GFR: -0.35% (95% confidence 
interval (CI) -0.68% to -0.03%)). This smaller brain volume was not due to smaller GM 
volume, but rather due to smaller total and normal WM volume (figure 2 and table 2). Also, 
persons with low GFR had a larger volume of WML (difference in WML volume, expressed 
as percentage of intra-cranial volume, between lowest and upper quartile of GFR 0.47% 
(95% CI 0.02% to 0.92%); difference per SD decrease 0.19% (95% CI 0.03% to 0.36%)) (see 
also figure 2 and table 2).
Table 1. Characteristics of the study population.
Total cohort, n=484
Age, year 73.4 (7.8)
Women, n 245 (51%)
Systolic blood pressure, mmHg 145.7 (20.5)
Diastolic blood pressure, mmHg 76.5 (11.5)
Blood pressure-lowering medication use, n 185 (38%)
Diabetes mellitus, n 24 (5%)
Smoking, pack years 20.4 (24.7)
History of myocardial infarction, n 37 (8%)
C-reactive protein, mg/l 3.71 (6.22)
Homocysteine, μmol/l 11.96 (4.47)
Total cholesterol, mmol/l 5.88 (1.05)
High-density lipoprotein cholesterol, mmol/l 1.28 (0.36)
Serum creatinine, μmol/l 89.9 (20.6)
Glomerular filtration rate, ml/min/1.73m² 54.8 (13.0)
Values are means (standard deviation) or numbers (percentages).
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Investigating lobar and deep tissue volumes separately showed that decreased GFR was 
associated with both smaller lobar and deep WM volume. However, this association was 
weak for lobar WM, whereas it was very strong for deep WM (table 3 and figure 3). GFR was 
also related to lobar WML, and to a somewhat lesser extent deep WML (table 3). We did not 
find any association between GFR and either lobar or deep GM volume.
When additionally adjusting for cardiovascular risk factors, the associations attenuated 
marginally, but GFR was still related to volume of WML, to deep WM volume, and (border-
line) to brain volume (tables 2 and 3).
Figure 2. The association between quartiles of kidney function 
and z-scores of global brain tissue volumes. A. brain volume; B. 
grey matter; C. normal white matter; D. total white matter; E. white matter 
lesions.
Total white matter is the sum of normal white matter and white matter 
lesions. White matter lesions are further natural log transformed. The 
range of glomerular filtration rate for each quartile was as follows: 
quartile 1: 18.23–45.57 ml/min/1.73 mm2, quartile 2: 45.58–54.37 ml/
min/1.73 mm2, quartile 3: 54.38–64.26 ml/min/1.73 mm2, quartile 4: 
64.27–98.25 ml/min/1.73 mm2. Dots represent the age and sex adjusted 
means. Lines represent standard errors. * significantly different from 
persons in the highest quartile (p<0.05).
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Finally, persons with lower GFR had a higher prevalence of lacunar infarcts, although 
this was not statistically significant (age and sex adjusted prevalence odds-ratio of lacunar 
infarcts per SD decrease in GFR: 1.11 (95% CI 0.81 to 1.51)).
Figure 3. The association between quartiles of kidney function and z-scores of lobar and deep white matter volumes. 
A. normal white matter, lobar; B. total white matter, lobar; C. white matter lesions, lobar; D. normal white matter, deep; E. total white 
matter, deep; F. white matter lesions, deep.
Total white matter is the sum of normal white matter and white matter lesions. White matter lesions are further natural log transformed. 
The range of glomerular filtration rate for each quartile was as follows: quartile 1: 18.23–45.57 ml/min/1.73 mm2, quartile 2: 
45.58–54.37 ml/min/1.73 mm2, quartile 3: 54.38–64.26 ml/min/1.73 mm2, quartile 4: 64.27–98.25 ml/min/1.73 mm2. Dots represent 
the age and sex adjusted means. Lines represent standard errors. * significantly different from persons in the highest quartile (p<0.05).
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Repeating the analyses after adjusting for or excluding persons with a cortical infarct on 
MRI did not change any of the associations. Finally, separate analyses for men and women 
yielded no consistent results different from the overall analyses.
DiSCuSSiOn
In this population-based study we found that persons with a decreased kidney function, as 
measured by low GFR, had smaller brain volume, smaller deep WM volume and more WML. 
GFR was not associated with GM volume or lobar WM volume. These associations were 
independent of cardiovascular risk factors.
Strengths of our study include the population-based setting, the large sample size of 
elderly persons aged 60 years and older, and our focus on various subclinical manifestations 
of cerebral small vessel disease. Moreover, the automated MR-analysis not only allowed us 
to accurately quantify GM and WM atrophy, but also to investigate lobar and subcortical 
brain atrophy separately.
Before interpreting our data some methodological issues need to be considered. The 
study is based on a cross-sectional study design, which limits the interpretation of our 
results with respect to cause and effect. Another consideration is that we used the Cock-
croft Gault equation to estimate GFR and not the abbreviated Modification of Diet in Renal 
Disease (MDRD).32 However, the MDRD equation has been developed in a population for 
which a large part of our participants would not meet inclusion criteria.33 Therefore, using 
the MDRD in our population would yield misclassified measures of kidney function and 
would lead to dilution of the associations. For this reason and because participants were 
predominantly of only one ethnicity, we chose to use the Cockcroft-Gault equation in our 
present study. We measured serum creatinine only once, ignoring possible intra-individual 
fluctuations in serum creatinine levels. This may have caused our estimates to be slightly 
underestimated. Furthermore, serum creatinine is influenced by nonrenal factors and addi-
tional measurement of urinary albumin might have improved the sensitivity and specificity 
of our assessment of kidney function. Also, cystatin C is considered a superior measure of 
kidney function to serum creatinine. However, neither urinary albumin nor cystatin C were 
measured in our study.
We cannot exclude that in some cases lacunar infarcts may have been misclassified as dilated 
perivascular spaces and vice versa. However, given that no association has been reported yet 
between kidney function and dilated perivascular spaces we feel that any misclassification 
would probably be random and would lead to an underestimation of the true effect.
We defined subcortical (deep) brain regions according to the protocol by Bokde et al,29, 
30 which could be criticized for using arbitrarily defined borders between lobar and deep 
regions. Insular cortex for example is included in the deep brain region, whereas white 
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matter adjacent to occipital horns for example is not. We are aware that this division may 
not fully correspond to the ‘true’ position of the borders, and might not completely disen-
tangle the separate effects of kidney function on lobar and deep brain regions. However, 
because the ‘true’ position of the borders itself is still largely unknown, we chose to apply 
a protocol that was designed for its practical use in population-based studies. 
Several studies have shown that poor kidney function is associated with cardiovascu-
lar complications due to large-vessel disease, such as arterial calcification, heart failure, 
myocardial infarction and cardiac mortality.4, 14, 34, 35 Only a few studies investigated kidney 
function specifically in relation to cerebrovascular disease and found that poor kidney 
function indicated an increased risk of clinical and subclinical stroke.15, 16, 36, 37
We found that decreased GFR was related to WML, subcortical atrophy, and to a lesser 
extent lacunar infarcts. We hypothesize that small vessel disease may underlie this associa-
tion. The vascular beds of both the kidney and the brain have very low resistance and are 
passively perfused at high flow throughout systole and diastole.14 Because of these unique 
features, which are not present in other organs, the blood vessels in the kidney and brain 
are highly susceptible to fluctuations in blood pressure and flow. Indeed, high blood pres-
sure and other vascular risk factors have been shown to lead to glomerular lipohyalinosis 
and endothelium dysfunction, both of which are characteristics of small vessel disease in 
the kidney.7, 38 Lipohyalinosis and endothelium dysfunction are also underlying features of 
WML and lacunar infarcts in the brain.39 Moreover, because cerebral small vessel disease 
affects deep perforating arterioles, it is also characterized by atrophy in this deep subcorti-
cal region.40 This is reflected in our dataset by the relationship between GFR and deep WM 
atrophy.
 We did not find any association between GFR and GM volume. This observation is in line 
with our previous report showing that cardiovascular risk factors, such as diastolic blood 
pressure and smoking, were more related to WM atrophy than to GM atrophy.21
Previously, we have reported that several cardiovascular risk factors are associated with 
cerebral small vessel disease, including blood pressure,20 CRP,41 and homocysteine.42 We 
found that adjustment for such cardiovascular risk factors only marginally changed the 
associations of GFR with cerebral small vessel disease. This could mean that these associa-
tions are not mediated by these risk factors, but by a different mechanism. A possibility is 
that GFR reflects risk factors for cerebral small vessel disease that we did not measure in 
our study, e.g. genetic factors.  Another explanation could be that GFR is a better marker of 
small vessel disease than these concomitantly measured cardiovascular risk factors. How-
ever, more studies are needed to elucidate the exact mechanism underlying the association 
of GFR with cerebral small vessel disease.
In conclusion, our study shows that impaired kidney function, as measured by decreased 
GFR, is related to subclinical markers of cerebral small vessel disease, independent of car-
diovascular risk factors. Therefore, GFR might be used as an easily measurable indicator of 
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cerebral small vessel disease. Moreover, given that cerebral small vessel disease is related to 
an increased risk of stroke, cognitive decline and dementia,11-13 our data provide important 
information in addition to the known risk of adverse cardiac outcomes in persons with 
poor kidney function. Thus, our study further emphasizes the importance of identifying 
those with subclinical kidney disease. These persons might then benefit from installment 
of proper therapy. However, more studies are needed to investigate the extent to which any 
intervention can be beneficial.
referenCeS
 1. Duncan L, Heathcote J, Djurdjev O, Levin A. Screening for renal disease using serum creatinine: 
who are we missing? Nephrol Dial Transplant. 2001;16:1042-1046
 2. Nissenson AR, Pereira BJ, Collins AJ, Steinberg EP. Prevalence and characteristics of individu-
als with chronic kidney disease in a large health maintenance organization. Am J Kidney Dis. 
2001;37:1177-1183
 3. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights 
into old concepts. Clin Chem. 1992;38:1933-1953
 4. Brugts JJ, Knetsch AM, Mattace-Raso FU, Hofman A, Witteman JC. Renal function and risk 
of myocardial infarction in an elderly population: the Rotterdam Study. Arch Intern Med. 
2005;165:2659-2665
 5. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C. 
Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 
2005;352:2049-2060
 6. Foley RN, Wang C, Collins AJ. Cardiovascular risk factor profiles and kidney function stage in the 
US general population: the NHANES III study. Mayo Clin Proc. 2005;80:1270-1277
 7. Kang DH, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, Schreiner GF, Johnson RJ. Role 
of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol. 2002;13:806-
816
 8. Ikram MK, De Jong FJ, Van Dijk EJ, Prins ND, Hofman A, Breteler MM, De Jong PT. Retinal vessel 
diameters and cerebral small vessel disease: the Rotterdam Scan Study. Brain. 2006;129:182-
188
 9. Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM. Prevalence and risk factors of 
silent brain infarcts in the population-based Rotterdam Scan Study. Stroke. 2002;33:21-25
 10. Greenberg SM. Small vessels, big problems. N Engl J Med. 2006;354:1451-1453
 11. Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts 
and white matter lesions increase stroke risk in the general population: the Rotterdam Scan 
Study. Stroke. 2003;34:1126-1129
 12. Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM. 
Cerebral white matter lesions and the risk of dementia. Arch Neurol. 2004;61:1531-1534
 13. Au R, Massaro JM, Wolf PA, Young ME, Beiser A, Seshadri S, D’Agostino RB, DeCarli C. Association 
of white matter hyperintensity volume with decreased cognitive functioning: the Framingham 
Heart Study. Arch Neurol. 2006;63:246-250
67
Kidney function and structural brain changes
 14. O’Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in 
brain and kidney: cause and logic of therapy. Hypertension. 2005;46:200-204
 15. Seliger SL, Longstreth WT, Jr., Katz R, Manolio T, Fried LF, Shlipak M, Stehman-Breen CO, Newman 
A, Sarnak M, Gillen DL, Bleyer A, Siscovick DS. Cystatin C and subclinical brain infarction. J Am 
Soc Nephrol. 2005;16:3721-3727
 16. Kobayashi S, Ikeda T, Moriya H, Ohtake T, Kumagai H. Asymptomatic cerebral lacunae in patients 
with chronic kidney disease. Am J Kidney Dis. 2004;44:35-41
 17. Khatri M, Wright CB, Nickolas TL, Yoshita M, Li L, Kranwinkel G, DeCarli C, Sacco RL. Chronic 
kidney disease is associated with white matter hyperintensity volume: The Northern Manhattan 
Study. Stroke. 2007;38:539 (abstract)
 18. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and dis-
ability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol. 1991;7:403-422
 19. den Heijer T, Vermeer SE, van Dijk EJ, Prins ND, Koudstaal PJ, Hofman A, Breteler MM. Type 
2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia. 
2003;46:1604-1610
 20. de Leeuw FE, de Groot JC, Oudkerk M, Witteman JC, Hofman A, van Gijn J, Breteler MM. A follow-
up study of blood pressure and cerebral white matter lesions. Ann Neurol. 1999;46:827-833
 21. Ikram MA, Vrooman HA, Vernooij MW, van der Lijn F, Hofman A, van der Lugt A, Breteler MM. 
Brain tissue volumes in the general elderly population. The Rotterdam Scan Study. Neurobiol 
Aging. 2007;doi:10.1016/j.neurobiolaging.2006.12.012 in press
 22. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 
1976;16:31-41
 23. Wang Y, Moss J, Thisted R. Predictors of body surface area. J Clin Anesth. 1992;4:4-10
 24. Vervoort G, Willems HL, Wetzels JF. Assessment of glomerular filtration rate in healthy subjects 
and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation. Neph-
rol Dial Transplant. 2002;17:1909-1913
 25. Vrooman HA, Cocosco CA, Stokking R, Ikram MA, Vernooij MW, Breteler MM, Niessen WJ. kNN-
based multi-spectral MRI brain tissue classification: manual training versus automated atlas-
based training. Proc. SPIE. Medical Imaging: Image process. 2006;6144:1142-1150
 26. Anbeek P, Vincken KL, van Bochove GS, van Osch MJ, van der Grond J. Probabilistic segmenta-
tion of brain tissue in MR imaging. Neuroimage. 2005;27:795-804
 27. Rueckert D, Sonoda LI, Hayes C, Hill DL, Leach MO, Hawkes DJ. Nonrigid registration using 
free-form deformations: application to breast MR images. IEEE Trans Med Imaging. 1999;18:712-
721
 28. Klein S, Staring M, Pluim JP. Comparison of gradient approximation techniques for optimisation 
of mutual information in nonrigid registration. Proc. SPIE. Medical Imaging: Image process. 
2005;5747:192-203
 29. Bokde AL, Teipel SJ, Zebuhr Y, Leinsinger G, Gootjes L, Schwarz R, Buerger K, Scheltens P, Moeller 
HJ, Hampel H. A new rapid landmark-based regional MRI segmentation method of the brain. J 
Neurol Sci. 2002;194:35-40
 30. Bokde AL, Teipel SJ, Schwarz R, Leinsinger G, Buerger K, Moeller T, Moller HJ, Hampel H. Reli-
able manual segmentation of the frontal, parietal, temporal, and occipital lobes on magnetic 
resonance images of healthy subjects. Brain Res Brain Res Protoc. 2005;14:135-145
 31. Vermeer SE, Den Heijer T, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM. Incidence and 
risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke. 
2003;34:392-396
Chapter 2.2
68
 32. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate 
glomerular filtration rate from serum creatinine: a new prediction equation. Modification of 
Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470
 33. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G. The effects of dietary 
protein restriction and blood-pressure control on the progression of chronic renal disease. 
Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994;330:877-884
 34. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of 
death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305
 35. Guerin AP, Adda H, London GM, Marchais SJ. Cardiovascular disease in renal failure. Minerva Urol 
Nefrol. 2004;56:279-288
 36. Seliger SL, Gillen DL, Longstreth WT, Jr., Kestenbaum B, Stehman-Breen CO. Elevated risk of 
stroke among patients with end-stage renal disease. Kidney Int. 2003;64:603-609
 37. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak 
MJ. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a 
pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15:1307-1315
 38. Wong TY, Coresh J, Klein R, Muntner P, Couper DJ, Sharrett AR, Klein BE, Heiss G, Hubbard LD, 
Duncan BB. Retinal microvascular abnormalities and renal dysfunction: the atherosclerosis risk 
in communities study. J Am Soc Nephrol. 2004;15:2469-2476
 39. Fernando MS, Simpson JE, Matthews F, Brayne C, Lewis CE, Barber R, Kalaria RN, Forster G, 
Esteves F, Wharton SB, Shaw PJ, O’Brien JT, Ince PG. White matter lesions in an unselected 
cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury. 
Stroke. 2006;37:1391-1398
 40. Scheltens P, Barkhof F, Leys D, Wolters EC, Ravid R, Kamphorst W. Histopathologic correlates of 
white matter changes on MRI in Alzheimer’s disease and normal aging. Neurology. 1995;45:883-
888
 41. van Dijk EJ, Prins ND, Vermeer SE, Vrooman HA, Hofman A, Koudstaal PJ, Breteler MM. C-reactive 
protein and cerebral small-vessel disease: the Rotterdam Scan Study. Circulation. 2005;112:900-
905
 42. Vermeer SE, van Dijk EJ, Koudstaal PJ, Oudkerk M, Hofman A, Clarke R, Breteler MM. Homo-
cysteine, silent brain infarcts, and white matter lesions: The Rotterdam Scan Study. Ann Neurol. 
2002;51:285-289
Chapter 
2.3
unrecognized myocardical infarction 
and Structural Brain Changes

Chapter 
2.3.1
unrecognized myocardial infarction and 
the risk of Stroke. the rotterdam Study
M. Arfan Ikram, Monika Hollander, Michiel J. Bos, Jan A. Kors, Peter J. Koudstaal, 
Albert Hofman, Jacqueline C.M. Witteman, Monique M.B. Breteler
ABStrACt
Objective: To investigate the relationship between unrecognized myocardial infarction and 
the risk of stroke in a population-based cohort study.
Methods: We followed 6,439 participants from the Rotterdam Study for stroke until Janu-
ary 2002. Participants were free from stroke and presence of myocardial infarction was 
assessed at baseline (1990-1993). We calculated hazard ratios of stroke for persons with 
unrecognized or recognized myocardial infarction compared to persons without myocar-
dial infarction. Analyses were adjusted for age, sex and cardiovascular risk factors.
Results: In 52,915 person-years of follow-up, 505 strokes occurred. Recognized myocardial 
infarction was only borderline associated with an increased risk of stroke. Unrecognized 
myocardial infarction increased the risk of stroke by 76% (age and sex adjusted hazard 
ratio 1.76, 95% CI 1.31 to 2.37). Stratification for sex showed that the increased risk was 
only found in men (hazard ratio for men 2.53, 95% CI 1.68 to 3.81, hazard ratio for women 
1.27, 95% CI 0.82 to 1.96). After adjusting for cardiovascular risk factors at baseline, the risk 
remained significantly increased in men (hazard ratio for stroke 2.13, 95% CI 1.35 to 3.36). 
Subtyping of strokes revealed that unrecognized myocardial infarction was particularly 
associated with cortical ischemic strokes (hazard ratio for men 3.57, 95% CI 1.79 to 7.12).
Conclusions: Men with unrecognized myocardial infarction have an increased risk of 
stroke.
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intrODuCtiOn
Vascular disease outside the brain, such as clinically recognized myocardial infarction (MI), 
is associated with an increased risk of stroke.1-3 However, a large proportion of MI in the 
elderly is unrecognized and is identified only by EKG.4, 5 Various studies have shown that be-
tween 21 and 68% of MI are unrecognized and that this proportion is higher in women than 
in men.6-14 The prevalence in the general elderly population varies between 1.2 and 6.4%.4, 
12, 15 With respect to the prognosis of unrecognized MI, most studies show an increased risk 
of new cardiac events and mortality of the same magnitude as the risk increase associated 
with recognized MI.6-9 One study reported that men with unrecognized MI even had a 60 
to 70% higher risk of death than men with recognized MI.10 However, few data are present 
for subsequent non-cardiac events, e.g. stroke. Only the Framingham Study reported that in 
persons with unrecognized MI stroke occurred at a two to fivefold increased rate versus 
persons without MI.6 Thus far, no study focused on the various subtypes of stroke. We 
examined the relationship between unrecognized MI and incident stroke and its subtypes 
in the Rotterdam Study, a large population-based cohort study.
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methODS
Study population
The Rotterdam Study is a prospective population-based study of 7,983 participants (aged 
55 years and over) from Ommoord, a district of Rotterdam, The Netherlands. The study 
aims to investigate determinants and causes of chronic diseases in the elderly, including 
cerebrovascular disease.16 The study was approved by the Medical Ethics Committee of the 
Erasmus University. Participants gave written informed consent to participate in the study 
and to obtain information from treating physicians. At baseline (1990-1993) participants 
were interviewed and underwent physical examination and blood sampling.16 At baseline 
we assessed prior stroke by asking “Did you ever suffer a stroke, diagnosed by a physician?”. 
Medical records of persons who answered ‘yes’ were checked and a previous stroke was 
considered present if medical records confirmed it. These persons were excluded from our 
study, leaving 7,717 participants without stroke at baseline.
Assessment of myocardial infarction 
At baseline participants were asked the following questions: “Did you ever experience a 
heart attack?” and if so, “At what age?”, “Who made the diagnosis?” and “Were you admitted 
to a hospital?”. Afterwards a 12-lead EKG was recorded with an ACTA-electrocardiograph 
(Esaote, Florence, Italy) with a sampling frequency of 500 Hz. All EKGs were processed by 
the Modular EKG Analysis System (MEANS)17 to obtain EKG measurement and interpreta-
tion. To determine MI MEANS uses a comprehensive set of criteria that partly derive from 
the Minnesota codes.18 The MEANS program has been extensively evaluated previously.17, 
19 Of persons with EKG evidence of MI but without self-report, information from GPs 
and cardiologists was collected to confirm that no clinically manifest MI had occurred. 
Additional information was also collected of persons with self-reported MI without EKG 
evidence of MI. This was done to distinguish persons who had suffered a non-Q-wave MI 
or whose Q-wave had disappeared over time, from persons who mistook other symptoms 
for MI.
Based on this procedure at baseline, we classified participants as follows. Recognized MI 
(n=442) included persons with self-reported MI confirmed by matching EKG characteris-
tics or clinical data. Unrecognized MI (n=361) were all participants without documented or 
self-reported MI, but with EKG characteristics matching an MI. The non-MI reference group 
(n=5,636) consisted of all persons without indication of MI on EKG and no self-report or 
medical documentation of an earlier MI.
Of the 7,717 participants without prior stroke, digital EKG data were unavailable for 
1,278 persons, mostly due to technical difficulties or insufficient personnel to operate the 
EKG-apparatus. This left a total of 6,439 participants in the present study.
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Assessment of stroke
Assessment and subtyping of strokes in the Rotterdam Study have been extensively de-
scribed.1, 20 In summary, after entrance into the Rotterdam Study, participants were con-
tinuously monitored for major events through automated linkage of the study database 
with files from general practitioners and the municipality. Also, nursery home physicians’ 
files and files from general practitioners of participants who moved out of the district 
were reviewed. For reported events, additional information (including neuroimaging) was 
obtained from hospital records. Research physicians discussed information on all potential 
strokes and TIAs with an experienced stroke neurologist (P.J.K.) to verify all diagnoses. This 
was done blinded for presence of MI. Subarachnoid hemorrhages and retinal strokes were 
excluded. Follow-up was completed until January 1st, 2002. All strokes were subsequently 
classified as ischemic, hemorrhagic or unspecified as follows: A stroke was classified as 
ischemic when a patient had typical symptoms and a CT or MRI scan performed within 4 
weeks after the stroke ruled out other diagnoses, or when indirect evidence (deficit limited 
to 1 limb or completely resolved within 72 hours, atrial fibrillation in absence of anticoagu-
lants) pointed at an ischemic nature of the stroke. A stroke was classified as hemorrhagic 
when a relevant hemorrhage was shown on CT or MRI scan, or when the participant lost 
consciousness permanently or died within hours after onset of focal signs. If a stroke did 
not match these criteria, it was classified as unspecified. Neuroimaging was available for 
65% of all events. Although some strokes could be classified based on clinical information 
only, most strokes without neuroimaging were categorized as unspecified. Of all ischemic 
stroke events 92% had undergone neuroimaging; for hemorrhagic strokes this was 81%.
Ischemic strokes were further subdivided into clinical syndromes. A hemispheric lacu-
nar ischemic stroke syndrome was diagnosed when a patient suffered from a pure motor 
stroke, pure sensory stroke, ataxic hemiparesis, or dysarthria and a clumsy hand or arm, 
in the absence of cortical symptoms or signs (dysphasia, hemineglect, apraxia, acalculia, 
dysgraphia, or visual field defects). A hemispheric cortical ischemic stroke syndrome was 
diagnosed when any cortical symptom or sign was present. Ischemic strokes that did not fit 
into either category remained unspecified. Also, possible posterior fossa ischemic strokes 
were not analyzed separately, because of too small numbers (n=43).
Possible confounders
A computerized questionnaire was used to obtain information on current health status and 
medical history at baseline. Smoking status was verified during the baseline interview and 
participants were classified into one of three categories: current smoker, former smoker, or 
never smoker. At the research center, sitting blood pressure was measured on the right up-
per arm using a random-zero sphygmomanometer. In the analyses the average of two mea-
surements, measured at one occasion, was used. Diabetes mellitus was defined as random 
or post-load serum glucose level exceeding 11.1 mmol/l or the use of oral blood glucose 
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lowering drugs or insulin. Atrial fibrillation was assessed on an electrocardiogram. Ankle-
arm pressure index was measured as described previously.21 Non-fasting blood samples 
were taken and serum total cholesterol and high-density lipoprotein cholesterol (HDL) 
were determined by means of an automated enzymatic procedure. Use of cardiovascular 
drugs was assessed by interview and pharmacy records. These drugs included nitrates, 
antihypertensives, statins and antithrombotic agents, including aspirin.
In the analyses, we adjusted for baseline values of these potential confounders.
Data analysis
We used Cox’ proportional hazards regression model, adjusted for age and sex, to assess 
the relationship between MI and risk of stroke, which included ischemic strokes, hemor-
rhagic strokes and unspecified strokes. Subsequently, we investigated ischemic stroke and 
its subtypes separately. Persons without MI were taken as reference group. We added an 
interaction term sex*unrecognized MI to the model to investigate differences between the 
sexes in prognosis after unrecognized MI. To assess the impact of adjustment for cardio-
vascular risk factors, we additionally adjusted for systolic blood pressure, diastolic blood 
pressure, smoking, total and HDL cholesterol, atrial fibrillation, diabetes mellitus, ankle-arm 
pressure index and use of cardiovascular drugs. Results are presented as hazard ratios (HR) 
with 95% CI.
reSultS
Table 1 shows the baseline characteristics of the study population. During 52,915 person-
years of follow-up (mean 8.2 years) 505 (213 in men) strokes occurred, of which 299 (133 
in men) were ischemic strokes, 48 hemorrhages (20 in men) and 158 unspecified. Of the 
Table 1. Baseline characteristics of the study population. Values are percentages or means (SD).
without mi
n=5,636
unrecognized mi
n=361
recognized mi
n=442
Women (%) 62.0 56.0 31.4
Age (yr) 68.3 (8.5) 72.1 (8.8) 71.1 (8.0)
Present smoker (%) 22.6 27.4 21.0
Former smoker (%) 40.9 38.2 60.2
Diabetes mellitus (%) 9.2 15.2 15.8
Systolic blood pressure (mmHg) 139 (22) 145 (20) 135 (23)
Diastolic blood pressure (mmHg) 74 (11) 75 (12) 70 (11)
Total cholesterol (mmol/l) 6.64 (1.21) 6.53 (1.31) 6.55 (1.20)
HDL-cholesterol (mmol/l) 1.37 (0.36) 1.31 (0.34) 1.16 (0.30)
Atrial fibrillation (%) 2.3 5.3 3.9
Ankle-arm pressure index 1.07 (0.22) 1.00 (0.26) 1.02 (0.27)
Use of cardiovascular drugs (%) 32.8 38.2 83.3
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ischemic strokes 149 (65 in men) were cortical and 74 (32 in men) 
lacunar; the remaining ischemic strokes were either posterior fossa 
strokes (n=43) or unspecified.
Table 2 shows the age and sex adjusted HR for stroke. Persons with 
unrecognized MI at baseline had an almost doubled risk of stroke (HR 
1.76, 95%CI 1.31 to 2.37); for persons with recognized MI the risk 
was lower and only borderline significantly increased. Stratification 
for sex showed that the increased risk of stroke after unrecognized 
MI was confined to men (HR in men 2.53, 95%CI 1.68 to 3.81; HR 
in women 1.27, 95%CI 0.82 to 1.96). The p-value was 0.017 for 
interaction between sex and unrecognized MI. The risk of stroke 
after recognized MI was similar for men and women. Figure 1 shows 
Kaplan-Meier curves for these relationships.
Men had a significantly increased risk of ischemic stroke and 
particularly cortical ischemic stroke after either a recognized or 
an unrecognized MI (table 3). The risk increase was however much 
higher after an unrecognized than a recognized MI. In women, neither 
recognized nor unrecognized MI was related to the risk of ischemic 
stroke or ischemic stroke subtypes (table 3).
Additional adjustment for cardiovascular covariates slightly di-
minished the risk estimates, yet the risk of stroke associated with 
unrecognized MI remained significantly increased in men (table 4). 
Analyzing the various cardiovascular drugs separately did not change 
the results in any way.
DiSCuSSiOn
We found that unrecognized MI is associated with a strongly increased 
risk of stroke in men, but not in women. In contrast, recognized MI 
was only borderline associated with an increased risk of stroke after 
adjustment for vascular covariates. The risk increase was largest for 
ischemic strokes, particularly cortical ischemic strokes.
Strengths of our study include a mean follow-up of about 8 years, 
a large sample size, and standardized ascertainment of MI and stroke. 
Another strength is that our stringent stroke monitoring procedures 
allowed us to also include stroke patients who were not referred to a 
hospital, for example persons in nursery homes or persons suffering 
fatal strokes. Therefore, loss to follow-up was minimal. A disadvantage T
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is that in these cases neuroimaging was often lacking (65% of 
all stroke cases had neuroimaging) and clinical information was 
not thorough enough to subclassify 158 strokes into ischemic or 
hemorrhagic. These strokes were thus classified as unspecified. 
However, although persons suffering unspecified strokes were 
older than persons with a specified stroke, these groups did not 
differ from each other in percentage women or the prevalence of 
unrecognized or recognized MI. Therefore, this could not have led 
to bias in our analyses. Moreover, the proportion of unspecified 
strokes in our study is similar to other population-based22 or even 
hospital-based23 studies. Most importantly, because the physicians 
making the diagnosis of stroke were blinded for presence of MI, 
any resulting misclassification is likely to have been non-differential T
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Figure 1. Kaplan-Meier curves for stroke-free survival in persons with unrecognized, recognized 
and no myocardial infarction, stratified for sex. A: men. B: women
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and would result in an underestimation of the effect. Another possible limitation of our 
study is that EKG data were missing in 1,278 persons. Because persons were invited in 
random order to the research center, this could not have biased our results. 
We focused on stroke, whereas most other studies investigating the prognosis of unrec-
ognized MI did not evaluate stroke separately.6-10 We found that men with unrecognized MI 
have a higher risk of stroke than men with recognized MI. These data are in accordance 
with studies that showed an increased risk of cardiovascular morbidity and mortality in 
men with unrecognized MI,6, 10 and with the finding in the Framingham Study of an 1.5 fold 
increased risk of stroke in men with unrecognized MI versus men with recognized MI.6
The important question is why unrecognized MI would be associated with a much higher 
risk of stroke than recognized MI. A possible explanation is that lack of preventive treat-
ment and specific lifestyle advice contributed to a poorer prognosis after unrecognized MI. 
Support for this explanation comes from the observation that at baseline the proportions 
of former smokers and cardiovascular drug users were much higher among persons with a 
recognized than an unrecognized MI (table 1).
Another explanation would be that men with recognized MI are more likely to die, e.g. of 
a new MI, while men with unrecognized MI live longer and remain longer at risk for stroke. 
However, in our dataset the age-adjusted hazard ratios for all mortality (except fatal stroke) 
and for MI prior to stroke were not significantly increased in men with unrecognized versus 
recognized MI (HR for mortality, except stroke 1.12 (95% CI 0.83 to 1.51); HR for new MI 
0.82 (95% CI 0.45 to 1.48)).
In contrast to our findings in men, we did not find an increased risk of stroke in women 
with unrecognized MI. This was in accordance with observations in the Framingham study.6 
An explanation for the difference between men and women with unrecognized MI might 
be that men suffered a clinical stroke, whereas women suffered an asymptomatic or unrec-
ognized stroke. This may have led to underestimation of the risk of stroke in women with 
unrecognized MI. Indeed, the prevalence and incidence of asymptomatic or unrecognized 
strokes are reportedly higher in women than in men.24, 25 Studies investigating unrecognized 
MI in relation to both clinical strokes and asymptomatic strokes are needed to elucidate 
this issue.
Table 4. Multivariable adjusted hazard ratios (95% CI) for all stroke and ischemic stroke in persons with 
unrecognized or recognized MI compared to persons without MI, in strata of sex.
All stroke ischemic stroke
men women men women
HR* (95%CI) HR* (95%CI) HR* (95%CI) HR* (95%CI)
Without MI 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Unrecognized MI 2.13 (1.35-3.36) 1.25 (0.77-2.04) 2.87 (1.66-4.96) 1.35 (0.70-2.60)
Recognized MI 1.37 (0.86-2.19) 1.36 (0.75-2.46) 1.76 (1.00-3.08) 1.01 (0.41-2.51)
* Adjusted for age, systolic blood pressure, diastolic blood pressure, smoking, total and HDL cholesterol, atrial fibrillation, 
diabetes mellitus, ankle-arm pressure index and use of cardiovascular drugs.
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The risk was particularly increased for cortical ischemic strokes and not for lacunar 
ischemic strokes. This probably reflects a different etiology of these subtypes of stroke. 
A substantial proportion of cortical strokes is considered to have a cardiogenic cause, 
whereas lacunar strokes are more often caused by small vessel disease.24 Furthermore, a 
large proportion of lacunar strokes remains clinically asymptomatic and therefore are not 
reflected in our analyses.25
After adjusting for cardiovascular risk factors, the risk of stroke and ischemic stroke 
remained increased in men with unrecognized MI. There are several explanations for this. 
Firstly, unrecognized MI may give a better indication of the cardiovascular damage that 
has accumulated over time than cardiovascular risk factors measured at baseline. Secondly, 
unrecognized MI may cause global ventricular dysfunction, which may lead to formation 
of thrombi that become a source of emboli causing stroke.26 Finally, residual confound-
ing might be present in the following ways: it is possible that unrecognized MI reflect 
cardiovascular risk factors that we did not measure at baseline, such as genetic risk factors. 
Additionally, because we adjusted for baseline values of measured risk factors, change in 
risk factors during follow-up will not be accounted for. Moreover, measurement of risk 
factors might be imprecise.
At baseline, we did not report presence of unrecognized MI to participants or general 
practitioners. The decision reflected the perception at that time that an unrecognized MI 
was less severe than a recognized MI, and was motivated by lack of evidence that treatment 
after an unrecognized MI could effectively reduce the risk of subsequent cardiovascular 
events.6, 10, 27 Our study therefore adequately reflects the situation in the general elderly 
population where a large proportion of MI remains unrecognized and hence untreated. 
More recently in the Rotterdam Study, we have started to report findings of unrecognized 
MI to the participants and their general practitioners. Whether and to what extent this has 
affected the prognosis of unrecognized MI remains to be seen.
In our study, presence of unrecognized MI in men was particularly related to cortical 
ischemic strokes that produce large neurological deficits. This suggests that screening the 
elderly for unrecognized MI using EKG can contribute to identifying persons at increased 
risk of stroke. Given that EKG-systems are readily available and EKG measurements are 
easily obtained, whereas their interpretation might be facilitated by computer software,15 
EKGs could be incorporated in prevention programs for stroke. For example, men with 
unrecognized MI identified in this way, might benefit from installment of preventive treat-
ment and life-style advice. However, it remains to be investigated whether screening for 
unrecognized MI would be cost-effective.
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unrecognized myocardial infarction 
in relation to risk of Dementia and 
Cerebral Small Vessel Disease
M. Arfan Ikram, Marieke van Oijen, Frank Jan de Jong, Jan A. Kors, Peter J. Koudstaal, 
Albert Hofman, Jacqueline C.M. Witteman, Monique M.B. Breteler
ABStrACt
Background and purpose: Men, but not women, with an unrecognized myocardial infarc-
tion (MI) have an increased risk of cardiac events and stroke compared with those without 
MI or with recognized MI. We investigated whether unrecognized MI is also a risk factor for 
dementia and cerebral small vessel disease (white matter lesions (WML) and brain infarc-
tion) in two population-based cohort studies.
Methods: In the Rotterdam Study 6,347 participants were classified at baseline (1990-1993) 
into those with recognized MI (subdivided in Q-wave and non-Q-wave MI), unrecognized 
MI and without MI based on electrocardiography and interview, and were followed for 
incident dementia (n=613) until January 1st 2005. In the Rotterdam Scan Study, 436 non-
demented persons were similarly classified based on electrocardiography and interview, 
and underwent brain MR-imaging for the assessment of WML and brain infarction.
Results: In men, unrecognized MI was associated with an increased risk of dementia 
(compared with men without MI hazard ratio 2.14 (95%CI 1.37-3.35)), and with more 
WML and more often brain infarction on MRI. In women, no associations were found with 
unrecognized MI. Recognized MI was not associated with the risk of dementia in either sex. 
Men, but not women, with recognized MI had more often any brain infarction or asymp-
tomatic brain infarction, especially if they had had a Q-wave MI. No consistent associations 
were found between recognized Q-wave or non-Q-wave MI and severity of WML. Additional 
adjustment for cardiovascular risk factors did not change the results.
Conclusions: Men with unrecognized MI have an increased risk of dementia and more 
cerebral small vessel disease.
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intrODuCtiOn
In the elderly, between 21 to 68% of all myocardial infarctions (MI) that can be identified 
by electrocardiography (EKG), are asymptomatic or remain clinically unrecognized.1, 2 Men 
with an unrecognized MI have an increased risk of clinical cardiac disease when compared 
with men without MI,3-5 and even when compared with men with recognized MI.6 For 
women, no such differences have been reported. In line with the findings regarding cardiac 
disease, we found that men, but not women, with unrecognized MI also have an increased 
risk of clinical stroke compared with persons without MI or recognized MI.7 However, most 
cerebrovascular disease in the elderly occurs subclinically as small vessel disease, which 
can be visualized with magnetic resonance imaging  (MRI) as white matter lesions (WML) 
and asymptomatic (lacunar) brain infarcts.8, 9 Cerebral small vessel disease may be clinically 
asymptomatic, but is not innocuous, as it is related to an increased risk of clinical stroke,10 
cognitive decline and dementia.11-13 Whether unrecognized MI is related to cerebral small 
vessel disease is unknown.
Markers of vascular disease and vascular risk factors have been implicated in the etiology 
of dementia as well.14, 15 Few studies investigated whether recognized MI was associated 
with an increased risk of dementia, and those that did reported inconsistent results.16, 17 No 
study thus far investigated unrecognized MI in relation to risk of dementia.
We hypothesized that unrecognized MI might be an important risk factor for both cere-
bral small vessel disease and dementia. Therefore, we investigated the association of unrec-
ognized MI with dementia in the Rotterdam Study and with cerebral small vessel disease in 
the Rotterdam Scan Study. Furthermore, given the unexplained yet consistent finding of an 
especially unfavorable prognosis of unrecognized MI in men, we also examined whether 
these associations were different between men and women.
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methODS
Study populations
The Rotterdam Study is a prospective population-based cohort study of 7,983 participants 
(aged 55 years and over) from Ommoord, a district of Rotterdam, The Netherlands.18 The 
study aims to investigate determinants and causes of chronic diseases in the elderly, in-
cluding dementia. Participants gave written informed consent to participate in the study 
and to obtain information from treating physicians. At baseline (1990-1993) participants 
were interviewed and underwent physical examination and blood sampling. We excluded 
persons, who were not cognitively screened or were demented at baseline, which left a 
total of 7,046 persons eligible for the present study. Digitized EKGs were obtained in 6,347 
persons.
In 1995-1996, 563 participants from the Rotterdam Study, who were still non-demented 
and who were randomly selected by sex and 5-year age strata, participated in the Rot-
terdam Scan Study.19 In these participants a separate interview, physical examination, blood 
sampling was repeated in 1995-1996, and they also underwent a brain MRI scan. The MRI 
scan was acquired at the most two weeks after the repeat interview and examination. In 
436 of these persons we obtained a digitized EKG.
In both studies, interviews and examinations were held independently from spouse or 
other family members. Missing EKGs in both studies were random and due to technical 
problems or too few personnel to operate the apparatus. Both the Rotterdam Study and 
the Rotterdam Scan Study have been approved by the Medical Ethics Committee of the 
Erasmus Medical Center, The Netherlands.
Assessment of myocardial infarction on EKG
Assessment of MI was done as reported previously7 and similarly for both the Rotterdam 
Study and Rotterdam Scan Study. Participants were asked the following questions: “Did 
you ever experience a heart attack?” and if so, “At what age?”, “Who made the diagnosis?” 
and “Were you admitted to a hospital?”. Afterwards a 12-lead EKG was recorded with an 
ACTA-electrocardiograph (Esaote, Florence, Italy) with a sampling frequency of 500 Hz. All 
EKGs were processed by the Modular EKG Analysis System (MEANS) to obtain EKG mea-
surement and interpretation.20 MEANS determines common onsets and offsets for all 12 
leads together on one representative averaged beat, using template matching techniques.20 
To determine MI, MEANS uses a comprehensive set of criteria that partly derive from the 
Minnesota codes.21 Pathological Q-waves are central in the diagnosis of MI using MEANS. 
The MEANS program has been extensively evaluated previously.22-24 Of persons with EKG 
evidence of MI but without self-report, information from GPs and cardiologists was col-
lected to confirm that no clinically manifest MI had occurred. Additional information was 
also collected of persons with self-reported MI without EKG evidence of MI. This was 
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done to distinguish persons who had suffered a non-Q-wave MI or whose Q-wave had 
disappeared over time, from persons who mistook other symptoms for MI.
Based on this procedure, we classified participants as follows. Recognized Q-wave MI 
included persons with self-reported MI confirmed by matching EKG characteristics. Rec-
ognized non-Q-wave MI included persons with self-reported MI confirmed only by clinical 
data. Unrecognized MI were all participants without documented or self-reported MI, but 
with EKG characteristics matching an MI. All unrecognized MI were therefore Q-wave MI. 
The non-MI reference group consisted of all persons without indication of MI on EKG and 
no self-report or medical documentation of an earlier MI.
Ascertainment of incident dementia
In the Rotterdam Study the diagnosis of incident dementia was made following a three-
step protocol.25 At baseline (1990-1993) and during three follow-up visits (1993-1994, 
1997-1999, 2002-2004) two brief tests of cognition (Mini-Mental State Examination (MMSE) 
and Geriatric Mental State schedule (GMS) organic level) were used to screen all subjects. 
Screen-positives (MMSE score < 26 or GMS organic level > 0) underwent the Cambridge 
examination for mental disorders of the elderly (Camdex). Persons who were suspected of 
having dementia were examined by a neuropsychologist if additional neuropsychological 
testing was required for diagnosis. When available, imaging data were used. In addition, 
the total cohort was continuously monitored for incident dementia through computerized 
linkage between the study database and digitalized medical records from general prac-
titioners and the Regional Institute for Outpatient Mental Health Care. The diagnosis of 
dementia and major subtypes of dementia was made in accordance with internationally 
accepted criteria for dementia (DSM-III-R), Alzheimer’s disease (NINCDS-ADRDA), and vas-
cular dementia (NINDS-AIREN) by a panel of a neurologist, neuropsychologist and research 
physician. Follow-up was complete until January 1st, 2005.
MRI procedures
Within the Rotterdam Scan Study, cranial MRI scanning was performed in all participants 
with a 1.5-T scanner (VISION-MR, Siemens, Erlangen, Germany) using standard T1, T2 and 
proton-density weighted MR sequences. MRI acquisition parameters have been described.9, 
26
We obtained continuous volumetric measures of WML (expressed as percentage of intra-
cranial volume to correct for individual head-size differences) using validated automated 
image analysis.26 We defined brain infarction on MRI as focal hyperintensities on T2-weighted 
images, 3 mm in size or larger. Proton-density scans were used to distinguish infarctions 
from dilated perivascular spaces. Hyperintensities in the white matter also had to have 
corresponding prominent hypointensities on T1-weighted images, in order to distinguish 
them from WML. History of stroke and TIA was assessed by self-report and by checking 
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medical records, independent from MRI data. We defined asymptomatic brain infarctions 
as evidence of one or more infarctions on MRI without a history of corresponding TIA or 
stroke. Intrarater agreement for detection of infarcts was good (κ=0.80).26
Assessment of covariables
In both the Rotterdam Study and the Rotterdam Scan Study physical examinations were 
performed using the same protocol and computerized questionnaires were used to obtain 
information on current health status and medical history. Smoking status was verified dur-
ing the interview. Sitting blood pressure was measured on the right upper arm using a 
random-zero sphygmomanometer. We used the average of two measurements, measured at 
one occasion. Diabetes mellitus was defined as random or post-load serum glucose level 
exceeding 11.1 mmol/l or the use of oral blood glucose lowering drugs or insulin. Carotid 
intima-media thickness was measured by longitudinal 2-dimensional ultrasound of the 
carotid artery. We calculated the mean common carotid artery intima-media thickness as 
the mean of 4 locations: the near and far wall of both the right and left common carotid 
artery. Atrial fibrillation was assessed on an EKG. Serum total cholesterol and high-density 
lipoprotein cholesterol (HDL) were determined by means of an automated enzymatic 
procedure in non-fasting blood samples. Use of cardiovascular drugs was assessed by inter-
view and pharmacy records. These drugs included nitrates, antihypertensives, statins and 
antithrombotic agents, including aspirin. Genotyping of APOE was performed on coded 
DNA specimens without knowledge of the outcomes.
Statistical analysis
We tested differences in baseline demographic covariables between the three groups using 
Student’s t-test for continuous variables and χ2-test for dichotomous variables.
In the Rotterdam Study we assessed the association of recognized Q-wave MI, recog-
nized non-Q-wave MI, and unrecognized MI with risk of dementia and major subtypes of 
dementia with Cox’ proportional hazard models, adjusted for age and sex. Additionally we 
adjusted for cardiovascular risk factors. Because previous reports suggested a difference 
in prognosis of unrecognized MI between men and women,5, 7 we subsequently examined 
the association between MI and dementia in men and women separately and computed 
an interaction term between MI and sex. To assess whether the association between MI 
and dementia was mediated by stroke, we repeated the analyses excluding persons with 
prevalent stroke and censoring those with incident stroke at time of stroke.
In the Rotterdam Scan Study we used general linear models to calculate mean WML 
volume in persons with no MI, unrecognized MI, and recognized MI (Q-wave and non-Q-
wave MI separately). We used logistic regression models to calculate odds ratios for brain 
infarction in persons with recognized or unrecognized MI compared with persons without 
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MI. All analyses were adjusted for age and sex and subsequently stratified by sex. Addition-
ally, we adjusted for cardiovascular risk factors.
reSultS
Tables 1 and 2 show the characteristics of the study population. In the Rotterdam Study, 
424 participants (297 in men) had had a recognized MI, of whom 197 (130 in men) had a 
non-Q-wave MI. Of the 345 persons with unrecognized MI, 159 were men. In the Rotterdam 
Scan Study 40 persons (32 in men) had had a recognized MI, of whom 24 (19 in men) had 
a non-Q-wave MI. Twenty-two persons (6 in men) had had an unrecognized MI. In both 
studies there were no significant differences in baseline characteristics between persons 
with a recognized Q-wave MI and those with a recognized non-Q-wave MI. In both studies 
persons with recognized Q-wave MI or non Q-wave MI used more often cardiovascular 
drugs than those with unrecognized MI or without MI. Moreover, in the Rotterdam Study 
persons with unrecognized MI had a higher blood pressure and were more often smokers 
than persons without MI or with recognized Q-wave or non-Q-wave MI.
Incident dementia
During 58,712 person years of follow-up in the Rotterdam Study we identified 613 dementia 
patients, of whom 479 were diagnosed with Alzheimer’s disease, 71 with vascular dementia 
Table 1. Characteristics of the study population at baseline of the Rotterdam Study.
no mi recognized mi‡ unrecognized mi§
N 5578 424 345
Age (yrs) 68.3 (8.5) 71.2 (8.2)* 71.8 (8.8)*
Women % 61.4 30.0* 53.9*†
Presence APOE ε4 allele % 25.3 25.1 21.6 
Body mass index (kg/m2) 26.3 (4.0) 26.4 (3.4)* 27.0 (4.5)*
Current smokers % 22.9 20.3 28.1*†
Systolic blood pressure (mmHg) 139.1 (22.3) 135.2 (22.0)* 145.3 (20.6)*†
Diastolic blood pressure (mmHg) 73.9 (11.4) 70.3 (11.3)* 75.4 (11.9)*†
Cholesterol (mmol/l) 6.6 (1.2) 6.6 (1.2)* 6.6 (1.3)
HDL-cholesterol (mmol/l) 1.4 (0.4) 1.1 (0.3)* 1.3 (0.3)*†
Intima media thickness (mm) 0.78 (0.15) 0.85 (0.18)* 0.83 (0.16)*
Diabetes mellitus % 9.0 17.0* 13.0*†
Atrial fibrillation % 2.1 3.4 6.1*
Use of cardiovascular drugs % 33.0 83.0* 39.0†
Values are percentages or means (standard deviation)
* Significantly different (p-value <0.05) from persons without MI (age and sex adjusted, if applicable) 
† Significantly different (p-value <0.05) from persons with recognized MI (age and sex adjusted, if applicable)
‡ This group includes both persons with a Q-wave MI and a non-Q-wave MI. No significant differences were present between 
these two subgroups
§ This group included only persons with Q-wave MI
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and 63 with dementia due to other causes. The incidence rate of dementia among persons 
without MI was 9.95 per 1,000 person-years; among those with recognized Q-wave MI this 
was 10.28 per 1,000 person-years and among those with recognized non-Q-wave MI 15.85 
per 1,000 person-years; finally, among persons with unrecognized MI the incidence rate 
was 16.40 per 1,000 person-years.
Table 3 shows that unrecognized MI was associated with a more than doubled risk of 
dementia, but only in men. In men, unrecognized MI was associated with an increased 
risk of both Alzheimer’s disease and vascular dementia: age-adjusted hazard ratios (95% 
confidence interval (CI)) were 2.53 (1.49-4.30) for Alzheimer’s disease (126 cases) and 
2.03 (0.71-5.80) for vascular dementia (37 cases). Recognized MI was not significantly as-
sociated with the risk of dementia (table 3). The p-value of the interaction term between 
unrecognized MI and sex was <0.01, between recognized Q-wave MI and sex 0.42, and 
between recognized non-Q-wave MI and sex 0.28. Additional adjustment for cardiovascular 
risk factors did not change the estimates (table 3). Excluding previous stroke cases and 
censoring incident stroke cases at time of stroke did not attenuate the estimates either; if 
anything the association became stronger: age-adjusted hazard ratio (95% CI) for dementia 
in men with unrecognized MI was 2.33 (1.38-3.95).
Table 2. Characteristics of the study population of the Rotterdam Scan Study.
no mi recognized mi‡ unrecognized mi§
N 374 40 22
Age (yrs) 72.9 (8.0) 74.3 (7.1) 74.6 (8.1)
Women % 52.7 20.0* 72.7†
Presence APOE ε4 allele % 31.6 31.6 23.5
Body mass index (kg/m2) 26.2 (3.6) 26.5 (3.0) 26.2 (3.5)
Current smokers % 18.0 12.5 4.5
Systolic blood pressure (mmHg) 145.3 (20.9) 145.5 (20.6) 147.5 (20.7)
Diastolic blood pressure (mmHg) 76.5 (11.6) 73.2 (10.7) 77.7 (9.5)
Cholesterol (mmol/l) 5.9 (1.0) 5.9 (1.0) 5.8 (1.1)
HDL-cholesterol (mmol/l) 1.3 (0.4) 1.0 (0.2)* 1.3 (0.4)†
Intima media thickness (mm) 0.86 (0.14) 0.95 (0.18)* 0.84 (0.13)†
Diabetes mellitus % 4.0 10.0 4.5
Atrial fibrillation % 2.1 2.5 9.1
Use of cardiovascular drugs % 43.9 97.5* 72.7*†
Values are percentages or means (standard deviation)
* Significantly different (p-value <0.05) from persons without MI (age and sex adjusted, if applicable) 
† Significantly different (p-value <0.05) from persons with recognized MI (age and sex adjusted, if applicable)
‡ This group includes both persons with a Q-wave MI and a non-Q-wave MI. No significant differences were present between 
these two subgroups
§ This group included only persons with Q-wave MI
Chapter 2.3.2
90
Ta
bl
e 
3.
 T
he
 a
ss
oc
ia
tio
n 
be
tw
ee
n 
m
yo
ca
rd
ia
l i
nf
ar
ct
io
n 
an
d 
de
m
en
tia
 b
y 
se
x.
to
ta
l
m
en
w
om
en
n
/n
h
r
 (
95
%
 C
i)
*
h
r
 (
95
%
 C
i)
†
n
/n
h
r
 (
95
%
 C
i)
*
h
r
 (
95
%
 C
i)
†
n
/n
h
r
 (
95
%
 C
i)
*
h
r
 (
95
%
 C
i)
†
N
o 
M
I
52
4/
5,
57
8
1.
00
(r
ef
)
1.
00
(r
ef
)
15
7/
2,
15
4
1.
00
(r
ef
)
1.
00
(r
ef
)
36
7/
3,
42
4
1.
00
(r
ef
)
1.
00
(r
ef
)
Re
co
gn
iz
ed
 M
I
43
/4
24
1.
06
 (0
.7
8-
1.
46
)
1.
12
 (0
.7
7-
1.
64
)
20
/2
97
0.
87
 (0
.5
5-
1.
39
)
0.
89
 (0
.5
1-
1.
54
)
23
/1
27
1.
35
 (0
.8
8-
2.
06
)
1.
58
 (0
.9
4-
2.
65
)
Q
-w
av
e 
M
I
18
/2
27
0.
83
 (
0.
52
-1
.3
3)
0.
96
 (
0.
56
-2
.1
3)
9/
16
7
0.
71
 (
0.
36
-1
.3
9)
0.
79
 (
0.
36
-1
.7
0)
9/
60
1.
01
 (
0.
52
-1
.9
9)
1.
48
 (
0.
69
-3
.1
9)
no
n-
Q
-w
av
e 
M
I
25
/1
97
1.
34
 (
0.
89
-2
.0
0)
1.
30
 (
0.
79
-2
.1
3)
11
/1
30
1.
07
 (
0.
58
-1
.9
8)
1.
00
 (
0.
48
-2
.0
7)
14
/6
7
1.
69
 (
0.
99
-2
.8
9)
1.
66
 (
0.
85
-3
.2
5)
U
nr
ec
og
ni
ze
d 
M
I
46
/3
45
1.
22
 (0
.9
0-
1.
65
)
1.
35
 (0
.9
5-
1.
92
)
22
/1
59
2.
14
 (1
.3
7-
3.
35
)
2.
23
 (1
.2
4-
4.
01
)
24
/1
86
0.
87
 (0
.5
8-
1.
32
)
1.
17
 (0
.7
4-
1.
83
)
n:
 n
um
be
r 
of
 d
em
en
tia
 c
as
es
, N
: t
ot
al
 n
um
be
r 
of
 p
er
so
ns
, H
R:
 h
az
ar
d 
ra
tio
, C
I: 
co
nfi
de
nc
e 
in
te
rv
al
* a
dj
us
te
d 
fo
r 
ag
e 
an
d 
se
x 
(if
 a
pp
lic
ab
le
)
† 
ad
ju
st
ed
 fo
r 
ag
e,
 s
ex
 a
nd
 a
dd
iti
on
al
ly
 a
dj
us
te
d 
fo
r 
pr
es
en
ce
 o
f A
PO
E 
ε4
 a
lle
le
, s
ys
to
lic
 b
lo
od
 p
re
ss
ur
e,
 d
ia
st
ol
ic
 b
lo
od
 p
re
ss
ur
e,
 b
od
y 
m
as
s 
in
de
x,
 a
tr
ia
l fi
br
ill
at
io
n,
 d
ia
be
te
s 
m
el
lit
us
, c
ur
re
nt
 s
m
ok
in
g,
 
in
tim
a 
m
ed
ia
 th
ic
kn
es
s, 
to
ta
l c
ho
le
st
er
ol
 a
nd
 h
ig
h-
de
ns
ity
 li
pi
d 
ch
ol
es
te
ro
l
Ta
bl
e 
4.
 T
he
 a
ss
oc
ia
tio
n 
be
tw
ee
n 
m
yo
ca
rd
ia
l i
nf
ar
ct
io
n 
an
d 
br
ai
n 
in
fa
rc
tio
n 
by
 s
ex
.
O
r
 (
95
%
 C
i)
 fo
r 
an
y 
br
ai
n
 in
fa
rc
ti
on
O
r
 (
95
%
 C
i)
 fo
r 
as
ym
pt
om
at
ic
 b
ra
in
 in
fa
rc
ti
on
to
ta
l
m
en
w
om
en
to
ta
l
m
en
w
om
en
N
o 
M
I
1.
00
(r
ef
)
1.
00
(r
ef
)
1.
00
(r
ef
)
1.
00
(r
ef
)
1.
00
(r
ef
)
1.
00
(r
ef
)
Re
co
gn
iz
ed
 M
I
3.
57
 (1
.7
4-
7.
34
)
3.
50
 (1
.5
4-
7.
96
)
4.
33
 (0
.9
2-
20
.2
8)
3.
25
 (1
.4
9-
7.
09
)
3.
35
 (1
.3
9-
8.
07
)
3.
32
 (0
.6
0-
18
.5
1)
Q
-w
av
e 
M
I
6.
39
 (
2.
13
-1
9.
16
)
6.
98
 (
2.
06
-2
3.
70
)
4.
63
 (
0.
38
-5
7.
11
)
5.
41
 (
1.
63
-1
7.
96
)
6.
50
 (
1.
75
-2
4.
15
)
2.
30
 (
0.
12
-4
5.
20
)
no
n-
Q
-w
av
e 
M
I
2.
41
 (
0.
97
-5
.9
9)
2.
13
 (
0.
75
-6
.1
1)
4.
17
 (
0.
61
-2
8.
60
)
2.
39
 (
0.
91
-6
.2
8)
2.
17
 (
0.
72
-6
.6
0)
3.
95
 (
0.
50
-3
1.
03
)
U
nr
ec
og
ni
ze
d 
M
I
2.
36
 (0
.9
3-
5.
97
)
7.
19
 (1
.1
7-
44
.0
7)
1.
51
 (0
.4
9-
4.
66
)
2.
43
 (0
.9
3-
6.
34
)
6.
49
 (0
.9
3-
45
.2
9)
1.
74
 (0
.5
6-
5.
38
)
Va
lu
es
 a
re
 o
dd
s-r
at
io
s 
(O
R)
 w
ith
 9
5%
 c
on
fid
en
ce
 in
te
rv
al
s 
(C
I)
, a
dj
us
te
d 
fo
r 
ag
e 
an
d 
se
x 
(if
 a
pp
lic
ab
le
)
91
Unrecognized myocardial infarction, dementia and small vessel disease
MRI outcomes
In the Rotterdam Scan Study, we found that men with unrecognized MI had on average 
more WML than men without MI (figure 1). Volume of WML did not differ between men 
with recognized Q-wave or non-Q-wave MI and men without MI. In contrast, women with 
unrecognized MI had an average WML load that was similar to that of women without MI. 
Women with a recognized Q-wave MI had on average more WML than women without MI. 
However, the interaction term between unrecognized MI and sex was significant (p=0.02), 
whereas the interaction term between recognized Q-wave MI and sex was not (p=0.07).
After adjustment for cardiovascular risk factors, the results were slightly attenuated, but 
the difference in volume of WML between men with unrecognized MI and without MI 
remained significant (fully adjusted difference in WML volume 1.18% (95%CI 0.08-2.29)).
Of the 374 persons without MI 90 had a brain infarction on MRI (75 of these were asymp-
tomatic). Among the 16 persons with recognized Q-wave MI 10 had a brain infarction (7 
asymptomatic). Among the 24 persons with recognized non-Q-wave MI 10 had a brain 
infarction (8 asymptomatic). Finally, among the 22 persons with unrecognized MI 10 had a 
brain infarction (9 asymptomatic). Men with a recognized MI were more likely to have any 
brain infarction or an asymptomatic brain infarction on their MRI scan than men without 
MI, especially if they had had a recognized Q-wave MI (odds ratio 6.98 (95% CI 2.06 to 
23.70); table 4). Likewise, the prevalence of any brain infarctions was more than 7-fold 
increased in men with unrecognized MI (table 4). Women with a recognized MI had a 
non-significantly increased prevalence of brain infarction on MRI, similarly for Q-wave and 
non-Q-wave MI. In contrast, unrecognized MI was not associated with the presence of 
Figure 1. Association between myocardial infarction and volume of white matter lesions (n=436). Volume is expressed as 
percentage of intra-cranial volume to adjust for head-size differences. Bars represent means, adjusted for age and sex (if applicable); 
lines represent standard errors. * significantly different from persons without MI (p<0.05).
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brain infarction in women. The p-values of the interaction term between unrecognized MI 
and sex were 0.15 for any brain infarction and 0.25 for asymptomatic brain infarction. The 
corresponding p-values of the interaction term between recognized Q-wave MI and sex 
were 0.77 for any brain infarction and 0.53 for asymptomatic brain infarction; and between 
recognized non-Q-wave MI and sex 0.55 for any brain infarction and 0.62 for asymptomatic 
brain infarction. Adjusting for cardiovascular risk factors did not change the associations. 
If anything, the odds-ratio of brain infarction associated with unrecognized MI became 
stronger in men (full-adjusted odds ratio 8.79 (95% CI 1.06-73.17)).
DiSCuSSiOn
We found that men, but not women, with unrecognized MI had an increased risk of demen-
tia, more WML, and more often any brain infarction or an asymptomatic brain infarction 
compared with those without MI, even when known cardiovascular risk factors were 
accounted for. Recognized MI, both Q-wave and non-Q-wave, was not associated with the 
risk of dementia in either sex. Men, but not women, with recognized MI had more often 
any brain infarction or an asymptomatic brain infarction on MRI, especially if they had 
had a Q-wave MI. No consistent associations were found between recognized Q-wave or 
non-Q-wave MI and severity of WML.
The strengths of our studies include the population-based setting, the large number of 
participants, and the virtually complete follow-up for dementia. Moreover, we focused on 
clinical and subclinical manifestations of both cardiac and cerebrovascular disease. A limita-
tion is the cross-sectional study design of the Rotterdam Scan Study, which might limit our 
interpretation of the data with respect to the temporal relationship between MI and MRI 
parameters. Another possible limitation could be that MI on EKG was diagnosed using 
the MEANS computer program, which might have led to misclassification. However, this 
program has been extensively validated and diagnoses correlate well with diagnoses made 
by an experienced cardiologist.20, 23 Also, any misclassification is likely to be non-differential 
since MEANS diagnoses were made independent from clinical diagnosis of dementia and 
assessment of MRI outcomes.
Most studies reporting on the prognosis of unrecognized MI did not investigate neu-
rological outcomes, but focused on cardiac events.3, 4 Only the Rotterdam Study and the 
Framingham study have looked at clinical stroke separately.5, 7 In the present study we 
focused on dementia and cerebral small vessel disease.
Our observation regarding the association between unrecognized MI and subclinical ce-
rebral small vessel disease is in line with our previous report with respect to clinical stroke.7 
Indeed, both clinical and subclinical cerebrovascular disease have been shown to be closely 
associated with each other10, 27, 28 and to share similar (cardiovascular) risk factors.29
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In turn, our finding that persons with unrecognized MI have an increased risk of demen-
tia fits well with previous studies reporting that markers of vascular disease and vascular 
risk factors are involved in the pathogenesis of dementia,14, 15 presumably by leading to 
subclinical cerebral small vessel disease.30, 31
Moreover, we found that the increased risk was confined to men, and not women. This 
is in accordance with studies that showed an increased risk of cardiovascular morbidity 
and clinical stroke in men with unrecognized MI, but not in women.5, 7 An explanation for 
this difference between men and women might be the higher background prevalence of 
cerebrovascular disease in men compared with women. Another possibility is that misclas-
sification of MI on EKG may occur more often in women. EKG abnormalities that can be 
mistaken for MI, but are not caused by coronary disease are more often seen in women 
than in men, possibly caused by difficulties in correctly placing the electrodes due to breast 
tissue.32 Because of this possible non-differential misclassification of our determinant, dilu-
tion of the effect might have occurred and therefore the true effect may have been missed 
in women in our dataset. Such misclassification might also explain the higher prevalence 
of unrecognized MI among women than men. Finally, to rule out the possibility that sex 
differences occurred by chance, other studies should seek to replicate our findings.
In contrast to our findings in persons with unrecognized MI, we did not find consistent 
associations of recognized MI, neither Q-wave nor non-Q-wave MI with dementia, WML 
or brain infarction, for either sex. We only found statistically significant associations for 
recognized Q-wave MI with any brain infarction or an asymptomatic brain infarction in 
men and with WML in women. This is in line with published data on differences between 
unrecognized and recognized MI with respect to prognosis for cardiovascular morbidity.6, 7 
A possible explanation for this difference is that inherent lack of preventive treatment and 
specific lifestyle advice contributed to a poorer prognosis after unrecognized MI. Support 
for this comes from the observation that in both the Rotterdam Study and Rotterdam Scan 
Study the proportions of cardiovascular drug users were higher among persons with a 
recognized than with an unrecognized MI. Still, adjusting for cardiovascular risk factors did 
not change the associations. This may indicate that unrecognized MI gives a better indica-
tion of the cardiovascular damage that has accumulated over time than cardiovascular risk 
factors measured only once at baseline.
In conclusion, our study shows that presence of unrecognized MI is associated with 
an increased risk of dementia and a higher prevalence of cerebral small vessel disease in 
men, but not in women. Given the large proportion of MI that remain unrecognized in the 
general elderly population,1 our data suggest that screening men for unrecognized MI using 
EKG might identify those at an increased risk of various adverse outcomes. These persons 
could then benefit from subsequent installment of preventive therapy. However, before 
such screening is initiated, our results first need to be replicated in other population-based 
studies.
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ABStrACt 
Cerebral hypoperfusion has been associated with worse cognitive function. We investigated 
the association between cerebral blood flow and cognition and whether this association is 
independent of brain volume. In 892 participants aged 60-91 years of the population-based 
Rotterdam Scan Study, we measured total cerebral blood flow (tCBF) and brain volume 
using MRI. Lower tCBF was associated with worse information processing speed, execu-
tive function and global cognition. However, after correcting tCBF for brain volume, these 
associations disappeared. The association between tCBF and cognition may be mediated 
or confounded by brain atrophy. Future studies on tCBF should take into account brain 
atrophy.
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intrODuCtiOn
Elderly persons often suffer from deterioration of cognitive function. Vascular risk factors 
may contribute to cognitive impairment by affecting blood flow to the brain.1 Moreover, 
it has been suggested that cerebral hypoperfusion precedes and possibly contributes to 
onset of clinical dementia.2 To assess perfusion at the brain tissue level is difficult as most 
measurement techniques are invasive and complex. Phase-contrast magnetic resonance 
imaging (MRI) enables fast and accurate measurement of total cerebral blood flow (tCBF) 
and has shown to be applicable in population-based studies.3 Previous studies showed that 
lower tCBF assessed with phase-contrast MRI was related to poorer cognition, in particu-
lar information processing speed, and dementia.4, 5 However, these studies did not assess 
whether this association was independent of brain atrophy. It can be hypothesized that 
smaller brain volume leads to decreased cerebral metabolic demand, and as such confounds 
the association between cerebral blood flow and cognitive function.
Thus, the aim of our study was to investigate whether diminished cerebral blood flow is 
associated with specific domains of cognitive function independent of brain volume. 
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methODS
Participants
This study is embedded within the Rotterdam Study, a large population-based cohort study 
in the Netherlands.6 The original study population consisted of 7,983 participants aged 
55 years and older from the Ommoord area, a suburb of Rotterdam. In 2000, the cohort 
was expanded with 3,011 persons (≥ 55 years).6 From August 2005 to May 2006, we 
randomly selected 1,073 members of this cohort expansion for participation in the Rot-
terdam Scan Study, a population based brain-imaging study. After exclusion of individuals 
who were demented or had MRI contraindications 975 persons were eligible, of whom 
907 participated and gave written informed consent. Due to physical inabilities (e.g. back 
pain), imaging could not be performed or completed in 12 individuals. Therefore, a total of 
895 complete MR examinations were performed. The institutional review board approved 
the study.
MRI scan protocol
MRI of the brain was performed on a 1.5-Tesla MRI scanner (General Electric Healthcare, 
Milwaukee, WI, USA), using an 8-channel head coil. For flow measurement, 2D phase-contrast 
imaging was performed as described previously.7 In brief, a sagittal 2D phase-contrast MRI 
angiographic scout image was performed. On this scout image, a transverse imaging plane 
perpendicular both to the precavernous portion of the internal carotid arteries and to 
the middle part of the basilar artery was chosen for a 2D gradient-echo phase-contrast se-
quence (repetition time= 20ms, echo time= 4 ms, field-of-view= 19 cm2, matrix= 256x160, 
flip angle= 8°, number of excitations= 8, bandwidth= 22.73 kHz, velocity encoding= 120 
cm/s, slice thickness= 5 mm). For an example, see (Vernooij et al. 2007). Acquisition time 
was 51 seconds, and no cardiac gating was performed.3 We further performed three high-
resolution axial MRI sequences, i.e. a T1 weighted sequence, a proton-density weighted 
sequence, and a fluid attenuated inversion recovery (FLAIR) sequence.7
Measurement of tCBF and total brain perfusion
Flow was calculated from the phase-contrast images using Interactive Data Language 
(IDL)-based custom software (Cinetool version 4, General Electric Healthcare, Milwaukee, 
WI, USA).7 Two independent experienced technicians drew all manual regions of interest 
(ROI) drawing and performed subsequent flow measurements (inter rater correlations 
(n=533) > 0.94 for all vessels).7 In three persons, tCBF could not be measured due to 
incorrect positioning of the phase-contrast imaging plane, leaving a total of 892 persons 
in our analysis. 
We calculated total brain perfusion (in ml/min per 100 ml) by dividing tCBF (ml/min) by 
each individual’s brain volume (ml) and multiplying the obtained result by 100.7
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Assessment of brain volume
For the assessment of brain volume, the structural MRI scans (T1-weighted, PD-weighted, 
FLAIR) were transferred to a Linux workstation. Preprocessing steps and the classification 
algorithm have been described elsewhere.8 In summary, preprocessing included coreg-
istration, nonuniformity correction and variance scaling. We used the k-nearest neighbor 
classifier9 to classify scans into brain tissue and cerebrospinal fluid using the multispectral 
MR intensities. All segmentation results were visually inspected and if needed manually cor-
rected. To remove non-cerebral tissue, e.g. eyes, skull, and cerebellum, we applied nonrigid 
registration10 to register to each brain a template scan in which these tissues were manually 
masked. Brain volume was calculated by summing all voxels across the whole brain, to 
yield volumes in ml.
Cognitive function
Cognitive function was assessed with a neuropsychological test battery comprising the 
Mini-Mental State Examination (MMSE), the Stroop test, the Letter-Digit Substitution Task 
(LDST)(number of correct digits in one minute), the Word Fluency Test (WFT) (animal 
categories), and a 15-Word Verbal Learning Test (15-WLT) (based on Rey’s recall of words).11 
For each participant z-scores were calculated for each test separately (individual test score 
minus mean test score divided by the standard deviation), except for MMSE. To obtain 
more robust measures, we constructed compound scores for information processing 
speed, executive function, memory and global cognitive function. The compound score for 
information processing speed was the average of the z-scores for the Stroop reading and 
Stroop color naming subtask and the LDST. Executive function included the z-scores of the 
Stroop interference subtask, the LDST and the WFT (number of animals in one minute). 
The compound score for memory was the average of the z-scores for the immediate and 
delayed recall of the 15-WLT. For global cognitive function we used the average of the 
z-scores of the Stroop test (average of the reading, color naming and interference subtask), 
the LDST, the WFT, and the immediate and delayed recall of the 15-WLT.11
Covariates
We assessed the level of education and current smoking by interview. Systolic and diastolic 
blood pressures were measured twice on the right arm with a random-zero sphygmoma-
nometer. The mean of the two readings was used in the analyses. Diabetes mellitus was 
defined as the use of blood glucose-lowering medication or fasting serum glucose level ≥ 
7.0 mmol/l. Carotid plaque score was assessed by Doppler ultrasound.12
Data analysis
We evaluated the association of both tCBF (ml/min) and total brain perfusion (ml/min per 
100 ml brain tissue) per standard deviation (SD) increase with cognitive function using 
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multiple linear regression models. All analyses were adjusted for age, sex and education. To 
examine whether associations were independent of vascular risk factors, we additionally 
adjusted for current smoking, systolic and diastolic blood pressure, diabetes mellitus and 
carotid plaque score.
reSultS
Characteristics of the study population are shown in Table 1. Lower tCBF was associated 
with worse performance on tests of information processing speed, executive function and 
global cognition, but not with MMSE score and memory performance (Table 2).
Total brain volume was a strong determinant of tCBF (per SD increase in brain volume 
36.00 ml/min increase in tCBF; 95% confidence interval 30.00; 42.10). The associations of 
tCBF with cognition disappeared upon correcting for brain volume (Table 2). Adjustments 
for vascular risk factors did not change any of these associations (Table 2). 
DiSCuSSiOn
We found that persons with a low tCBF performed significantly worse on tasks assessing 
information processing speed, executive function and global cognitive function compared 
with persons with higher tCBF. However, total brain perfusion, indicating the flow in ml per 
100 ml of brain tissue volume, was not associated with cognitive function. Adjustments for 
vascular risk factors did not change the results.
Table 1. Characteristics of the Study Population.
Characteristics Participants (n=892)
Men, n 441 (49.4)
Age, years 67.5 (5.5)
Primary education, n 38 (4.4 %)
Systolic Blood Pressure, mmHg 143.8 (18.5)
Diastolic Blood Pressure, mmHg 81.0 (10.2)
Diabetes Mellitus, n 85 (9.6 %) 
Current Smokers, n 267 (29.9 %)
Plaques in Carotid Artery, range 0-12* 3.0 (1.0-5.0)
Mini Mental State Examination, score 27.9 (1.8)
Brain Volume, ml 976.8 (114)
Total Cerebral Blood Flow, ml/min 497.4 (86.2)
Total Brain Perfusion, ml/min/100ml brain tissue 51.2 (8.8)
Values are means (SD) or numbers (percentages)
* median, interquartile range
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Before interpreting the results, some method-
ological issues need to be addressed. The strengths 
of our study are its population-based setting, the 
high response rate and the large sample size. A 
limitation is the cross-sectional design, which re-
stricts our interpretation of the data with respect 
to cause and consequence. Furthermore, we only 
assessed average brain perfusion. Hence, we can-
not exclude that brain perfusion in distinct brain 
regions may relate differently to cognitive perfor-
mance. Finally, we could not measure blood flow 
into the cerebellum as we measured blood flow 
in the basilar artery at the level after the anterior 
and posterior inferior cerebellar arteries arise. 
It can be hypothesized that cerebral hypoperfu-
sion causes brain atrophy that subsequently leads 
to cognitive decline.1, 13 On the other hand, it may 
also be that because of a diminished demand, 
brain atrophy itself affects cerebral blood flow. 
Thus, the association between tCBF and cogni-
tive function may be mediated or confounded by 
brain atrophy. 
In the past, CBF velocity measured by Transcra-
nial Doppler ultrasonography has been used as 
a proxy measure for cerebral blood flow. Several 
studies using CBF velocity reported that subjects 
with greater CBF velocity were less likely to have 
dementia.2 Furthermore, a greater CBF velocity 
was found to be related with larger hippocampal 
and amygdalar volumes.2 
More recently, associations of tCBF with speed, 
executive function4 and dementia5 were found us-
ing phase-contrast MRI. Our data are in line with 
these studies, since we also found the strongest 
associations for cognitive domains of speed and 
executive function.4, 5 However, none of those 
previous studies assessed whether the associa-
tions between cerebral blood flow and cognitive 
function were independent of brain volume. We T
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went a step further by correcting for brain volume, and found no associations between 
total brain perfusion and cognitive function.
Thus far, only a few small studies reported that regional patterns of hypoperfusion in 
the brain may relate to cognitive decline or dementia independent of global differences.14, 
15 As mentioned, we could not evaluate this in our study. Further studies are needed to 
investigate this.
In conclusion, our findings show that the relation between total cerebral blood flow 
and worse performance on several domains of cognitive function is dependent on brain 
volume.
Our study emphasizes that future studies on tCBF should take into account brain atrophy.
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ABStrACt
A relation between vascular disease and brain atrophy has been suggested, but evidence 
remains limited. Retinal vessels may reflect the condition of intracerebral vessels. Par-
ticularly, wider retinal venular diameters are associated with cerebrovascular disease. We 
investigated whether retinal vessel diameters are related to brain atrophy in 683 elderly 
persons (mean age 67.0 and 52% women). Retinal arteriolar and venular diameters were 
semi-automatically measured on digitized fundus transparencies. Using automated quanti-
fication of MRI-scans we obtained whole-brain volume and volumes of grey matter, white 
matter, and white matter lesions (WML). Brain infarcts were rated visually. Both arteriolar 
and venular diameters were associated with whole brain volume. However, venular diam-
eter but not arteriolar diameter was associated with white matter volume. This association 
was independent from cardiovascular risk factors. Arteriolar diameter was associated with 
WML, but this attenuated after adjustment.  No associations were found with grey matter 
volume or brain infarcts. Our data provide further evidence that vascular pathology as 
reflected by wider venular diameter is associated with brain atrophy, particularly white 
matter atrophy.
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intrODuCtiOn
Cerebral small vessel disease (white matter lesions (WML) and brain infarcts) and cardio-
vascular risk factors have been associated with whole-brain atrophy.1-3 Studies investigating 
grey matter (GM) and white matter (WM) separately suggested that these associations were 
stronger for WM atrophy than GM atrophy.4, 5
Retinal vessels may reflect the condition of the intracerebral vessels.6-8 Whereas previous 
studies reported on the ratio of retinal arterioles to venules (AV-ratio), it is now increas-
ingly being recognized that arterioles and venules differ with respect to determinants and 
outcomes.9-12 Narrower arterioles are related to blood pressure and hypertension, while 
wider venules are associated with atherosclerosis, hypoxia, inflammation, and also stroke.11, 
13-17 This distinct pattern between arterioles and venules was further confirmed by a recent 
study showing smaller arteriolar diameter to be associated with poorer large vessel compli-
ance and larger venular diameter with poorer compliance of small vessels.18
Previously, a lower AV-ratio has also been related with visually rated whole-brain atrophy 
scores.19 However, arteriolar and venular diameters have not been studied separately. More-
over, that previous study did not investigate GM and WM separately.
We investigated how retinal arteriolar and venular diameters are related to volumetric 
measures of whole-brain atrophy and WM and GM atrophy separately.
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methODS
Study population
The Rotterdam Study is a population-based cohort study ongoing since 1990.20 The cohort 
was expanded in 2000-2002 with 3,011 persons (≥ 55 years), who underwent a follow-up 
examination, including eye examinations, in 2002-2004. Between August 2005 and May 2006, 
we randomly invited 1,073 of the 3,011 persons for participation in the Rotterdam Scan 
Study. The institutional review board approved the study. We excluded persons who were 
demented (as assessed by a three-step protocol21) or who had MRI contraindications. This 
left 975 eligible persons, of whom 907 participated and gave written informed consent. 
Complete and usable MRI examinations were available in 871 persons; missing datasets 
were mostly due to claustrophobia or motion artifacts. Eye examinations including fundus 
transparencies were available in 775 of those 871 participants. After additional exclusion of 
92 subjects with ungradable fundus transparencies on both eyes, a sample of 683 persons 
remained for the current study. The mean duration between the eye examinations and the 
MRI scan was 1.0 year (SD 0.5 years).
Assessment of retinal vessels
Fundus transparencies were taken centered on the optic disc after pharmacological mydria-
sis, and digitized with a high-resolution scanner.14 For each participant the qualitatively best 
digitized image of either eye was analyzed with the Retinal Vessel Measurement System.22 
Retinal arteriolar and venular diameters were measured and summarized using Parr-Hubbard-
Knudtson formulas and Littmann’s formula to adjust for refractive errors of the eye.11 Two 
trained graders performed the assessments, masked to participants’ clinical characteristics. 
Pearson’s correlation coefficients for intergrader agreement were 0.87 for arteriolar and 
0.91 for venular diameters. Intragrader agreement ranged from 0.65 to 0.86.14
Assessment of brain parameters
Brain MRI was performed on a 1.5-Tesla scanner and included T1 weighted, proton-density 
weighted, and FLAIR sequences. Imaging parameters and classification algorithms have 
been described elsewhere.5, 14 In summary, we used the k-nearest neighbor classifier to 
classify scans into cerebrospinal fluid, GM, normal WM, and WML. Validation results against 
manual segmentations have been reported and were very good to excellent.5 We removed 
non-cerebral tissue with validated non-rigid registration23 to register to each brain a tem-
plate scan in which these tissues were manually masked.
Lacunar infarcts were rated visually and defined as lesions ≥ 3 mm in size exhibiting 
the same signal characteristics as cerebrospinal fluid on all sequences, and, if located su-
pratentorially, with a hyperintense rim on the FLAIR sequence. Cortical infarcts were those 
infarcts showing involvement of cortical gray matter.5, 24
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Assessment of covariates
We used the following cardiovascular risk factors measured in 2002-2004 as possible 
confounders: smoking status (current, former, or never), blood pressure, atherosclerotic 
plaques in the carotid artery, body mass index, fasting serum total and HDL cholesterol, 
leukocyte count, diabetes mellitus, and arteriolar oxygen saturation. Details on the assess-
ment of these covariates have been described.14
Statistical analysis
All volumes were expressed as percentage of intra-cranial volume to correct for head-size. 
Whole-brain volume was defined as intra-cranial volume minus cerebrospinal fluid volume. 
Total WM was defined as normal WM plus WML. WML were further natural log transformed 
because of skewness of the untransformed measure.
To enable better comparison between the effects of retinal vessels on different tissue 
types we calculated z-scores for each tissue type separately (z-score = (tissue volume - 
mean tissue volume) / SD). We investigated the association of retinal vessels with brain 
tissue volumes and WML volume using linear regression models and with lacunar infarcts 
using logistic regression models. 
All analyses were adjusted for age, sex, and following recent recommendations9 the other 
vessel diameter (analyses of venular diameter adjusted for arteriolar diameter and vice 
versa). Next, we adjusted for cardiovascular risk factors. Subsequently, we redid all analyses 
after excluding persons with a cortical infarct on MRI (n=16).
reSultS
The table shows the characteristics of persons with gradable and no or ungradable fundus 
transparencies. Persons with no or non-gradable transparancies were significantly older 
than those with good quality transparencies, but no other differences were present be-
tween the two groups. Seventy-six persons had a brain infarct on MRI, of whom 60 had 
lacunar infarcts only. The Figure shows the associations between retinal vessel diameters 
and brain tissue volumes. Both narrower arterioles and wider venules were associated with 
smaller whole-brain volume. For narrower arterioles this was due to both smaller GM and 
WM volumes, but not statistically significantly. In contrast, for wider venules the smaller 
brain volume was not due to smaller GM volume, but instead significantly due to smaller 
(normal and total) WM volume. Finally, narrower arteriolar diameter was significantly as-
sociated with larger WML volume.
Adjusting for cardiovascular risk factors hardly changed the associations of larger venu-
lar diameter with normal WM (–0.08 (95%CI –0.17;0.01)) and total WM (–0.08 (95%CI 
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–0.17;0.01)). However, the association of arterioler diameter with WML attenuated (–0.05 
(95%CI –0.14;0.04)).
No associations were seen between retinal vessel diameters and any brain infarct (odds-
ratio per SD increase in arteriolar diameter: 0.98 (95%CI 0.73;1.32); odds-ratio per SD 
increase in venular diameter: 1.02 (95%CI 0.76;1.37)).
Excluding persons with cortical infarcts did not change any of the associations.
DiSCuSSiOn
In this population-based study both narrower arterioles and wider venules were associ-
ated with whole-brain atrophy. However, wider venules but not narrower arterioles were 
associated with WM atrophy, independent from cardiovascular risk factors. Narrower 
arterioles were associated with more WML, but this association attenuated after adjusting 
for cardiovascular risk factors.
Strengths of our study include the population-based setting, large sample size and the 
quantitative assessment of separate brain tissue volumes on MRI. Since participants were 
from the cohort expansion, no overlap exists with individuals in our previous studies on 
retinal vessels. A limitation is the cross-sectional study design, which limits the interpreta-
tion of the results with respect to cause and effect.
table. Characteristics of the study population
Variable Gradable transparencies
n = 683
No or non-gradable 
transparencies
n = 188
Age, years 67.0 (5.0) 69.0 (6.5) *
Women, n 357 (52%) 86 (46%)
Carotid plaques, score 2.80 (2.65) 3.39 (2.99)
Systolic blood pressure, mmHg 143 (18) 146 (20)
Diastolic blood pressure, mmHg 81 (10) 81 (10)
Total cholesterol, mmol/l 5.7 (0.9) 5.7 (1.0)
High density lipoprotein cholesterol, mmol/l 1.4 (0.4) 1.4 (0.4)
Diabetes, n 59 (9%) 25 (13%)
Body mass index, kg/m2 27.5 (3.9) 27.6 (3.1)
Current smoking, n 199 (29%) 59 (31%)
Past smoking, n 275 (40%) 79 (42%)
Leukocyte count, 109/l 6.7 (1.8) 6.6 (1.5)
Arterial oxygen saturation, % 96.7 (1.2) 96.6 (1.1)
Arteriolar diameter, μm 149 (15) NA
Venular diameter, μm 232 (22) NA
Values are unadjusted means (standard deviation) or number (percentages)
* significantly different from persons with gradable transparencies (sex-adjusted p-value<0.05)
NA: not applicable
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Retinal vessels and structural brain changes
This report expands on recent findings that retinal arteriolar and venular diameters differ 
with respect to determinants and clinical correlates.9, 10, 12, 13, 15, 25 Previously, wider venules 
were shown to be related with atherosclerosis, hypoxia, and inflammation,13, 14 which are 
known risk factors for cerebral small vessel disease. Moreover, whereas narrower arterioles 
have been associated with large vessel compliance, wider venular diameter correlates with 
poorer compliance of small vessels.18 In turn, small vessel disease both in the brain and in 
other parts of the body is closely associated with WM atrophy.2, 4, 5 Accordingly, we showed 
that wider venular diameter was associated with WM atrophy. Therefore, our data provide 
further evidence that vascular pathology as reflected by wider venular diameter may play a 
role in the pathogenesis of cerebral small vessel disease and WM atrophy.
We also found that additional adjustment for cardiovascular risk factors only marginally 
changed the association between venular diameter and WM atrophy. An explanation is that 
venular diameter is an independent and perhaps better marker of WM atrophy than those 
risk factors. Another possibility is that venules reflect risk factors for WM atrophy that we 
did not measure in our study, e.g. genetic factors.
Our study showed an association between arteriolar diameter and WML. This is seem-
ingly in contrast to our previous report showing venular diameters to be related with 
WML and brain infarcts.16 However, in our previous report we did not find any association 
cross-sectionally, but only with progression of WML and brain infarcts in a longitudinal 
analysis. Indeed, in the current report we also do not find an association cross-sectionally 
between retinal vessel diameters and brain infarcts. Moreover, the cross-sectional associa-
tion between arteriolar diameter and WML attenuated after adjustment for cardiovascular 
risk factors.
Finally, we did not find an association between retinal vessel diameters and GM atrophy, 
which fits our previous reports suggesting that vascular risk factors are more associated 
with WM atrophy than GM atrophy.4, 5
In conclusion, we found that wider venular diameters are related to WM atrophy, provid-
ing further insights into the vascular basis of brain atrophy, particularly WM atrophy, and 
cerebral small vessel disease.
referenCeS
 1. DeCarli C, Massaro J, Harvey D, Hald J, Tullberg M, Au R, Beiser A, D’Agostino R, Wolf PA. Measures 
of brain morphology and infarction in the framingham heart study: establishing what is normal. 
Neurobiol Aging. 2005;26:491-510
 2. Jernigan TL, Archibald SL, Fennema-Notestine C, Gamst AC, Stout JC, Bonner J, Hesselink JR. 
Effects of age on tissues and regions of the cerebrum and cerebellum. Neurobiol Aging. 
2001;22:581-594
Chapter 2.5
112
 3. Schmidt R, Launer LJ, Nilsson LG, Pajak A, Sans S, Berger K, Breteler MM, de Ridder M, Dufouil 
C, Fuhrer R, Giampaoli S, Hofman A. Magnetic resonance imaging of the brain in diabetes: the 
Cardiovascular Determinants of Dementia (CASCADE) Study. Diabetes. 2004;53:687-692
 4. Ikram MA, Vernooij MW, Hofman A, Niessen WJ, van der Lugt A, Breteler MM. Kidney function is 
related to cerebral small vessel disease. Stroke. 2008;39:55-61
 5. Ikram MA, Vrooman HA, Vernooij MW, van der Lijn F, Hofman A, van der Lugt A, Niessen WJ, 
Breteler MM. Brain tissue volumes in the general elderly population. The Rotterdam Scan Study. 
Neurobiol Aging. 2008;29:882-890
 6. Baker ML, Hand PJ, Wang JJ, Wong TY. Retinal signs and stroke: revisiting the link between the 
eye and brain. Stroke. 2008;39:1371-1379
 7. Qiu C, Cotch MF, Sigurdsson S, Garcia M, Klein R, Jonasson F, Klein BE, Eiriksdottir G, Harris TB, 
van Buchem MA, Gudnason V, Launer LJ. Retinal and cerebral microvascular signs and diabetes: 
the age, gene/environment susceptibility-Reykjavik study. Diabetes. 2008;57:1645-1650
 8. Wong TY, Klein R, Sharrett AR, Couper DJ, Klein BE, Liao DP, Hubbard LD, Mosley TH. Cerebral 
white matter lesions, retinopathy, and incident clinical stroke. Jama. 2002;288:67-74
 9. Liew G, Sharrett AR, Kronmal R, Klein R, Wong TY, Mitchell P, Kifley A, Wang JJ. Measurement 
of retinal vascular caliber: issues and alternatives to using the arteriole to venule ratio. Invest 
Ophthalmol Vis Sci. 2007;48:52-57
 10. Wong TY, Kamineni A, Klein R, Sharrett AR, Klein BE, Siscovick DS, Cushman M, Duncan BB. 
Quantitative retinal venular caliber and risk of cardiovascular disease in older persons: the 
cardiovascular health study. Arch Intern Med. 2006;166:2388-2394
 11. Ikram MK, de Jong FJ, Vingerling JR, Witteman JC, Hofman A, Breteler MM, de Jong PT. Are retinal 
arteriolar or venular diameters associated with markers for cardiovascular disorders? The Rot-
terdam Study. Invest Ophthalmol Vis Sci. 2004;45:2129-2134
 12. Kifley A, Wang JJ, Cugati S, Wong TY, Mitchell P. Retinal vascular caliber and the long-term risk 
of diabetes and impaired fasting glucose: the blue mountains eye study. Microcirculation. 
2008;15:373-377
 13. Klein R, Klein BE, Knudtson MD, Wong TY, Tsai MY. Are inflammatory factors related to retinal 
vessel caliber? The Beaver Dam Eye Study. Arch Ophthalmol. 2006;124:87-94
 14. de Jong FJ, Vernooij MW, Ikram MK, Ikram MA, Hofman A, Krestin GP, van der Lugt A, de Jong PT, 
Breteler MM. Arteriolar oxygen saturation, cerebral blood flow, and retinal vessel diameters. The 
Rotterdam Study. Ophthalmology. 2008;115:887-892
 15. Wang JJ, Rochtchina E, Liew G, Tan AG, Wong TY, Leeder SR, Smith W, Shankar A, Mitchell P. 
The long-term relation among retinal arteriolar narrowing, blood pressure, and incident severe 
hypertension. Am J Epidemiol. 2008;168:80-88
 16. Ikram MK, De Jong FJ, Van Dijk EJ, Prins ND, Hofman A, Breteler MM, De Jong PT. Retinal vessel 
diameters and cerebral small vessel disease: the Rotterdam Scan Study. Brain. 2006;129:182-
188
 17. Wong TY. Is retinal photography useful in the measurement of stroke risk? Lancet Neurol. 
2004;3:179-183
 18. Cheung N, Islam FM, Jacobs DR, Jr., Sharrett AR, Klein R, Polak JF, Cotch MF, Klein BE, Ouyang 
P, Wong TY. Arterial compliance and retinal vascular caliber in cerebrovascular disease. Ann 
Neurol. 2007;62:618-624
 19. Wong TY, Mosley TH, Jr., Klein R, Klein BE, Sharrett AR, Couper DJ, Hubbard LD. Retinal micro-
vascular changes and MRI signs of cerebral atrophy in healthy, middle-aged people. Neurology. 
2003;61:806-811
113
Retinal vessels and structural brain changes
 20. Hofman A, Breteler MM, van Duijn CM, Krestin GP, Pols HA, Stricker BH, Tiemeier H, Uitterlinden 
AG, Vingerling JR, Witteman JC. The Rotterdam Study: objectives and design update. Eur J Epide-
miol. 2007;22:819-829
 21. Ott A, Breteler MM, van Harskamp F, Stijnen T, Hofman A. Incidence and risk of dementia. The 
Rotterdam Study. Am J Epidemiol. 1998;147:574-580
 22. Hubbard LD, Brothers RJ, King WN, Clegg LX, Klein R, Cooper LS, Sharrett AR, Davis MD, Cai J. 
Methods for evaluation of retinal microvascular abnormalities associated with hypertension/
sclerosis in the Atherosclerosis Risk in Communities Study. Ophthalmology. 1999;106:2269-
2280
 23. Klein S, Staring M, Pluim JP. Comparison of gradient approximation techniques for optimisation 
of mutual information in nonrigid registration. Proc. SPIE. Medical Imaging: Image process. 
2005;5747:192-203
 24. Vernooij MW, Ikram MA, Tanghe HL, Vincent AJ, Hofman A, Krestin GP, Niessen WJ, Breteler 
MM, van der Lugt A. Incidental findings on brain MRI in the general population. N Engl J Med. 
2007;357:1821-1828
 25. Ikram MK, de Jong FJ, Bos MJ, Vingerling JR, Hofman A, Koudstaal PJ, de Jong PT, Breteler MM. 
Retinal vessel diameters and risk of stroke: the Rotterdam Study. Neurology. 2006;66:1339-
1343

Part 3

Chapter 
3.1
Brain tissue Volumes in relation to 
Cognitive function and risk of Dementia
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ABStrACt
We investigated in a population-based cohort study the association of global and lobar 
brain tissue volumes with specific cognitive domains and risk of dementia. Participants 
(n=490;60-90years) were non-demented at baseline (1995-1996). From baseline brain MRI-
scans we obtained global and lobar volumes of CSF, GM, normal WM, white matter lesions 
and hippocampus. We performed neuropsychological testing at baseline to assess informa-
tion processing speed, executive function, memory function and global cognitive function. 
Participants were followed for incident dementia until January 1st 2005. Larger volumes of 
CSF and WML were associated with worse performance on all neuropsychological tests, 
and an increased risk of dementia. Smaller WM volume was related to poorer information 
processing speed and executive function. In contrast, smaller GM volume was associated 
with worse memory function and increased risk of dementia. When investigating lobar 
GM volumes, we found that hippocampal volume and temporal GM volume were most 
strongly associated with risk of dementia, even in persons without objective and subjective 
cognitive deficits at baseline, followed by frontal and parietal GM volumes.
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intrODuCtiOn
Several biomarkers for cognitive impairment and dementia have been identified using 
magnetic resonance imaging (MRI) of the brain. Medial temporal lobe atrophy, including 
hippocampal atrophy, is closely related to memory impairment and is a strong predictor 
of dementia even in asymptomatic persons.1-5 Subcortical vascular disease, as reflected by 
white matter lesions (WML) and lacunar infarcts, is thought to contribute to the develop-
ment of dementia by primarily affecting a different cognitive domain than memory, namely 
information processing speed.6, 7
Several studies have suggested that persons with whole-brain atrophy also have poorer 
global cognition and suffer more often from dementia than persons without atrophy.8, 9 
However, little is known whether this applies evenly to atrophy of all brain regions and for 
all cognitive domains. Moreover, few studies distinguished between grey matter (GM) and 
white matter (WM) atrophy. Previous studies have used visual ratings of sulcal width as an 
indirect marker of GM atrophy, and ventricular enlargement as an indirect marker of WM 
atrophy, and found inconsistent results regarding their relationship with specific cognitive 
domains.10-13 Recent advances in the analysis of brain MRI-data have opened the way for 
automated in vivo volumetric quantification of the whole brain, and of GM and WM.14, 15 
The use of these direct volumetric measures of GM and WM atrophy may allow for a better 
assessment of specific effects on cognition.
Atrophy of the hippocampus, which is a predominantly GM structure, is thought to be 
one of the first detectable signs of dementia.1 Post-mortem and neuroimaging studies in 
dementia patients have shown that atrophic changes in GM are present throughout the 
brain, and that these changes probably develop later in the disease course.16-20 Little is 
known about whether brain atrophy outside the hippocampus is discernible during the 
preclinical phase of dementia.
We investigated in a population-based cohort study the association of GM and WM volume 
with specific cognitive domains and with the risk of dementia. Furthermore, we investi-
gated how atrophy of the different cerebral lobes was related to dementia, and whether 
lobar atrophy predicted dementia in asymptomatic persons.
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methODS
Participants
This study is based on the Rotterdam Scan Study, a large population-based cohort study in 
the Netherlands, investigating age-related brain changes on MRI.6, 21 At baseline (1995-1996), 
we randomly invited participants (60-90 years) stratified by sex and 5-year age strata from 
the Zoetermeer Study and the Rotterdam Study to participate in the Rotterdam Scan Study.6, 
22 Individuals who were demented, blind or had an MRI contraindication were excluded 
from the study. The present study is restricted to participants originating from the Rotter-
dam Study (n=563), because their scanning protocol included an additional high-resolution 
MR sequence. All persons gave written informed consent and the study was approved by 
the medical ethical committee of the Erasmus Medical Center, Rotterdam.
MRI measures at baseline
Brain scans were performed on a 1.5-Tesla MRI System (VISION MR, Siemens AG, Erlangen, 
Germany). We obtained a proton-density, a T2-weighted, and a high-resolution inversion-
recovery double contrast 3D HASTE sequence for our multi-spectral volumetry.23 Among 
the 563 participants, 52 developed claustrophobia during MRI acquisition and 21 additional 
datasets were unusable due to various technical reasons (e.g. excessive motion artifacts) 
leaving a total of 490 participants in our present study.
Image preprocessing and the tissue classification algorithm have been described else-
where.23, 24 Briefly, preprocessing included co-registration, non-uniformity correction and 
intensity normalization. Afterwards, we used the k-nearest-neighbor classifier25 to classify 
voxels into cerebrospinal fluid (CSF), GM, normal WM, and WML. To remove non-cerebral 
tissue, we used non-rigid transformation26, 27 to register to each brain a template scan, in 
which all non-cerebral tissue was manually masked. Validation methods and results have 
been described and showed very good to excellent agreement between automated clas-
sification and manual classification as reference.23, 24 For an example of the classification 
result see Ikram et al.24
For measurement of lobar brain tissue volumes, we first created a template scan, in 
which the lobes were labeled according to a slightly modified version of the segmenta-
tion protocol as described by Bokde et al.28, 29 Subsequently, we used a validated non-rigid 
registration algorithm to map this template to each brain.26, 27 Figure 1 shows an example 
of this segmentation, which uses anatomical landmarks and cerebral fissures as boundaries 
to distinguish the four major lobes (frontal, parietal, occipital, and temporal). By combining 
this lobar segmentation with the tissue classification algorithm we were able to obtain 
lobar volumes of GM, normal WM and WML separately.
Hippocampal volumes were manually outlined on coronal HASTE-slices reconstructed 
perpendicular to the long axis of the hippocampus.3 Brain infarcts were rated visually as 
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focal hyperintensities on T2-weighted images, 3 mm in size or larger and with a correspond-
ing prominent hypointensity on T1-weighted images. Intrarater agreement for detection of 
infarcts was good (κ=0.80).21
Cognitive function at baseline
At baseline, participants underwent the following neuropsychological tests: the Mini-Mental 
State Examination (MMSE),30 the Stroop test,31 the Letter-Digit Substitution Task,32 a verbal 
fluency task,33 and a 15-word verbal learning test (based on Rey’s recall of words).34 For 
each participant, we calculated z-scores for each test separately, except for MMSE (z-score = 
Figure 1. Haste-Odd sequence and the result after segmentation into the various brain lobes using non-rigid 
registration. Red: left frontal lobe; white: right frontal lobe; dark green: left parietal lobe; light green: right parietal lobe; dark blue: 
left temporal lobe; light blue: right temporal lobe; yellow: left occipital lobe; purple: central region comprising basal ganglia and corpus 
callosum. The right occipital lobe is not shown on these cross-sections. See this figure in color in the Appendix. 
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test score minus mean test score divided by the standard deviation). To obtain more robust 
outcome measures for cognition, we used the individual neuropsychological test scores to 
construct compound scores for information processing speed, for executive function, for 
memory, and for global cognitive function.6 The compound score for information process-
ing speed was calculated as the average of the z-scores for the first and second subtask 
of the Stroop test and the Letter-Digit Substitution Task. The score for executive function 
was the average of the z-scores for the third subtask of the Stroop test, the Letter-Digit 
Substitution Task, and the verbal fluency task. The compound score for memory was the 
average of the z-scores for the immediate and delayed recall of the 15-word verbal learning 
test. The compound score for global cognitive function was the average of the z-scores for 
the Stroop test (averaged across the three subtasks), the Letter-Digit Substitution Task, the 
verbal fluency test, and the immediate and delayed recall of the 15-word verbal learning 
test.6
Memory impairment as measured with neuropsychological tests is the first detectable 
neuropsychological sign of incipient dementia.35 Moreover, subjective memory complaints 
too are thought to be highly predictive of incident dementia.36 Therefore, we also ques-
tioned persons at baseline on subjective memory complaints by asking a single question: 
“Do you have complaints about your memory performance?” This question has been shown 
to predict incident dementia.37
Ascertainment of incident dementia
Assessment and subtyping of dementia cases in the Rotterdam Scan Study followed the pro-
tocol of the Rotterdam Study.38 We screened all participants for dementia at baseline and at 
two follow-up examinations (1999-2000, 2001-2002) using a three-step protocol: Two brief 
tests of cognition (MMSE and Geriatric Mental State schedule (GMS) organic level) were 
used to screen all participants. Screen-positives (MMSE score < 26 or GMS organic level > 
0) underwent the Cambridge examination for mental disorders of the elderly (Camdex).39 
Persons who were suspected of having dementia were examined by a neuropsychologist if 
additional neuropsychological testing was required for the diagnosis.
In addition, the total cohort was continuously monitored for incident dementia through 
computerized linkage between the study database and digitalized medical records from 
general practitioners and the Regional Institute for Outpatient Mental Health Care. The 
diagnosis of dementia was made in accordance with internationally accepted criteria for 
dementia (DSM-III-R). Follow-up for incident dementia was complete until January 1st 
2005.
Covariates
At baseline, information on education and current health status was obtained by interview 
and physical exam. Smoking status was verified and participants were classified into one 
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of three categories: current smoker, former smoker or never smoked. Blood pressure was 
measured twice at the right arm with a random-zero sphygmomanometer. The average of 
the two values measured at one occasion was used. Hypertension was defined as one of the 
following: a systolic blood pressure of 160 mm Hg or higher, or a diastolic blood pressure 
of 100 mm Hg or higher, or current use of blood pressure lowering drugs for the indica-
tion of hypertension (Grades 2 and 3 according to the 1999 World Health Organization 
guidelines).40 Diabetes mellitus was defined as non-fasting serum glucose level exceeding 
11.1 mmol/l or the use of oral blood glucose lowering drugs or insulin. APOE genotype was 
determined in 420 participants.
Statistical analysis
All brain tissue volumes were expressed as percentage of intra-cranial volume (= CSF + GM 
+ normal WM + WML) to correct for individual head-size differences. Therefore, a larger 
relative volume of CSF indicates a smaller whole-brain volume. Total WM was defined as the 
sum of normal WM and WML. WML were further natural log transformed because of skew-
ness of the untransformed measure. Because initial analyses did not show any consistent 
differences between left and right lobar volumes, we summed volumes of both sides for 
further analyses.
With linear regression we investigated the relationship between global brain tissue volumes 
and cognitive function. With Cox’ proportional hazards model we calculated hazard ratios 
for dementia per standard deviation increase in global brain tissue volumes. All analyses 
were adjusted for age, sex, education level, and additionally for cardiovascular risk factors 
and presence of brain infarcts, and stratified on presence of the APOE ε4-allele. In similar 
analyses we investigated how lobar brain tissue volumes were related to cognitive function 
and risk of dementia. We performed these analyses per standard deviation (SD) increase in 
the various volumes in order to be able to compare the magnitude of the effect of these 
volumes with each other.
Initially, we studied the whole cohort. Subsequently, we investigated whether the rela-
tionships between brain tissue volumes and risk of dementia were present even in persons 
without objective and subjective cognitive problems at baseline. For this, we stepwise 
excluded persons with increasingly less severe cognitive problems at baseline.3 We first 
excluded persons with subjective memory complaints AND z-memory < 1.5 SD of age- and 
education-specific means (which was calculated by regressing age and education with 
memory and taking those persons whose standardized residual was lower than 1.5). Sec-
ondly, we additionally excluded persons without subjective memory complaints but with 
z-memory < 1.5 SD of age- and education-specific means. Next, we also excluded persons 
with z-memory < 1.0 SD of age- and education-specific means. Finally, all persons with 
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subjective memory complaints OR z-memory < 1.5 of age- and education-specific means 
were excluded.
reSultS
Table 1 shows the baseline characteristics of the study population. Table 2 shows the cross-
sectional association between global brain tissue volumes and cognitive performance. 
Larger volumes of CSF and WML were related to a lower MMSE score and all cognitive 
domains. Larger volumes of total WM and normal WM were related to better performance 
on the MMSE, higher information processing speed, and borderline with better executive 
function, whereas larger GM volume was significantly related to better memory function. 
Investigating lobar brain tissue volumes in relation to cognitive function yielded similar 
effects for all lobar volumes (data not shown). Adjusting for cardiovascular risk factors and 
brain infarcts did not change the results.
During a mean follow-up of 5.9 years (standard deviation 1.6; range 0.1-9.0 years), 46 
persons developed dementia (incidence-rate 16.0 per 1000 person-years). Table 3 shows 
the risk of dementia associated with global brain tissue volumes. Larger volumes of CSF 
and WML were related to an increased risk of dementia. Larger GM volume indicated a 
Table 1. Baseline characteristics of the study population.
n 490
Age, yr 73.4 (7.9)
Women 249 (51)
Primary education only 149 (30)
Hypertension 250 (51)
Diabetes mellitus 24 (5)
Current smoker 87 (18)
Former smoker 264 (54)
APOE ε4 carriers a 131 (31)
MMSE, score 27.7 (2.2)
Brain infarcts 137 (28)
Cerebrospinal fluid, %ICV 22.6 (3.7)
Grey matter, %ICV 46.6 (4.1)
Normal white matter, %ICV 29.5 (6.4)
Total white matter, %ICV 30.8 (5.7)
White matter lesions, %ICV b -0.33 (1.26)
Hippocampal volume, %ICV 0.57 (0.08)
Values are means (standard deviation) or numbers (%). MMSE Mini-Mental State Examination; ICV Intra-cranial volume
a assessed in 420 persons
b natural log transformed
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decreased risk of dementia, whereas total and normal 
WM volumes were not related to the risk of dementia.
All relations remained unchanged after adjusting for 
cardiovascular risk factors and brain infarcts (Table 3). 
Also, stratification by APOE genotype did not alter the 
results.
Figure 2 shows the association of hippocampus 
volume and GM volume in various lobes with the risk 
of dementia. Hippocampus volume was most strongly 
associated with the development of subsequent de-
mentia, followed by volumes of temporal GM, frontal 
GM and parietal GM, whereas occipital GM volume was 
not associated with the risk of dementia. As expected, 
the more people we excluded from the lower end of 
the memory performance distribution at baseline the 
weaker the associations became of hippocampus and 
GM volumes with the risk of dementia, although the 
overall pattern in strength of the associations remained 
unchanged (Figure 2). However, even after excluding 
persons with z-memory below 1.0 SD of age- and 
education-specific means at baseline, hippocampus 
volume and temporal GM volume remained signifi-
cantly associated with dementia (Figure 2). Only after 
excluding persons with subjective memory complaints 
OR z-memory below 1.5 SD (which was 33% of the 
cohort) did the associations of hippocampus and 
temporal GM with dementia become statistically non-
significant.
Of note is that global GM and temporal GM volumes 
also included hippocampal volume; however, subtract-
ing hippocampal volume from these volumes did not 
change the results in any way.
In line with our observations on global volumes of 
normal and total WM, lobar volumes of WM were not 
associated with the risk of dementia.
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Table 3. Global brain tissue volumes and the risk of dementia.
Brain tissue volume
risk of dementia
hr (95% Ci)
Model I Model II
Cerebrospinal fluid, %ICV (per SD) 2.51 (1.56; 4.06) 2.46 (1.51; 4.01)
Grey matter, %ICV (per SD) 0.66 (0.48; 0.91) 0.66 (0.48; 0.91)
Total white matter, %ICV (per SD) 1.02 (0.71; 1.47) 1.04 (0.73; 1.50)
Normal white matter, %ICV (per SD) 0.88 (0.61; 1.27) 0.90 (0.62; 1.30)
White matter lesions, %ICV (per SD) a 1.52 (1.02; 2.27) 1.57 (1.03; 2.38)
HR hazard ratios, CI confidence intervals, ICV Intra-cranial volume, SD standard deviation
Model I: adjusted for age, sex and education
Model II: additionally adjusted for diabetes mellitus, smoking, hypertension and brain infarcts
a natural log transformed
Figure 2. The association of hippocampus volume and grey matter volume in various lobes with the risk of dementia. 
Symbols represent hazard ratios per standard deviation increase in volume, adjusted for age, sex and education; horizontal error bars 
represent the 95% confidence interval. Note that the x-axis is depicted on a logarithmic scale. SD standard deviation
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DiSCuSSiOn
In this population-based cohort study we found that volumes of WM and GM relate differ-
ently to specific cognitive domains and to the risk of dementia. Atrophy of WM was related 
to worse MMSE scores, lower psychomotor speed and worse executive function, but not to 
risk of dementia. In contrast, GM atrophy was related to worse memory performance and to 
an increased risk of dementia. When analyzed at the lobar level, hippocampal and temporal 
GM atrophy were most strongly associated with dementia, followed by frontal GM atrophy 
and parietal GM atrophy. Occipital GM atrophy was not associated with risk of dementia. 
Upon step-wise excluding persons with increasingly less severe objective or subjective 
cognitive deficits at baseline, this pattern remained, although the effect estimates became 
smaller and ultimately non-significant.
Strengths of our study include the population-based setting, the large sample size, the volu-
metric quantification of global and lobar brain tissue volumes, and the long and virtually 
complete follow-up for dementia. Moreover, by taking into account memory complaints 
and neuropsychological performance at baseline, we were able to also investigate asymp-
tomatic persons. A possible limitation is that in some cases misclassification in diagnosis or 
subtyping of dementia could have occurred. However, because the diagnosis and subtyping 
was made blinded for brain tissue volumes at baseline, any misclassification is likely to 
be non-differential and will lead to an underestimation of the effect we found. Another 
consideration is that we focused on selected cognitive domains (i.e. memory, information 
processing speed, and executive function), but did not investigate other cognitive domains 
such as visuospatial processing, visuoperceptual tasks, or naming. Moreover, we studied 
global and lobar tissue volumes but not subcortical tissue volumes or volumes of specific 
regions within lobes. Future research using a more extensive test battery coupled with 
more detailed regional volumes might reveal subtle associations that we could not assess 
in this study.
Thus far, several imaging studies have shown that whole-brain atrophy is related to poorer 
cognition and increased risk of dementia.8, 9, 41 In our dataset, this is reflected in the associa-
tions of larger CSF volume with poor cognitive function, and with the risk of dementia. 
However, we went a step further by making a distinction between WM and GM volumes 
and found that these had different effects on cognitive performance and dementia.
We found that WM atrophy was related to worse MMSE score and information processing 
speed. In the cerebral WM, the axonal structures are covered by myelin sheets, which are 
pivotal in increasing the speed of information transfer.42 Damage to myelin may therefore 
lead to poorer performance on tests measuring information processing speed. These my-
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elin sheets are usually very susceptible to ischemic damage caused by subcortical vascular 
disease.42, 43 Subcortical vascular disease can be seen on structural MRI not only as WML and 
lacunar infarcts, but also as WM atrophy.42, 44 Moreover, on diffusion-tensor-imaging (DTI) 
damage to myelin sheets is reflected in loss of microstructural integrity of WM. Our data 
using structural MRI are in line with studies using DTI that show that a decline in white 
matter microstructural integrity is related to lower MMSE score, information processing 
speed and executive function, but not to memory.45, 46
We found that GM atrophy was related to poorer memory performance and an increased 
risk of dementia. In contrast, Mungas et al.47, 48 reported that (change in) GM was related to 
global cognition, executive function and speed, but not to memory. However, that study was 
based on a heterogeneous study population including cognitively impaired and demented 
persons, whereas we focused on persons who were non-demented at baseline. Differences 
in study population and severity of cognitive impairment might therefore explain these 
seemingly contradictory findings. This is supported by the fact that exclusion of demented 
persons in the study by Mungas et al.48 attenuated the relation between decrease in GM and 
decline in executive function.
Memory impairment is a pivotal symptom of dementia, and both are related to neuronal 
loss,49 which can be visualized as GM atrophy on MRI.50 Previously, we did not find an 
association between increasing age and global GM atrophy in the general non-demented 
population.24 This suggests that GM atrophy is a process specific to those, who are at an 
increased risk of dementia. When analyzing the separate lobar tissue volumes we found 
that atrophy of the hippocampus and temporal GM was most strongly associated with 
dementia, followed by frontal GM atrophy and parietal GM atrophy. This fits well with 
several imaging studies that have investigated patterns of GM atrophy in persons with mild 
cognitive impairment or in persons who are in the early stages of dementia: these studies 
too have found that the temporal GM is most severely affected, followed by several subre-
gions in the frontal and parietal lobes.51-54 This pattern of lobar atrophy has also consistently 
been confirmed by various post-mortem studies in dementia patients.17, 18 Moreover, we 
found this same pattern of lobar GM atrophy even after exclusion of persons with objec-
tive or subjective cognitive deficits at baseline. Although we do not separately diagnose 
mild cognitive impairment in our cohort, persons with subjective memory complaints 
AND z-memory below 1.5 SD of age- and education-specific means closely fit the criteria.55 
Our findings therefore emphasize that dementia has a long pre-clinical phase in which 
atrophic changes are already taking place without these being clinically apparent, even 
as mild cognitive impairment.8 More importantly, this indicates that the actual moment of 
clinical diagnosis of dementia and mild cognitive impairment is rather arbitrary and does 
not accurately reflect the actual disease process, which may have started several years 
before. Finally, we found that after excluding persons with subjective memory complaints 
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OR z-memory below 1.5 SD brain atrophy measures were no longer predictive of dementia. 
Therefore, future studies should also focus on brain changes other than atrophy taking 
place pre-clinically in those persons, who are cognitively normal at baseline, but do develop 
dementia during follow-up.
referenCeS
 1. de Leon MJ, Convit A, DeSanti S, Golomb J, Tarshish C, Rusinek H, Bobinski M, Ince C, Miller DC, 
Wisniewski HM, et al. The hippocampus in aging and Alzheimer’s disease. Neuroimaging Clin N 
Am. 1995;5:1-17
 2. Smith CD, Chebrolu H, Wekstein DR, Schmitt FA, Jicha GA, Cooper G, Markesbery WR. Brain 
structural alterations before mild cognitive impairment. Neurology. 2007;68:1268-1273
 3. den Heijer T, Geerlings MI, Hoebeek FE, Hofman A, Koudstaal PJ, Breteler MM. Use of hippocam-
pal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively 
intact elderly people. Arch Gen Psychiatry. 2006;63:57-62
 4. Fox NC, Crum WR, Scahill RI, Stevens JM, Janssen JC, Rossor MN. Imaging of onset and progres-
sion of Alzheimer’s disease with voxel-compression mapping of serial magnetic resonance 
images. Lancet. 2001;358:201-205
 5. Jack CR, Jr., Dickson DW, Parisi JE, Xu YC, Cha RH, O’Brien PC, Edland SD, Smith GE, Boeve BF, 
Tangalos EG, Kokmen E, Petersen RC. Antemortem MRI findings correlate with hippocampal 
neuropathology in typical aging and dementia. Neurology. 2002;58:750-757
 6. Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Jolles J, Koudstaal PJ, Hofman A, Breteler MM. 
Cerebral small-vessel disease and decline in information processing speed, executive function 
and memory. Brain. 2005;128:2034-2041
 7. Swan GE, DeCarli C, Miller BL, Reed T, Wolf PA, Carmelli D. Biobehavioral characteristics of 
nondemented older adults with subclinical brain atrophy. Neurology. 2000;54:2108-2114
 8. Jack CR, Jr., Shiung MM, Weigand SD, O’Brien PC, Gunter JL, Boeve BF, Knopman DS, Smith GE, 
Ivnik RJ, Tangalos EG, Petersen RC. Brain atrophy rates predict subsequent clinical conversion 
in normal elderly and amnestic MCI. Neurology. 2005;65:1227-1231
 9. Erten-Lyons D, Howieson D, Moore MM, Quinn J, Sexton G, Silbert L, Kaye J. Brain volume loss in 
MCI predicts dementia. Neurology. 2006;66:233-235
 10. Longstreth WT, Jr., Arnold AM, Manolio TA, Burke GL, Bryan N, Jungreis CA, O’Leary D, Enright PL, 
Fried L. Clinical correlates of ventricular and sulcal size on cranial magnetic resonance imag-
ing of 3,301 elderly people. The Cardiovascular Health Study. Collaborative Research Group. 
Neuroepidemiology. 2000;19:30-42
 11. Breteler MM, van Amerongen NM, van Swieten JC, Claus JJ, Grobbee DE, van Gijn J, Hofman A, 
van Harskamp F. Cognitive correlates of ventricular enlargement and cerebral white matter 
lesions on magnetic resonance imaging. The Rotterdam Study. Stroke. 1994;25:1109-1115
 12. Soderlund H, Nilsson LG, Berger K, Breteler MM, Dufouil C, Fuhrer R, Giampaoli S, Hofman 
A, Pajak A, de Ridder M, Sans S, Schmidt R, Launer LJ. Cerebral changes on MRI and cognitive 
function: the CASCADE study. Neurobiol Aging. 2006;27:16-23
 13. Mosley TH, Jr., Knopman DS, Catellier DJ, Bryan N, Hutchinson RG, Grothues CA, Folsom AR, 
Cooper LS, Burke GL, Liao D, Szklo M. Cerebral MRI findings and cognitive functioning: the 
Atherosclerosis Risk in Communities study. Neurology. 2005;64:2056-2062
129
Structural brain changes and cognition and dementia
 14. Fotenos AF, Snyder AZ, Girton LE, Morris JC, Buckner RL. Normative estimates of cross-sectional 
and longitudinal brain volume decline in aging and AD. Neurology. 2005;64:1032-1039
 15. DeCarli C, Massaro J, Harvey D, Hald J, Tullberg M, Au R, Beiser A, D’Agostino R, Wolf PA. Measures 
of brain morphology and infarction in the framingham heart study: establishing what is normal. 
Neurobiol Aging. 2005;26:491-510
 16. Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet. 2006;368:387-403
 17. Halliday GM, Double KL, Macdonald V, Kril JJ. Identifying severely atrophic cortical subregions 
in Alzheimer’s disease. Neurobiol Aging. 2003;24:797-806
 18. Braak H, Braak E, Bohl J. Staging of Alzheimer-related cortical destruction. Eur Neurol. 
1993;33:403-408
 19. Delacourte A, David JP, Sergeant N, Buee L, Wattez A, Vermersch P, Ghozali F, Fallet-Bianco C, 
Pasquier F, Lebert F, Petit H, Di Menza C. The biochemical pathway of neurofibrillary degenera-
tion in aging and Alzheimer’s disease. Neurology. 1999;52:1158-1165
 20. Sonnen JA, Larson EB, Crane PK, Haneuse S, Li G, Schellenberg GD, Craft S, Leverenz JB, Montine 
TJ. Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann 
Neurol. 2007;62:406-413
 21. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts 
and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215-1222
 22. Hofman A, Breteler MM, van Duijn CM, Krestin GP, Pols HA, Stricker BH, Tiemeier H, Uitterlinden 
AG, Vingerling JR, Witteman JC. The Rotterdam Study: objectives and design update. Eur J Epide-
miol. 2007
 23. Vrooman HA, Cocosco CA, van der Lijn F, Stokking R, Ikram MA, Vernooij MW, Breteler MM, Nies-
sen WJ. Multi-spectral brain tissue segmentation using automatically trained k-Nearest-Neighbor 
classification. Neuroimage. 2007;37:71-81
 24. Ikram MA, Vrooman HA, Vernooij MW, van der Lijn F, Hofman A, van der Lugt A, Niessen WJ, 
Breteler MM. Brain tissue volumes in the general elderly population. The Rotterdam Scan Study. 
Neurobiol Aging. 2007;doi:10.1016/j.neurobiolaging.2006.12.012 in press
 25. Anbeek P, Vincken KL, van Bochove GS, van Osch MJ, van der Grond J. Probabilistic segmenta-
tion of brain tissue in MR imaging. Neuroimage. 2005;27:795-804
 26. Rueckert D, Sonoda LI, Hayes C, Hill DL, Leach MO, Hawkes DJ. Nonrigid registration using 
free-form deformations: application to breast MR images. IEEE Trans Med Imaging. 1999;18:712-
721
 27. Klein S, Staring M, Pluim JP. Comparison of gradient approximation techniques for optimisation 
of mutual information in nonrigid registration. Proc. SPIE. Medical Imaging: Image process. 
2005;5747:192-203
 28. Bokde AL, Teipel SJ, Schwarz R, Leinsinger G, Buerger K, Moeller T, Moller HJ, Hampel H. Reli-
able manual segmentation of the frontal, parietal, temporal, and occipital lobes on magnetic 
resonance images of healthy subjects. Brain Res Brain Res Protoc. 2005;14:135-145
 29. Bokde AL, Teipel SJ, Zebuhr Y, Leinsinger G, Gootjes L, Schwarz R, Buerger K, Scheltens P, Moeller 
HJ, Hampel H. A new rapid landmark-based regional MRI segmentation method of the brain. J 
Neurol Sci. 2002;194:35-40
 30. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the 
cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198
 31. Houx PJ, Jolles J, Vreeling FW. Stroop interference: aging effects assessed with the Stroop Color-
Word Test. Exp Aging Res. 1993;19:209-224
Chapter 3.1
130
 32. Lezak MD, Howieson DB, Loring DW. Neuropsychological assessment. New York, NY: Oxford 
University Press; 2004.
 33. Welsh KA, Butters N, Mohs RC, Beekly D, Edland S, Fillenbaum G, Heyman A. The Consortium to 
Establish a Registry for Alzheimer’s Disease (CERAD). Part V. A normative study of the neuropsy-
chological battery. Neurology. 1994;44:609-614
 34. Bleecker ML, Bolla-Wilson K, Agnew J, Meyers DA. Age-related sex differences in verbal memory. 
J Clin Psychol. 1988;44:403-411
 35. DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet 
Neurol. 2003;2:15-21
 36. van Oijen M, De Jong FJ, Hofman A, Koudstaal PJ, Breteler MM. Subjective memory complaints, 
education, and risk of Alzheimer’s disease. Alzheimer’s & Dementia. 2007;3:92-97
 37. Geerlings MI, Jonker C, Bouter LM, Ader HJ, Schmand B. Association between memory com-
plaints and incident Alzheimer’s disease in elderly people with normal baseline cognition. Am 
J Psychiatry. 1999;156:531-537
 38. Ott A, Breteler MM, van Harskamp F, Stijnen T, Hofman A. Incidence and risk of dementia. The 
Rotterdam Study. Am J Epidemiol. 1998;147:574-580
 39. Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma S, Goddard R. CAMDEX. A stan-
dardised instrument for the diagnosis of mental disorder in the elderly with special reference 
to the early detection of dementia. Br J Psychiatry. 1986;149:698-709
 40. WHO. 1999 World Health Organization-International Society of Hypertension Guidelines for 
the Management of Hypertension. Guidelines Subcommittee. J Hypertens. 1999;17:151-183
 41. Jack CR, Jr., Shiung MM, Gunter JL, O’Brien PC, Weigand SD, Knopman DS, Boeve BF, Ivnik RJ, 
Smith GE, Cha RH, Tangalos EG, Petersen RC. Comparison of different MRI brain atrophy rate 
measures with clinical disease progression in AD. Neurology. 2004;62:591-600
 42. Fernando MS, Simpson JE, Matthews F, Brayne C, Lewis CE, Barber R, Kalaria RN, Forster G, 
Esteves F, Wharton SB, Shaw PJ, O’Brien JT, Ince PG. White matter lesions in an unselected 
cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury. 
Stroke. 2006;37:1391-1398
 43. Bartzokis G. Age-related myelin breakdown: a developmental model of cognitive decline and 
Alzheimer’s disease. Neurobiol Aging. 2004;25:5-18; author reply 49-62
 44. Scheltens P, Barkhof F, Leys D, Wolters EC, Ravid R, Kamphorst W. Histopathologic correlates of 
white matter changes on MRI in Alzheimer’s disease and normal aging. Neurology. 1995;45:883-
888
 45. Shenkin SD, Bastin ME, Macgillivray TJ, Deary IJ, Starr JM, Rivers CS, Wardlaw JM. Cognitive cor-
relates of cerebral white matter lesions and water diffusion tensor parameters in community-
dwelling older people. Cerebrovasc Dis. 2005;20:310-318
 46. Deary IJ, Bastin ME, Pattie A, Clayden JD, Whalley LJ, Starr JM, Wardlaw JM. White matter integrity 
and cognition in childhood and old age. Neurology. 2006;66:505-512
 47. Mungas D, Jagust WJ, Reed BR, Kramer JH, Weiner MW, Schuff N, Norman D, Mack WJ, Willis L, 
Chui HC. MRI predictors of cognition in subcortical ischemic vascular disease and Alzheimer’s 
disease. Neurology. 2001;57:2229-2235
 48. Mungas D, Harvey D, Reed BR, Jagust WJ, DeCarli C, Beckett L, Mack WJ, Kramer JH, Weiner 
MW, Schuff N, Chui HC. Longitudinal volumetric MRI change and rate of cognitive decline. 
Neurology. 2005;65:565-571
131
Structural brain changes and cognition and dementia
 49. Mortimer JA, Gosche KM, Riley KP, Markesbery WR, Snowdon DA. Delayed recall, hippocampal 
volume and Alzheimer neuropathology: findings from the Nun Study. Neurology. 2004;62:428-
432
 50. Bobinski M, de Leon MJ, Wegiel J, Desanti S, Convit A, Saint Louis LA, Rusinek H, Wisniewski 
HM. The histological validation of post mortem magnetic resonance imaging-determined hip-
pocampal volume in Alzheimer’s disease. Neuroscience. 2000;95:721-725
 51. Whitwell JL, Weigand SD, Shiung MM, Boeve BF, Ferman TJ, Smith GE, Knopman DS, Petersen RC, 
Benarroch EE, Josephs KA, Jack CR, Jr. Focal atrophy in dementia with Lewy bodies on MRI: a 
distinct pattern from Alzheimer’s disease. Brain. 2007;130:708-719
 52. Chetelat G, Baron JC. Early diagnosis of Alzheimer’s disease: contribution of structural neuroim-
aging. Neuroimage. 2003;18:525-541
 53. Killiany RJ, Gomez-Isla T, Moss M, Kikinis R, Sandor T, Jolesz F, Tanzi R, Jones K, Hyman BT, Albert 
MS. Use of structural magnetic resonance imaging to predict who will get Alzheimer’s disease. 
Ann Neurol. 2000;47:430-439
 54. Wolf H, Hensel A, Kruggel F, Riedel-Heller SG, Arendt T, Wahlund LO, Gertz HJ. Structural cor-
relates of mild cognitive impairment. Neurobiol Aging. 2004;25:913-924
 55. Jack CR, Jr., Petersen RC, Xu YC, O’Brien PC, Smith GE, Ivnik RJ, Boeve BF, Waring SC, Tangalos 
EG, Kokmen E. Prediction of AD with MRI-based hippocampal volume in mild cognitive impair-
ment. Neurology. 1999;52:1397-1403

Chapter 
3.2
Vascular Brain Disease in relation 
to Depression in the elderly
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ABStrACt
Background: Whereas cross-sectional studies show an association between vascular brain 
disease and depression, longitudinal data are scarce. In a population-based study we inves-
tigated this relationship both cross-sectionally and longitudinally.
Methods: 479 persons (60-90 years) underwent brain MRI. Brain atrophy, white matter le-
sions (WML) and brain infarcts reflected vascular brain disease. At baseline (1995-1996) and 
follow-up examinations we identified persons with depressive symptoms and syndromes 
using CES-D and psychiatric interview. Moreover, medical records were continuously moni-
tored to identify incident depression. Follow-up was complete until October 2005.
Results: At baseline 36 persons had depressive symptoms. Brain atrophy, WML, and infarcts 
were associated with presence of depressive symptoms. During follow-up 92 persons de-
veloped depressive symptoms, of whom 35 depressive syndrome. There was no association 
of any MRI-marker with incident depressive symptoms or syndromes.
Conclusions: Markers of vascular brain disease were associated with depression cross-
sectionally. However, no relationship was present between these markers and risk of 
depression longitudinally.
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intrODuCtiOn
Accumulating evidence indicates that vascular disease and depression in the elderly are 
closely related.1, 2 This has led to the ‘vascular depression’ hypothesis,3 which postulates a 
vascular basis of late-life depression.4-6 Magnetic resonance imaging (MRI) can be used to 
visualize markers of vascular brain disease, including white matter lesions (WML), brain 
infarcts, and brain atrophy. Various cross-sectional studies have shown an association of 
several MRI-markers with depression.4, 7-10 However, cross-sectional studies do not allow 
interpretation of the results with respect to cause and effect. Few studies have investigated 
the relationship of WML with depression longitudinally, but found inconsistent results.9, 11-13 
No study investigated brain atrophy and only one also considered brain infarcts.9
We investigated the relationship of several MRI-markers of subclinical vascular brain 
disease both cross-sectionally with prevalent depression, and longitudinally with incident 
depression.
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methODS AnD mAteriAlS
Study population
This study is based on an age-stratified (60-90 years) random sample of 563 participants 
from the population-based Rotterdam Study,14 who underwent brain MR-imaging in 1995-
1996 as part of the Rotterdam Scan Study.15 The institutional medical ethics committee 
approved the study and all participants gave written informed consent. All participants 
underwent a multi-sequence MRI examination. Of the 563 participants, 73 did not com-
plete MRI examination due to claustrophobia or technical reasons, and 4 persons did not 
undergo psychiatric assessment at baseline. Furthermore, persons using anti-depressants 
at baseline but without depressive symptoms (n=7) were excluded, because we could 
not determine whether the indication for using these drugs (namely depression) was still 
present. Therefore, a total of 479 persons were available for the present analysis.
MRI measures at baseline
Image acquisition, classification algorithm, and validation steps have been described else-
where.15 In summary, we used the k-nearest-neighbor (kNN) classifier to classify voxels 
into cerebrospinal fluid, grey matter, normal white matter, and WML. Using non-rigid 
transformation, non-cerebral tissues (e.g. eyes, skull) were stripped. For measurement of 
lobar and deep central brain volumes, we first created an atlas, in which the lobes were 
labeled according to a slightly modified version of the segmentation protocol as described 
by Bokde et al.16 Subsequently, we used validated non-rigid transformation to transform 
this atlas to each brain. Brain infarcts were rated visually as focal hyperintensities on T2-
weighted images, 3 mm in size or larger and with a corresponding prominent hypointensity 
on T1-weighted images.15
Assessment of depression
The assessment of depression has been extensively described elsewhere.17 In short, at the 
baseline visit and during three follow-up rounds (1997-1999, 1999-2000, 2000-2001) the 
Center for Epidemiological Studies Depression Scale (CES-D) was used as screening tool 
with a cut-off of 16. Screen-positive individuals then underwent the Present State Examina-
tion18 to diagnose major depression, dysthymia, and minor depression. Moreover, medical 
and pharmacy records of participants (e.g. hospital discharge letter, specialists’ reports, and 
notes of general practitioners) were continuously monitored for depressive episodes and 
for start of anti-depressants during the entire follow-up period by automated linkage of the 
general practitioners’ and pharmacists’ databases with the study database.
Depressive episodes were classified as depressive symptoms if persons were CES-D posi-
tive; or had at least one core symptom of depression (feeling depressed or loss-of-interest) 
recorded in medical files; or started anti-depressants (without documentation of clinical 
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symptoms). Depressive symptoms were further classified as depressive syndrome if per-
sons were diagnosed as suffering from major depression, minor depression, or dysthymia 
according to the psychiatric interview or medical files. Follow-up for incident depressive 
symptoms and syndromes was complete until October 1st 2005.
Covariates
Participants underwent the Mini-Mental State Examination, and they were asked about 
their education level. Other covariates – as previously described15 – included smoking, 
blood pressure, diabetes mellitus, body-mass index, and intima-media thickness.
Statistical analysis
All brain measure volumes were expressed as percentage of intra-cranial volume. Total 
white matter was the sum of normal white matter and WML. WML were analyzed as ln(WML 
volume), because of skewness of the untransformed measures.
We used logistic regression to calculate odds ratios for presence of depressive symptoms 
associated with brain imaging markers.
For the longitudinal analyses, we first excluded persons with depressive symptoms at 
baseline (n=36). We used Cox’ proportional-hazards models to calculate hazard ratios for 
incident depressive symptoms or syndromes associated with brain imaging markers. Per-
sons were followed-up until onset of depressive symptoms or depressive syndrome, loss to 
follow-up, or October 1st 2005, whichever came first.
reSultS
Table 1 shows the baseline characteristics of the study population. At baseline, 36 persons 
had depressive symptoms, of whom 6 had a depressive syndrome. The smaller the brain vol-
ume the more likely persons were to have depressive symptoms (Table 2). At the lobar level, 
particularly parietal and temporal lobe atrophy were associated with depressive symptoms. 
The likelihood of having depressive symptoms increased with increasing volume of WML, 
especially in the frontal lobe and deep central region, and with presence of brain infarcts. 
Numbers were too small to perform separate analyses for prevalent depressive syndromes 
(n=6).
During 3,373 person-years of follow-up (mean 7.5 years) a total of 92 persons developed 
depressive symptoms, of whom 35 suffered from a depressive syndrome. Global nor lobar 
brain tissue volumes were associated with depressive symptoms or depressive syndromes 
(Table 3). Neither WML nor brain infarcts were associated with incident depressive symp-
toms or depressive syndromes. Additional adjustment for cardiovascular risk factors did not 
change the results.
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DiSCuSSiOn
In this population-based cohort study of elderly persons we found that structural markers 
of vascular brain disease were cross-sectionally related to presence of depressive symptoms. 
However, we did not find any association between structural brain markers and incident 
depressive symptoms or depressive syndromes.
Strengths of our study include the population-based setting, and the cross-sectional as 
well as longitudinal design of the study with more than seven years of follow-up. Due to 
close collaboration with general practitioners and other health care institutions, the follow-
up for depressive episodes was virtually complete. Moreover, contrary to other studies we 
investigated various markers of vascular brain disease using automated quantification tech-
niques. A possible limitation is that we did not have reliable data on history of depression at 
baseline. Therefore, it is possible that some persons who developed depression or remained 
Table 1. Baseline characteristics of the study population.
n 479
Age, yr 73.4 (7.8)
Women 50%
Primary education only 30%
MMSE, score 27.7 (2.1)
Current smokers 18%
Former smokers 54%
Systolic blood pressure, mmHg 146 (21)
Diastolic blood pressure, mmHg 77 (12)
Diabetes mellitus 5.0%
Body mass index, kg/m2 26.2 (3.5)
Intima media thickness, mm 0.87 (0.14)
Whole brain volume, %ICV 77.4 (3.6)
Frontal lobe volume, %ICV 27.4 (1.9)
Parietal lobe volume, %ICV 15.8 (1.1)
Occipital lobe volume, %ICV 9.0 (0.7)
Temporal lobe volume, %ICV 15.5 (0.9)
Deep central region*, %ICV 9.7 (0.5)
Grey matter, %ICV 46.6 (4.1)
Normal white matter, %ICV 29.5 (6.3)
Total white matter, %ICV 30.8 (5.7)
White matter lesions, %ICV 1.33 (1.51)
Brain infarcts 28%
Values are percentages or means (standard deviation)
MMSE: Mini-Mental State Examination
ICV: Intra-cranial volume
* The deep central region includes the corpus callosum, insular cortex, basal ganglia, and the white matter surrounding the basal 
ganglia
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free of depression during follow-up might actually already have had a depression before 
baseline. This misclassification would lead to an underestimation of the true effect. A final 
consideration is that we excluded persons who used anti-depressants at baseline. However, 
post hoc analyses including these persons in either the depressed or non-depressed group 
yielded unchanged results.
In our cross-sectional analyses we found brain atrophy, brain infarcts and WML to be 
related to depressive symptoms (including depressive syndromes). This fits well with vari-
ous previous studies.4, 8, 9 Furthermore, when investigating at a lobar level our results are 
also in accordance with published data showing that particularly atrophy in the parietal 
and frontal lobes, and frontal and deep WML are related to depression.4, 10, 19
However, in our longitudinal analysis we did not find an association between any 
MRI-marker and incident depressive episodes. This is in contrast with results from the 
3C-Dijon Study and LADIS Study,12, 13 but in line with data from the PROSPER Study and 
the Cardiovascular Health Study.9, 11 A possible explanation for the discrepancies might be 
Table 2. Cross-sectional association between brain tissue volumes and prevalent depressive symptoms.
Odds ratio (95% confidence interval) for presence of depressive symptoms 
(n=36), including depressive syndromes (n=6)
Brain tissue volumes* Adjusted for age, sex, education, and 
MMSE-score
Additionally adjusted for 
cardiovascular risk factors§
Global brain tissue volumes
Whole brain volume 0.52 (0.31-0.87) 0.58 (0.34-0.99)
Grey matter 0.95 (0.67-1.33) 0.95 (0.67-1.34)
Normal white matter 0.70 (0.45-1.08) 0.73 (0.47-1.13)
Total white matter 0.81 (0.53-1.22) 0.86 (0.57-1.29)
Lobar brain tissue volumes†
Frontal lobe 0.68 (0.43-1.07) 0.75 (0.48-1.19)
Parietal lobe 0.56 (0.35-0.91) 0.61 (0.37-0.99)
Occipital lobe 0.87 (0.60-1.27) 0.89 (0.61-1.31)
Temporal lobe 0.65 (0.43-0.99) 0.65 (0.42-1.00)
Deep central region 1.08 (0.76-1.54) 1.17 (0.81-1.69)
WML volume‡ and brain infarcts
Global WML 1.55 (0.98-2.46) 1.71 (1.03-2.82)
Frontal WML 1.68 (1.07-2.63) 1.85 (1.14-3.00)
Parietal WML 1.30 (0.85-1.98) 1.39 (0.87-2.21)
Occipital WML 1.44 (0.93-2.23) 1.61 (0.99-2.63)
Temporal WML 1.35 (0.88-2.08) 1.41 (0.89-2.25)
Deep WML 1.82 (1.13-2.96) 1.99 (1.19-3.35)
Brain infarcts (yes versus no) 2.34 (1.12-4.89) 2.54 (1.19-5.42)
MMSE Mini-Mental State Examination, WML white matter lesion
* expressed per standard deviation increase
† these volumes included grey matter and total white matter together
‡ all white matter lesion volumes were natural log transformed
§ smoking, systolic blood pressure, diastolic blood pressure, diabetes mellitus, body-mass index, intima media thickness
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differences in assessment of depression, which ranged from using only a single test9, 13 to 
various combinations of different psychiatric tests.11, 12 Furthermore, differences in source 
population – clinical trial,11 a clinical setting,13 or a population-based setting9, 12 – might also 
have contributed to inconsistent findings between studies.
The question remains what underlies the strong cross-sectional association of brain mark-
ers with depression, if not a causal relationship from vascular brain disease to depres-
sion. One explanation might be that the causal pathway works the other way around, i.e. 
depression causes vascular brain disease. We did not have volumetric data on progression 
of white matter lesions in the Rotterdam Scan Study to investigate this issue. However, two 
studies have indeed reported a larger increase in WML in depressed compared with non-
depressed persons.9, 12 Though it is unclear how depression could lead to vascular brain 
Table 3. Risk of depressive symptoms and syndromes associated with brain tissue volumes.
Brain tissue volumes* Hazard ratio (95% CI) for incident 
depressive symptoms (including depressive 
syndromes)
(N=92)
Hazard ratio (95% CI) for 
incident depressive syndromes
(N=35)
Global brain tissue volumes
Whole brain volume 1.04 (0.78-1.41) 0.83 (0.51-1.34)
Grey matter 0.92 (0.74-1.14) 0.96 (0.67-1.36)
Normal white matter 1.10 (0.85-1.41) 0.90 (0.59-1.38)
Total white matter 1.10 (0.87-1.40) 0.96 (0.64-1.43)
Lobar brain tissue volumes†
Frontal lobe 0.88 (0.68-1.15) 0.87 (0.57-1.33)
Parietal lobe 1.04 (0.81-1.33) 0.85 (0.57-1.27)
Occipital lobe 1.08 (0.87-1.34) 1.09 (0.78-1.53)
Temporal lobe 1.14 (0.90-1.45) 0.85 (0.58-1.26)
Deep central region 1.10 (0.88-1.38) 1.00 (0.69-1.45)
WML volume‡ and brain infarcts
Global WML 0.89 (0.71-1.11) 0.85 (0.60-1.21)
Frontal WML 0.88 (0.71-1.09) 0.86 (0.61-1.20)
Parietal WML 0.88 (0.72-1.08) 0.89 (0.64-1.22)
Occipital WML 0.88 (0.71-1.09) 0.89 (0.63-1.25)
Temporal WML 0.93 (0.75-1.15) 0.89 (0.63-1.25)
Deep WML 0.93 (0.74-1.17) 0.91 (0.63-1.32)
Brain infarcts (yes versus no) 0.87 (0.52-1.46) 0.93 (0.38-2.25)
Values are adjusted for age, sex, education and Mini-Mental State Examination-score. Persons were censored at onset of 
depressive syndrome, onset of depressive symptoms, date last known to be alive in case of loss to follow-up, or October 1st 
2005, whichever came first.
CI confidence interval, WML white matter lesion
* expressed per standard deviation increase
† these volumes included grey matter and total white matter together
‡ all white matter lesion volumes were natural log transformed
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disease and brain atrophy, possible mechanisms include platelet dysfunction, hypotensive 
episodes, unhealthy lifestyle choices (e.g. smoking, drinking), and elevated cortisol levels 
in the brain, which in turn can cause glucocorticoid-mediated neurotoxicity.1, 5, 20 Another 
possible explanation is a common etiology (e.g. genetic predisposition) linking depression 
with vascular brain disease cross-sectionally, but not necessarily longitudinally. Indeed, in 
a twin study Scherrer et al. showed that the co-occurrence of cardiovascular disease and 
depression is partly explained by common genetic risk factors.21 Finally, it is possible that 
vascular brain disease does not cause depression, but is related to persistence of depres-
sion.9 Still, additional longitudinal studies are needed to test these hypotheses and further 
disentangle the exact mechanisms linking vascular brain disease and depression.
In conclusion, we found that MRI-markers of vascular brain disease were strongly associated 
with depression cross-sectionally. However, our study emphasizes that repeatedly finding 
an association cross-sectionally does not necessarily demonstrate causation, as we did not 
find any evidence for the ‘vascular depression’ hypothesis relating these brain markers to 
incident depression longitudinally.
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Brain tissue Volumes and Small Vessel 
Disease in relation to the risk of mortality
M. Arfan Ikram, Meike W. Vernooij, Henri A. Vrooman, Albert Hofman, 
Monique M.B. Breteler
ABStrACt
Brain atrophy and small vessel disease increase the risk of dementia and stroke. In a 
population-based cohort study (n=490; 60-90 years) we investigated how volumetric 
measures of atrophy and small vessel disease were related to mortality and whether this 
was independent of incident dementia or stroke. Brain volume and hippocampal volume 
were considered as measures of atrophy, whereas white matter lesions (WML) and lacunar 
infarcts reflected small vessel disease. We first investigated all-cause mortality in the whole 
cohort. In subsequent analyses we censored persons at incident dementia or incident stroke. 
Finally, we separately investigated cardiovascular mortality. The average follow-up was 8.4 
years, during which 191 persons died. Brain atrophy and hippocampal atrophy, as well as 
WML increased the risk of death. The risks associated with hippocampal atrophy attenu-
ated when censoring persons at incident dementia, but not at incident stroke. Censoring 
at either incident dementia or stroke did not change the risk associated with brain atrophy 
and WML. Moreover, WML were particularly associated with cardiovascular mortality.
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intrODuCtiOn
Subclinical structural brain changes, which can be visualized on magnetic resonance imag-
ing (MRI),1, 2 are important indicators of future adverse neurological events. Atrophy of the 
brain and the hippocampus are strong predictors of dementia and cognitive decline,3-5 and 
presence of cerebral small vessel disease (white matter lesions (WML) and lacunar infarcts) 
too is related to incident dementia6 and stroke.7 A few clinical studies have reported that 
markers of cerebral small vessel disease are also associated with increased mortality.8, 9 
The population-based Cardiovascular Health Study reported that WML and ventricular size, 
which is an indirect measure of brain atrophy, were related to mortality independent of 
incident dementia.10 The MRI measures used in these studies were rated visually on a semi-
quantitative scale.
The question remains how volumetric and therefore direct measures of atrophy and 
small vessel disease relate to mortality, and whether the relationship of these volumetric 
MRI measures with mortality is independent of adverse neurological events, such as de-
mentia or stroke.
In the population-based Rotterdam Scan Study we investigated how volumetric measures 
of brain atrophy, hippocampal atrophy and markers of cerebral small vessel disease are 
related to all-cause and cardiovascular mortality. Furthermore, we investigated whether the 
relationships were independent of incident dementia or stroke.
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methODS
Participants
The Rotterdam Scan Study is a large population-based cohort study in the Netherlands in-
vestigating age-related brain changes on MRI.7 The medical ethics committee of the Erasmus 
Medical Center, Rotterdam, The Netherlands, approved the study. At baseline (1995-1996), 
we randomly invited participants, aged 60-90 years, stratified by sex and 5-year age strata 
from the population-based Zoetermeer Study11 and Rotterdam Study12 to participate in the 
Rotterdam Scan Study. After exclusion of individuals who were demented or had MRI con-
traindications, 1,077 participants gave their written informed consent to participate in the 
study. At baseline, participants underwent an interview at home and a physical examination 
at the research center. Furthermore, an MRI scan of the brain was performed. The present 
study is restricted to persons originating from the Rotterdam Study (n=563), because they 
underwent an additional high-resolution 3D MR sequence. Among these 563 participants, 
52 developed claustrophobia during MRI acquisition, which prohibited completion of 
the scanning protocol. Twenty-one datasets were unusable for volumetric analysis due to 
excessive ghosting artifacts (n=5), scanning outside the range of coil sensitivity (n=10), or 
other reasons (n=6), leaving a total of 490 participants in our present study.
MRI measures at baseline
MR brain imaging was performed on a 1.5-Tesla MRI System (VISION MR, Siemens AG, 
Erlangen, Germany). The protocol included three axial scans, i.e. T1-weighted (repetition 
time (TR)=700, echo time (TE)=14, number of excitations (NEX)=1, matrix 192x256, field 
of view (FOV)=256x256, flip angle=80°, 20 slices), proton-density (PD) weighted (TR=2200, 
TE=20, NEX=1, matrix=192x256, FOV=256x256, flip angle=80°, 20 slices) and T2-weighted 
(TR=2200, TE=80, NEX=1, matrix=192x256, FOV=256x256, flip angle=80°, 20 slices). 
Slice thickness was 5 mm with an interslice gap of 20%. Furthermore, a high-resolution, 
inversion-recovery double contrast, 3-D half-Fourier acquisition single-shot turbo spin echo 
(HASTE) sequence was included (inversion time=4400ms, TR=2800, matrix=192x256, 
FOV=256x256, 128 contiguous sagittal slices of 1.25 mm). The interpolated voxel dimen-
sions were 1x1x1.25mm3. Two HASTE modules were sequentially acquired after the inver-
sion pulse (effective TE of 29 ms and 440 ms). Each HASTE module combined nonselective 
radio frequency excitations to provide a short interecho spacing of 3.9 ms. We used the 
proton-density, T2-weighted and the first HASTE module (HASTE-Odd) for our multi-spectral 
volumetry.
Data were stored onto a Linux Workstation. Preprocessing steps and the classification 
algorithm have been described.13, 14 In summary, preprocessing included co-registration, 
non-uniformity correction and variance scaling. Afterwards, we used the k-nearest-neighbor 
classifier to classify scans into cerebrospinal fluid (CSF), grey matter (GM), normal white 
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matter (WM), and WML.15 In order to minimize any misclassification of partial volume 
voxels as WML around cortical GM, we registered a manually created mask, within which 
voxels could be classified as WML. To remove non-brain tissue and infratentorial tissue, we 
used non-rigid transformation16, 17 to register to each brain a template scan, in which all 
these tissues were manually masked. For an example of the classification result, see Ikram 
et al.14
Finally, all scans were verified for proper classification by two trained neuro-imagers, 
blinded for clinical information. If needed, any voxels that were misclassified were manu-
ally reclassified appropriately. This was needed in only 45 of the scans, mostly due to mis-
classification because of slight motion artifacts. Validation methods and results have been 
described.13, 14 We used similarity indices (SI)18 and intra-class correlation coefficients (ICC) 
as validation measures. The SI between the automated classification and manual labeling 
was 0.91 for CSF, 0.92 for GM, 0.93 for normal WM and 0.63 for WML. The ICC between the 
automated classification and manual labeling was 0.89 for CSF, 0.94 for GM, 0.80 for normal 
WM and 0.84 for WML. The SIs and ICCs between two neuro-imagers were only slightly 
higher. These numbers indicate very good to excellent agreement and overlap.18
Hippocampal volumes were manually outlined on coronal HASTE-Odd scans recon-
structed perpendicular to the long axis of the hippocampus.19 Volumes were calculated 
by summing the areas multiplied by slice thickness in both the left and right hemispheres. 
Lacunar infarcts were rated visually as focal hyperintensities on T2-weighted images, 3 mm 
in size or larger and with a corresponding prominent hypointensity on T1-weighted images. 
Intra-rater agreement for detection of infarcts was good (κ=0.80).7
Follow-up for mortality
Information on vital status was obtained from the municipal health authorities in Rot-
terdam on a biweekly basis. Also, the general practitioners in the study area reported 
deaths on a continuous basis. After notification, information on cause and circumstances of 
death was obtained from general practitioners and by checking the medical records. Two 
research physicians independent from each other and blinded for brain tissue volumes 
coded all reported events according to the International Classification of Diseases, 10th 
edition (ICD-10).20 If the cause of death was coded as I20-I25, I46, I50, I60-70 and R96, 
the cause of death was labeled as death from a cardiovascular cause. Codes on which 
the research physicians disagreed were discussed in order to reach consensus. Finally, a 
medical expert in cardiovascular disease, whose judgment was considered final, reviewed 
all cardiovascular events.
Participants were followed from date of entry until date of death, date at which they 
were lost to follow-up, or August 15th 2006, whichever came first. Follow-up data on vital 
status were nearly complete (98.4%).
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Follow-up and diagnosis of dementia and stroke
After entrance into the Rotterdam Scan Study, participants were continuously monitored 
for major events, including stroke and dementia, through automated linkage of the study 
database with files from general practitioners, the municipality and the Regional Institute 
for Outpatient Mental Health Care. Also, nursery home physicians’ files and files from gen-
eral practitioners of participants who moved out of the district were reviewed.
In addition, during two follow-up visits to the research center (1999-2000, 2001-2002) 
all participants were screened for dementia following a three-step protocol as used in the 
Rotterdam Study.6, 21 Briefly, two brief tests of cognition (Mini-Mental State Examination 
(MMSE)22 and Geriatric Mental State schedule (GMS)23 organic level) were used to screen 
all subjects. Screen-positives (MMSE score < 26 or GMS organic level > 0) underwent the 
Cambridge examination for mental disorders of the elderly (Camdex).24 If needed for 
diagnosis, a neuropsychologist further examined persons suspected of having dementia. 
The diagnosis of dementia was made in accordance with internationally accepted criteria 
for dementia (DSM-III-R) by a panel consisting of a research physician, a neurologist and a 
neuropsychologist.
Stroke was defined as rapidly developing clinical signs of focal disturbance of cerebral 
function with no apparent cause other than a vascular origin, with duration of more than 
24 hours. For reported events, additional information was obtained from hospital records. 
Research physicians discussed information on all potential strokes and transient ischemic 
attacks with an experienced stroke neurologist to verify all diagnoses.
Assessment of confounders
At baseline, participants answered a computerized questionnaire at home and underwent 
physical examination at the research center to obtain information on medical history and 
current health status. Smoking status was verified and participants were classified into 
one of three categories: current smoker, former smoker, or never smoker. At the research 
center, blood pressure in a sitting position was measured twice on the right upper arm 
using a random-zero sphygmomanometer. In the analyses the average of these two mea-
surements was used. Diabetes mellitus was defined as random or post-load serum glucose 
level exceeding 11.1 mmol/l or the use of oral blood glucose lowering drugs or insulin. 
We calculated body-mass index as weight/height2 (kg/m2). Participants underwent B-mode 
ultrasonography of both carotid arteries to measure intima-media thickness.
In the analyses, we used baseline values (1995-1996) of these potential confounders.
Data analysis
All volumes were expressed as percentage of intra-cranial volume (= CSF + GM + normal 
WM + WML) to correct for individual head-size differences. Therefore, a larger relative 
volume of CSF indicates a smaller whole brain volume. Total WM was defined as the sum 
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of normal WM and WML. WML volume was further natural log transformed because of 
skewness of the untransformed measure.
With Cox’ proportional hazards model we calculated hazard ratios (HR) for all-cause mor-
tality associated with brain tissue volumes, WML volume, and brain infarcts (yes versus no). 
We first investigated brain tissue volumes and WML volume in quartiles of their distribution 
and calculated trends over the quartiles. Afterwards, we used these volumes as continuous 
measures (per standard deviation (SD)). We also combined quartiles of CSF volumes and 
WML volumes; and calculated interaction terms between the continuous measures of CSF 
and WML. 
To investigate the effect of incident dementia or stroke on these associations, we subse-
quently performed analyses after censoring persons at onset of dementia, or at occurrence 
of stroke. For better comparison with the Cardiovascular Health Study,10 we also performed 
these analyses by taking incident dementia or stroke as time-dependent covariate. Finally, 
we conducted separate analyses for mortality due to a cardiovascular cause.
All analyses were adjusted for age, sex (model I), and additionally for systolic blood 
pressure, diastolic blood pressure, body-mass index, current smoking, former smoking, 
intima-media thickness and diabetes mellitus (model II). Results are presented with cor-
responding 95% confidence interval (CI). Analyses were done using SPSS 11.0.1, Illinois, 
USA for Windows.
reSultS
Table 1 shows the baseline characteristics of the study population. Follow-up was complete 
until August 15th 2006. During a mean follow-up of 8.4 years a total of 191 persons died 
(incidence rate 46.3 deaths per 1,000 person-years), of whom 49 due to a cardiovascular 
cause. A total of 46 persons developed dementia, of whom 8 died within one year after 
onset and a total of 32 died during the whole of the follow-up period (6 of these 32 died 
due to a cardiovascular cause). Forty-eight persons suffered a stroke, of whom 18 died 
within one year after stroke and 37 died during the whole of the follow-up period (19 of 
these 37 died due to a cardiovascular cause).
Table 2 shows the risk of all-cause mortality after categorizing brain tissue volumes 
into quartiles. Persons in the upper quartile of CSF volume had an increased risk of death 
compared to persons in the lowest quartile. Persons with larger GM or larger total WM had 
a decreased risk of death, though this did not reach statistical significance. Those with a 
larger hippocampal volume also had a decreased risk of all-cause mortality compared to 
the lowest quartile. Larger WML volume was associated with an increased risk of death. 
When analyzing brain tissue volumes continuously, similar associations were found (Table 
2). Persons in the highest quartile of both CSF and WML volume had a more than three-fold 
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increased risk of death as compared with those in the lowest quartile of both CSF and 
WML volume (hazard ratio 3.06, 95% CI 1.34-6.99); the interaction term, however, was not 
significant (p=0.30), indicating an additive rather than a multiplicative effect. 
Adjusting for cardiovascular risk factors only marginally changed the results (data not 
shown).
After censoring persons at onset of dementia, hippocampal volume was no longer associ-
ated with all-cause mortality (Table 2). The risk associated with CSF volume, WML volume 
and lacunar infarcts remained largely unchanged. When censoring persons at occurrence 
of stroke, the associations did not change (Table 2). Adding incident dementia or stroke 
as time-dependent covariate to the model yielded results similar to censoring persons at 
incident dementia or stroke.
Finally, hippocampal volume and CSF volume were not associated with cardiovascular 
mortality (Table 3). In contrast, WML infarcts showed a strongly increased risk of cardiovas-
cular death, whereas the risk associated with lacunar infarcts also increased, though it did 
not reach statistical significance (Table 3, model I). Additional adjustment for cardiovascular 
risk factors did not change the associations (Table 3, model II), nor did excluding fatal 
strokes from the cardiovascular deaths (data not shown).
Table 1. Baseline characteristics of the study population.
Total cohort, n=490
Age, yr 73.4 (7.9)
Women, n 249 (51)
Systolic blood pressure, mmHg 146 (21)
Diastolic blood pressure, mmHg 77 (12)
Body mass index, kg/m2 26.2 (3.5)
Intima-media thickness, mm 0.87 (0.14)
Diabetes mellitus, n 24 (5)
Current smoker, n 87 (18)
Former smoker, n 264 (54)
Cerebrospinal fluid, % of ICV 22.6 (3.7)
Grey matter, % of ICV 46.6 (4.1)
Normal white matter, % of ICV 29.5 (6.4)
Total white matter, % of ICV 30.8 (5.7)
Hippocampus, % of ICV 0.57 (0.08)
White matter lesions, % of ICV a -0.33 (1.26)
Lacunar infarcts, n 112 (23)
Values are means (standard deviation) for continuous variables, or numbers (percentage) for dichotomous variables. ICV intra-
cranial volume
a natural log transformed
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DiSCuSSiOn
In this population-based cohort study 
of elderly, we found that brain atrophy, 
hippocampal atrophy and WML in-
creased the risk of all-cause mortality. 
The risk of mortality associated with 
hippocampal atrophy diminished after 
censoring persons at onset of dementia, 
but not after censoring at occurrence 
of stroke. The risk of mortality as-
sociated with brain atrophy and WML 
remained unchanged after censoring 
for either incident dementia or stroke. 
Finally, WML were particularly related 
to cardiovascular mortality, whereas 
brain and hippocampal atrophy were 
not.
Strengths of our study include the pop-
ulation-based setting, large sample size, 
meticulous case finding, and virtually 
complete follow-up for mortality and 
dementia and stroke. Most importantly, 
in contrast to previously used semi-
quantitative indirect rating scales,10, 25 
we used automated quantification of 
brain MR-images to obtain volumetric 
and direct measures of brain tissue 
volumes. A limitation of our study 
could be that in some cases the cause 
of death could have been misclassified. 
However, because research physicians 
were blinded for brain tissue volumes, 
any misclassification is likely to have 
been non-differential and would lead 
to an underestimation of the effect. 
Another consideration is that despite 
our meticulous efforts to detect all T
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dementia cases, very early and mild cases of dementia might have been missed by our 
follow-up screening exams. Especially, upon death or towards the end of the study period 
these persons would also still have been too mildly demented to be picked up by our 
continuous monitoring. This would have led to a slight underestimation of the total number 
of dementia cases in our study.
We found that brain atrophy and hippocampal atrophy indicated an increased risk of 
all-cause mortality, which is in line with results from the Cardiovascular Health Study.10 
Both brain atrophy and hippocampal atrophy are also known predictors of cognitive de-
cline and dementia.3, 6, 19 The risk of death associated with hippocampal atrophy attenuated 
after censoring for dementia. This suggests that it is the dementia process itself, of which 
hippocampal atrophy can be a marker, rather than a small hippocampus itself, that is associ-
ated with increased mortality.26-28 However, the causes of increased mortality in dementia 
patients are still largely unknown.28
The attenuation of the risk of mortality after taking into account incident dementia was 
only present for hippocampal atrophy and not for brain atrophy. This is in accordance with 
previous findings that in the general population hippocampal atrophy is more strongly 
associated with dementia than is brain atrophy.29
We found that WML increased the risk of all-cause mortality, which fits with observations 
from several other studies in demented or depressed patients,8, 9 or in the general popula-
tion.10, 25 Although the presence of cerebral small vessel disease is associated with cognitive 
decline,4 dementia,6 and stroke,7 censoring persons at onset of dementia or occurrence of 
stroke only marginally changed the risk estimates for all-cause mortality associated with 
WML and lacunar infarcts. Moreover, in our dataset WML and to a lesser extent lacunar in-
farcts also indicated a strongly increased risk of cardiovascular death, even after excluding 
fatal strokes. This suggests that persons with cerebral small vessel disease not only have an 
increased risk of adverse neurological outcomes, but are also prone to other cardiovascular 
Table 3. Risk of cardiovascular mortality associated with brain tissue volumes and markers of small vessel disease.
Brain tissue risk of cardiovascular mortality
Model I Model II
Cerebrospinal fluid, % of ICV (per SD) 1.35 (0.89-2.02) 1.38 (0.91-2.09)
Grey matter, % of ICV (per SD) 0.91 (0.69-1.21) 0.98 (0.73-1.31)
Normal white matter, % of ICV (per SD) 0.81 (0.58-1.13) 0.74 (0.53-1.03)
Total white matter, % of ICV (per SD) 0.97 (0.70-1.33) 0.90 (0.66-1.24)
Hippocampus, % of ICV (per SD) 0.97 (0.70-1.35) 0.96 (0.68-1.36)
White matter lesions, % of ICV (per SD) a 2.01 (1.37-2.96) 2.52 (1.65-3.84)
Lacunar infarct (yes versus no) 1.70 (0.90-3.21) 1.88 (0.98-3.60)
Values are hazard ratios with 95% confidence interval. ICV intra-cranial volume, SD standard deviation
Model I: adjusted for age, sex
Model II: adjusted for age, sex, systolic blood pressure, diastolic blood pressure, body-mass index, current smoking, former 
smoking, intima-media thickness and diabetes mellitus
a natural log transformed
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events, which can lead to their death. However, because cerebral small vessel disease is 
closely associated with vascular risk factors,30, 31 confounding may play a role in the as-
sociation between cerebral small vessel disease and cardiovascular mortality. We found that 
additional adjustment for vascular risk factors did not change this association (model II). 
Thus, presence of cerebral small vessel disease may reflect cardiovascular damage in the 
whole body better than these cardiovascular risk factors. An additional explanation could 
be that cerebral small vessel disease also reflects other cardiovascular determinants that 
we did not measure in our study, e.g. genetic factors. Finally, the possibility of residual 
confounding due to measurement error cannot be fully ruled out.
Our automated classification algorithm yielded total volume of WML and did not distin-
guish WML according to their location. Given the proposed difference between subcortical 
and periventricular WML in etiology and cognitive outcomes,32-34 future studies should 
investigate whether the prognosis for death also differs according to location of WML.
In conclusion, we showed that brain atrophy and hippocampal atrophy are related to 
death probably by leading to dementia. In contrast, presence of cerebral small vessel dis-
ease indicates an increased risk of death, in particular cardiovascular death, independent 
of incident dementia or stroke. This emphasizes the need of studies investigating whether 
installment of preventive strategies in those with atrophy or cerebral small vessel disease 
is indicated and effective in preventing mortality.
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ABStrACt
Background: To identify genetic variants underlying stroke, we performed a prospective 
meta-analysis of genome-wide association data in white subjects from four large cohort 
studies comprising the Cohorts for Heart and Aging Research in Genomic Epidemiology 
(CHARGE) consortium, and replicated our finding in an African-American cohort. 
Methods: Each discovery cohort used genotype information to impute to HapMap’s CEU panel 
and age- and sex-adjusted Cox models to relate 2.2 million SNPs to incident stroke.  Study-
specific findings were combined in a fixed-effects meta-analysis including 19,602 stroke-free 
individuals (mean age 63) who developed 1,544 initial incident strokes (1,164 ischemic) over 
an average follow-up of 11 years.  Findings were replicated in 2,430 African-Americans (mean 
age 53), of whom 215 developed incident stroke (191 ischemic) over 15 years.
Results: Two intergenic SNPs at one locus were significantly associated with incident 
total and ischemic stroke (p<5x10-8).  For the first SNP, the risk per allele in the discovery 
cohort was 31% (95%CI:19-44%) higher for total stroke, and 39% (95%CI:27-46%) higher 
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for ischemic stroke yielding population attributable risks of 11 and 14%, respectively. In 
African-Americans, corresponding risks were 39% (95%CI:5-84%) and 43% (95%CI:6-92%).
Conclusions: Our community-based GWAS uncovered a novel association for incident 
stroke. Exploring the epidemiological, molecular and clinical correlates of genetic variation 
at this locus may permit new insights into the pathophysiology of stroke.
intrODuCtiOn
Identification of genetic and environmental risk factors for stroke is important  because 
stroke is the leading neurological cause of mortality and morbidity.1 Twin and familial-
aggregation studies suggest that stroke risk has a substantial genetic component.2-4 Whereas 
several monogenic disorders are known to cause stroke, the genes underlying stroke risk in 
the general population remain undetermined.  Previous studies that used candidate gene as 
well as classical linkage approaches have yielded inconsistent findings.5
The application of unbiased genome-wide association study (GWAS) techniques to large 
samples has uncovered previously unsuspected common variants underlying the risk for 
other complex diseases such as diabetes6 and coronary artery disease.7, 8 A prior GWAS 
of stroke was limited by its small sample size (249 patients) and a case-control design 
restricted to prevalent cases.9 Although an efficient and powerful design, case-control stud-
ies, especially for the study of late-onset disorders such as stroke, may suffer from selection 
and survival biases. Such biases are avoided in prospective studies of incident events but 
individual cohort studies have a limited number of events. We combined data from white 
participants in four large, prospective population-based cohort studies: the Atherosclerosis 
Risk in Communities (ARIC) Study,10 the Cardiovascular Health Study (CHS),11 the Framing-
ham Heart Study (FHS),12, 13 and the Rotterdam Study14 to study the genetics of stroke. 
Together with the Aging Gene-Environment Susceptibility- Reykjavik Study (AGES-RS)15 
these studies form the Cohorts for Heart and Aging Research in Genomic Epidemiology 
(CHARGE) consortium. However, the AGES-RS does not have data on incident stroke and 
hence did not contribute to this meta-analysis. We present findings from a GWAS of inci-
dent total stroke and ischemic stroke as the primary and secondary outcomes, respectively, 
based on this discovery sample of four population-based cohorts with follow up of 19,602 
white participants, and on a replication sample of 2,430 African-American participants in 
the ARIC study.
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methODS
Consortium organization
The CHARGE consortium includes large prospective community-based cohort studies that 
have genome-wide variation data coupled with extensive data on multiple phenotypes. All 
participating studies approved guidelines for collaboration, and a neurology working-group 
arrived at a consensus on phenotype harmonization, covariate selection and analytic plans 
for within-study analyses and meta-analysis of results. Each study has an Institutional Review 
Board that approved the consent procedures, examination and surveillance components, 
data security processes, genotyping protocols and current study design. All participants 
gave written informed consent for study participation and for use of DNA for genetic 
research.
Setting
Details of cohort selection, risk factor assessment and stroke surveillance in the four stud-
ies have been described previously.10-14 The ARIC study enrolled 15,792 men and women 
(including 11,478 non-Hispanic whites) from four U.S. communities. Participants were 
between age 45 and 64 years at their baseline examination in 1987-1989. The CHS enrolled 
adults ≥65 years from four field centers (N=5,888 including 5,201 whites); the baseline 
examination was either in 1989-90 or 1992-93. The FHS is a single-site, study that comprises 
three generations of participants (N=10,333, virtually all white), the Original cohort fol-
lowed since 1948,12 their Offspring and spouses of the offspring followed since 1971,13 
and children from the largest offspring families followed since 2000 (Gen 3).16 Gen 3 
participants were not included in this analysis since they are young (mean age 40±9 years) 
and few have suffered strokes. The Rotterdam Study enrolled inhabitants from a district 
of Rotterdam (Ommoord) aged ≥55 years (N=7,983, virtually all white) at the baseline 
examination in 1990-93.
Study population
Participants who were stroke free entered the current study on the date of the blood draw 
used for their genotyping, and were then followed prospectively for incident stroke. FHS 
and Rotterdam participants were almost entirely European whites; so only non-Hispanic 
white ARIC and CHS participants were included in our analyses. Participants were ex-
cluded if they declined consent or failed genotyping. In addition, CHS did not genotype 
participants with any form of clinical cardiovascular disease at baseline. The meta-analysis 
included 7,686 participants from ARIC, 2,022 from CHS, 4,131 from FHS and 5,763 from the 
Rotterdam Study who met these criteria. Demographic and clinical characteristics of the 
study samples, assessed at the baseline examination, are shown in Table 1.
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Stroke definition, surveillance and classification
All four studies defined stroke as a sudden onset focal neurological deficit of presumed 
vascular etiology lasting for at least 24 hours, or until death if the participant died less than 
24 hours after onset of symptoms. Details of stroke surveillance and diagnostic criteria 
for stroke and stroke types in each of the four studies have been published.17-20 Strokes 
were classified as ischemic, hemorrhagic or unknown type based on clinical and imaging 
criteria. For the analyses of total stroke, ischemic, hemorrhagic, and unknown strokes were 
included; subarachnoid hemorrhages were excluded.
Genotyping
The consortium was formed after the individual studies had finalized their GWAS platforms, 
and the four studies included used different platforms: the Affymetrix GeneChip® SNP Array 
6.0 for ARIC, the Illumina HumanCNV370-Duo® for CHS, the Affymetrix GeneChip® Human 
Mapping 500K Array Set and 50K Human Gene Focused Panel® for FHS, and the Illumina 
Infinium HumanHap550-chip v3.0® for the Rotterdam Study. All studies used their genotype 
data to impute to the 2.5 million non-monomorphic, autosomal, SNPs described in HapMap 
(CEU population). Extensive quality control (QC) analyses have been performed in each 
cohort.
Table 1. Characteristics of Study Participants in Analysis of Incident Total stroke and Incident Ischemic Stroke
StuDY AriC ChS fhS rotterdam
Number in sample* 7686 2022 4131 5763
Women % 53 55 55 59
Mean follow-up (yrs) 15 11 6 10
Mean Age ( ±SD) 
at DNA draw 54±6 73±6 66±12 69±9
at incident stroke 66±7 81±6 80±10 80±8
Number of incident total stroke 312 459 156 617
Number of incident ischemic stroke 277 389 131 367
Cardiovascular risk factor at baseline† 
Systolic Blood Pressure (mean ±SD) 118±17 138±22 131± 20 139±22
Diastolic Blood Pressure (mean ±SD) 72±10 71±11 74±10 74±12
Hypertension, % 27 61 52 61
Diabetes mellitus, % 6 14 12 10
Current Smoker,% 25 11 14 23
Prevalent CVD other than stroke, % 5 0‡ 16 10
ARIC: Atherosclerosis Risk in Communities;  CHS: Cardiovascular Health Study;  FHS: Framingham Heart Study
*Only includes those genotyped persons who also provided consent for these analyses and had high-quality genotyping (met 
QC criteria). 
† Definition of  baseline characteristics was uniform across all four studies: Hypertension was defined using JNC-7 criteria as 
systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg or being on antihypertensive treatment; Diabetes 
mellitus was defined as a casual or 2 hour post-prandial blood glucose ≥200mg/dl (11 mmol/L), a fasting blood glucose 
≥126mg/dl (7 mmol/L), or use of insulin or oral hypoglycemic agents; CVD (cardiovascular disease) was defined as presence of 
congestive heart failure, coronary heart disease or intermittent claudication.
‡ In CHS, persons with prevalent CVD were not genotyped.
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Statistical analyses within studies
Participants entered the analysis at the time of the DNA sample collection and were fol-
lowed for their first stroke event; participants were censored at death or at the time of their 
last follow-up examination or health status update when they were known to be free of 
stroke. For the analyses of ischemic stroke, persons were also censored when they suffered 
an alternative type of stroke (hemorrhagic or unknown). Persons with a subarachnoid 
hemorrhage were censored at the time of the event (n=28). Each study fit an additive 
genetic model – a 1 degree of freedom trend test – relating genotype dosage (0 to 2 copies 
of the minor allele) to study trait. We used Cox proportional hazards models to calculate 
hazard ratios with corresponding 95% confidence intervals. Primary analyses were adjusted 
only for age and sex to avoid adjusting for covariates that might lie along a causal pathway. 
In addition, ARIC and CHS also adjusted for study site, and FHS adjusted for familial struc-
ture (by employing a Cox model with robust variance estimator clustering on pedigree 
to account for family relationships) and for whether the DNA had been whole genome 
amplified. In a second step we additionally adjusted our most significant associations both 
for systolic blood pressure and for the presence or absence of hypertension (defined using 
criteria from the Seventh Report of the Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure as systolic blood pressure ≥140 mm Hg, 
diastolic blood pressure ≥90 mm Hg or use of antihypertensive medications).21 All four 
studies screened for latent population substructure, which was negligible.
Meta-analysis
We conducted a meta-analysis of results from the four cohorts using inverse-variance 
weighting, also known as fixed-effects meta-analysis. Prior to the meta-analysis, strand 
alignment was verified across all studies. After QC, filtering, and imputation within each 
study, we restricted our meta-analysis to the 2,194,468 autosomal SNPs that were com-
mon to all studies. We decided a priori on a genome-wide significance threshold of 5x10-8 
which corresponds to a target α (p-value) of 0.05 with a Bonferroni correction for 1 mil-
lion independent tests. For 2.2 million tests, it corresponds to an expectation of only 0.11 
false positives, regardless of test-dependence. The linkage disequilibrium pattern seen in 
ongoing deep sequencing efforts within European populations also supports the use of 
this threshold.22 SNPs with 5x10-8<p<1x10-5 were considered highly suggestive associa-
tions, but not genome-wide significant; SNPs with 1x10-5<p<1x10-4 were considered only 
moderately suggestive associations.
Replication
We undertook in-silico replication of the findings for which we obtained genome-wide 
significance in the CHARGE cohort in an independent sample, the African-American par-
ticipants in the ARIC study.10 We studied 2430 persons (889 men; mean age: 53±6 years) 
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who were initially free of stroke and consented for genotyping.  Stroke definition and 
surveillance methods in this replication sample were identical to that used in white ARIC 
participants.20 Genotyping was undertaken using the Affymetrix GeneChip® SNP Array 6.0. 
Imputation was not attempted as current HapMap release versions do not have linkage 
disequilibrium data in African-Americans, but only in Africans. Only one of the two top snps 
was present on the array used and was investigated using additive genetic models.  The CHS 
had genotyping on 574 African Americans, but the platform used did not genotype the high 
signal SNPs.
reSultS
We observed 1,544 incident stroke events (1,164 ischemic strokes) among our study 
sample of 19,602 persons followed for an average of 11 years (Table 1). Figure 1A shows 
the genome-wide plot of p-values for the individual SNPs against their genomic position 
for total stroke, and Figure 1B for ischemic stroke. For highly suggestive loci with p<1x10-5, 
the hazard ratios and population attributable risks associated with the minor allele are 
presented in Table 2.  At a threshold of p<1x10-4 (i.e. moderately suggestive), a total of 347 
SNPs were associated with total stroke and 256 SNPs with ischemic stroke.
Two SNPs at one locus surpassed our preset threshold (p=5x10-8) for genome-wide sig-
nificance both for total stroke and ischemic stroke (Table 2). Despite the smaller number of 
events in the analyses of ischemic stroke the hazard ratios were slightly larger and p-values 
slightly smaller for the association of these two SNPs with ischemic stroke than in the 
analysis of total stroke. Each copy of a minor allele at these loci increased the hazard ratio 
for total stroke by 31 to 32% (95% CI: 19-44) and for ischemic stroke by 39 to 41% (95% 
CI: 27-56%). The corresponding population attributable risks are 11-13% for total stroke 
and 14-17% for ischemic stroke. For strokes other than confirmed ischemic strokes (i.e. 
hemorrhagic and unknown types) we found no effect (hazard ratio=1.13; 95%CI: 0.94-
1.36; p=0.20); thus the findings for total stroke reflect the strong association with ischemic 
stroke. The risk estimates for both SNPs were similar across the four studies as shown in 
the Forest plots (Figure 2A to D). Both SNPs were in significant linkage disequilibrium with 
each other (r2 = 0.73 based on HapMap CEU data, NCBI build #36). Figure 3 shows all SNPs 
within a 200kbp region on either side of these two SNPs, together with the recombina-
tion rates and the known genes in that region. Adjustments for systolic blood pressure or 
hypertension had negligible effects on the associations.
We were able to replicate the association of the first SNP in the African-American sample. 
Over a follow-up period of 15 years, 215 persons suffered an incident stroke and 191 of 
these were ischemic. The first SNP, with a minor allele frequency of 10%, was associated 
with incident total stroke (HR=1.39;95% CI:1.05-1.84;p=0.02) and incident ischemic stroke 
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(HR=1.43;95% CI:1.06-1.92;p=0.02).with population attributable risks among African-
Americans of 7% and 8%, respectively, per copy of the minor allele.
Figure 1A and B. Genome-wide signal intensity (Manhattan) plots showing the individual p-values (based on the fixed-effects meta-
analysis) against their genomic position for total stroke (A - top) and ischemic stroke (B - bottom). Within each chromosome, shown 
on the x-axis, the results are plotted left to right from the p-terminal end. The solid line indicates the threshold for p=10-5. Hits above 
this line are shown in Table 2. The dashed line indicates the threshold for p=10-4.
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We also examined associations with SNPs reported to be significantly associated with 
either total stroke or ischemic stroke in published meta-analysis; thus we examined SNPs 
on the following genes: MTHFR, F5, PDE4D, SERPINE1, F2, GP1BA, ALOX5AP, APOE and 
ACE. Rs16954257 in GPIBA, the glycoprotein 1 b alpha gene, a proxy SNP for rs2243093 
previously associated with stroke,23 was significantly associated with all stroke (p=0.02) 
and ischemic stroke (p=0.02) in our meta-analysis. For prothrombin (F2) the previously 
reported SNP was not present in our imputed dataset.24  However, six other SNPs at that 
locus reached p<10-4 for total stroke.
Table 2. Strongest single nucleotide polymorphism (SNP)-phenotype associations at meta-analysis for total stroke 
and ischemic stroke
SnP nr minor 
allele
mAf hazard ratio p-value PAr Additional SnPs at locus 
with p<10-5
total stroke
1 A 0.23 1.32 (1.20; 1.44) 4.8x10-9 0.13 3
2 A 0.19 1.31 (1.19; 1.44) 1.5x10-8 0.11 3
3 T 0.47 1.23 (1.13; 1.33) 9.1x10-7 0.18
4 A 0.11 1.41 (1.23; 1.62) 1.2x10-6 0.09
5 T 0.22 1.23 (1.13; 1.35) 4.4x10-6 0.10 49
6 G 0.20 1.31 (1.17; 1.48) 4.9x10-6 0.12
7 G 0.45 0.83 (0.77; 0.90) 6.4x10-6 § 14
8 T 0.45 1.22 (1.12; 1.33) 6.5x10-6 0.17
9 G 0.39 1.20 (1.11; 1.29) 7.8x10-6 0.14 1
10 C 0.06 1.44 (1.23; 1.69) 8.7x10-6 0.05
11 G 0.09 1.32 (1.27; 1.49) 9.8x10-6 0.06
ischemic stroke
1 A 0.23 1.41 (1.27; 1.56) 2.3x10-10 0.17 3
2 A 0.19 1.39 (1.25; 1.54) 2.6x10-9 0.14 3
3 A 0.11 1.49 (1.27; 1.75) 9.9x10-7 0.10
4 A 0.29 0.78 (0.70; 0.85) 2.1x10-6 §
5 T 0.43 1.24 (1.13; 1.35) 2.1x10-6 0.18 3
6 A 0.27 0.75 (0.66; 0.85) 3.0x10-6 §
7 T 0.47 1.26 (1.14; 1.38) 3.3x10-6 0.20
8 G 0.06 1.49 (1.26; 1.76) 3.6x10-6 0.05 1
9 G 0.16 1.36 (1.19; 1.55) 6.0x10-6 0.10
10 A 0.28 1.24 (1.13; 1.36) 6.9x10-6 0.12 2
11 C 0.09 1.53 (1.27; 1.84) 7.4x10-6 0.09
P-values, hazard ratios and 95% confidence intervals (CI) are based on fixed–effects (inverse variance-weighted) meta-analysis. 
Each row specifically identifies only the SNP-phenotype association with the lowest p-value for that locus, except for the two 
associations reaching genome-wide significance that are both shown here. SNPs highlighted in bold were associated with both 
total stroke and ischemic stroke. The last column shows the number of additional SNPs at the same locus, within 250kb of the 
specified SNP, that were also associated with the phenotype with a p-value <10-5. Complete details for these additional SNPs are 
provided in the Supplementary Tables A and B available online. 
*Alleles were identified based on the plus strand of the NCBI build #36. The minor allele was also the coded allele; MAF: Minor 
allele frequency is based on allele frequency in meta-analysis sample.
PAR: Population attributable risk
§ Population attributable risks are not reported for these minor alleles since they were protective.
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A. all stroke
Hazard ratio
0.5 1.0 1.5 2.5
ARIC   1.20 (1.00;1.45)
CHS   1.34 (1.02;1.76)
FHS   1.66 (1.29;2.12)
RS   1.29 (1.13;1.47)
Summary 1.32 (1.20;1.44)
B. all stroke
Hazard ratio
0.5 1.0 1.5 2.5
ARIC   1.20 (0.99;1.45)
CHS   1.33 (0.99;1.79)
FHS   1.57 (1.23;2.01)
RS   1.30 (1.14;1.48)
Summary 1.31 (1.19;1.44)
C. ischemic stroke
Hazard ratio
0.5 1.0 1.5 2.5
ARIC   1.25 (1.03;1.52)
CHS   1.50 (1.15;1.95)
FHS   1.89 (1.45;2.46)
RS   1.33 (1.12;1.57)
Summary 1.41 (1.27;1.56)
D. ischemic stroke
Hazard ratio
0.5 1.0 1.5 2.5
ARIC   1.22 (1.00;1.49)
CHS   1.47 (1.10;1.95)
FHS   1.78 (1.36;2.31)
RS   1.35 (1.14;1.60)
Summary 1.39 (1.25;1.55)
Figure 2: Forest plots for the first (A and C) and second (B and D) top SNP. Individual studies (boxes) are plotted against 
the individual effect sizes (hazard ratios). The size of the box is inversely proportional to the variance. Horizontal lines are the 95% 
confidence interval. The y-axis shows the value for no effect (hazard ratio=1). Note that the x-axis is on a logarithmic scale.
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Figure 3: Regional plot for associations in the region of 200 kbp on either side of the top SNPs. All SNPs are plotted with 
their meta-analysis p-values against their genomic position.  The triangles pointing down show meta-analysis p-values for total stroke, 
and the triangles pointing up for ischemic stroke. The light line represents the estimated recombination rates.
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DiSCuSSiOn  
In this meta-analysis of GWAS data from four large cohort studies of incident stroke events, 
two previously unsuspected common SNPs were consistently associated with total stroke 
and ischemic stroke in persons of European descent. We were able to replicate this finding 
in an independent sample of persons of African-American ethnicity.
We had a priori considered total stroke, a heterogenous phenotype, as our primary analy-
sis, but the finding that the association of our top SNPs was stronger for the phenotype of 
ischemic stroke, despite the smaller sample size than total stroke, and that the association 
was absent in the non-ischemic subgroup, indicates that these SNPs were primarily associ-
ated with ischemic stroke. The effect sizes were similar in all four discovery cohorts and in 
the replication cohort, and the minor alleles were associated with an increased ischemic 
stroke risk of 31-43% per copy of the allele.
Several of the highly suggestive SNP-phenotype associations were in or adjacent to genes 
that may be biologically plausible candidates to affect stroke risk since they modulate 
inflammation and coagulation, synaptic function, neuronal survival or cell adhesion). These 
highly suggestive findings for these genes need further examination in other studies.
The strengths of this study include the community-based prospective design, the large 
sample of incident cases of both fatal and non-fatal stroke, the high-quality of methods 
used to identify and classify stroke, and the ongoing surveillance that verifies cohort mem-
bers serving as controls have remained free of stroke; these strengths extend to both the 
discovery and replication cohorts. These associations are unlikely to be due to population 
stratification since the discovery sample was restricted to whites of European origin and 
was also investigated for latent population substructure. Moreover, we were able to repli-
cate our significant locus in an independent sample of different ethnicity.
The study also has limitations. The identified intergenic SNPs may not represent the causal 
variants but are expected to be in linkage disequilibrium with the causal variants, which 
remain to be uncovered. Further exploration of this genomic region with dense genotyping, 
expression and translational studies will be required. There were too few events to study 
genotype-phenotype associations underlying individual subtypes of ischemic stroke, such 
as cortical or lacunar ischemic strokes. Finally, we had limited power to detect associations 
with small effect sizes and associations with rare variants.
In conclusion, this meta-analysis of GWAS data from four large community-based stud-
ies has identified previously unsuspected associations with incident stroke. Exploring the 
epidemiological correlates and the molecular, cellular and clinical consequences of genetic 
variation at this locus may yield novel insights into the pathophysiology of stroke.
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the gAB2 gene and the risk of Alzheimer’s 
Disease: replication and meta-analysis
M. Arfan Ikram, Fan Liu, Ben A. Oostra, Albert Hofman, Cornelia M. van Duijn, 
Monique M.B. Breteler
ABStrACt
Background: In a recent genome-wide association study, the GAB2-gene has been suggested 
to modify the risk of late-onset Alzheimer’s disease (AD) among APOEε4-carriers. However, 
replication data are scarce and inconsistent.
Methods: In a population-based cohort study (n=5,507; age>55) with 443 incident AD cases 
we sought to replicate the association between rs4945261 and AD. Because we used high-
density genotyping of GAB2, we also investigated several other polymorphisms within and 
around this gene. Furthermore, we performed a meta-analysis with all previously published 
studies.
Results: We found that rs4945261 was associated with AD among APOEε4-carriers (p=0.02), 
but not among non-carriers (p=0.26). Fifteen of the 20 remaining polymorphisms within 
GAB2 and several polymorphisms in the 250kbp-region surrounding GAB2 were also as-
sociated with AD among APOEε4-carriers and only one among non-carriers. For rs2373115 
meta-analysis with published studies yielded an odds-ratio of 1.58 (1.17-2.14) with 
p=3.0*10-3 among APOEε4-carriers and 1.09 (0.97-1.23) with p=0.16 among non-carriers. 
For rs4945261 the pooled odds-ratio was 1.75 (1.21-2.55) with p=3.0*10-3 among APOEε4-
carriers and 1.20 (1.01-1.41) with p=0.03 among non-carriers.
Conclusions: We found the GAB2 gene to be associated with AD. When taken together with 
published data, our data suggest GAB2 to modify the risk of AD in APOEε4-carriers.
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intrODuCtiOn
The quest for finding genes that are related to Alzheimer’s disease (AD) has turned towards 
using high throughput genotyping analysis, in which thousands of polymorphisms can 
be studied concomitantly. Several genome-wide association studies have been conducted 
for AD so far and most found a consistent and strong hit in or around the Apolipoprotein 
E (APOE) gene, confirming earlier linkage and candidate gene studies.1-3 Reiman et al. 
carried out a genome-wide association analysis after stratification by the APOEε4-allele.4 
They showed that the gene encoding GRB-associated binding protein 2 (GAB2) was as-
sociated with AD in APOEε4-carriers, but not in non-carriers. Replication data are scarce 
and inconsistent: Chapuis et al.5 failed to find an association between GAB2 with AD in 
three independent study samples, either in APOEε4-carriers or non-carriers. Li et al.3 also 
did not confirm this finding in their genome-wide association study, but did not stratify by 
APOEε4-status. However, in a Belgian sample Sleegers et al.6 did find an association, and 
finally Miyashita et al.7 could not replicate this association in a Japanese population.
In the population-based Rotterdam Study, we sought to replicate the association between 
GAB2 and AD. We investigated rs4945261, which was one of the SNPs in the original re-
port. Moreover, because we used high-density genotyping, we also investigated other SNPs 
within GAB2 and within a 250kbp-region surrounding the gene. Finally, we meta-analyzed 
our results with those from previously published studies.
171
Replication study of GAB2 and Alzheimer’s disease
methODS AnD mAteriAlS
Study population
The Rotterdam Study is a prospective population-based cohort study of 7,983 Caucasian 
participants (aged 55 years and over) living in Ommoord, a district of Rotterdam, The Neth-
erlands.8 The study investigates determinants of chronic diseases in the elderly, including 
AD. Persons gave written informed consent to participate and the study was approved by 
the institutional medical-ethics committee. At baseline (1990-1993) participants were in-
terviewed and underwent physical examination and blood sampling. For the present study, 
only persons who were non-demented at baseline were eligible (n=7,046). No overlap 
exists between our study population and the Dutch sample reported on in the original 
report.4
Genotyping
Only participants with proper quality DNA-samples (n=6,449) were considered for genotyp-
ing using the version 3 Illumina-Infinium-II HumanHap550SNP chip-array as part of a large 
project on genetics of complex diseases. Genotyping procedures were followed according 
to manufacturer’s protocol.9 After quality control 5,974 persons remained with proper 
genotyped data. No population stratification was present in this sample.9 For the current 
report we extracted data on rs4945261. We also extracted other SNPs that were located in 
GAB2 (total of 20 SNPs) or within a 250-kbp region surrounding the gene (94 SNPs), and 
were in Hardy-Weinberg equilibrium (p>0.001). In order to pool our data with all previous 
studies we imputed allelic data for rs2373115 based on the local linkage disequilibrium 
structure using the MACH-imputation software (http://www.sph.umich.edu/csg/abecasis/
MACH). The quality of imputation was 99.8%.
APOE genotyping was performed on coded samples without knowledge of the other 
measurements as described elsewhere,10 and was unavailable in 467 persons mostly due to 
technical reasons leaving a total of 5,507 persons available in the current analysis.
Ascertainment of incident AD
The diagnosis of incident AD was made following a three-step protocol.11 At baseline (1990-
1993) and during three follow-up visits (1993-1994, 1997-1999, 2002-2004) two brief tests 
of cognition (MMSE and Geriatric Mental State schedule (GMS)) were used to screen all 
subjects. Screen-positives (MMSE score<26 or GMS>0) underwent the Cambridge examina-
tion for mental disorders of the elderly (Camdex). Persons suspected of having dementia 
were examined by a neuropsychologist if additional neuropsychological testing was re-
quired for diagnosis. When available, imaging data were used. In addition, the total cohort 
was continuously monitored for incident AD through computerized linkage between the 
study database and digitalized medical records from general practitioners and the Regional 
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Institute for Outpatient Mental Health Care. The diagnosis of AD was made in accordance 
with internationally accepted criteria by a panel of a neurologist, neuropsychologist and 
research physician. Follow-up was complete until January 1st, 2005.
Statistical analysis
We used the allelic χ2-test with one degree-of-freedom to investigate the association 
between rs4945261 and AD, before and after stratification by APOEε4-status. We used a 
threshold of p=0.05 for statistical significance, because our aim was to replicate previous 
genome-wide findings.
A similar approach was used when investigating the remaining 20 SNPs within GAB2. 
However, in this instance we also assessed multiple testing by calculating false-discovery 
rates12 and by permutation testing. Subsequently, we analyzed the 94 SNPs in the region 
surrounding GAB2.
We further explored these associations by using Cox’-proportional hazards models and 
adjusting for age, sex, and time-to-event. Finally, we tested for interaction by adding an 
interaction term SNP*APOEε4-status to the models.
For our meta-analysis strategy, see the Appendix.
reSultS
Table 1 shows the characteristics of the study population. APOEε4-carriers were younger 
than non-carriers and as expected had a shorter follow-up time with a larger percentage 
of incident AD cases.
Table 2 shows the association of SNPs in GAB2 with AD. Rs4945261, the only SNP similar 
to the discovery report, showed a significant association with AD (p=0.02). Stratification by 
the APOEε4-allele showed that the association was particularly marked in carriers of the 
APOEε4-allele. In non-carriers no significant association with AD was seen.
Table 1. Characteristics of the study population.
total APOEε4 non-carriers APOEε4 carriers p-value
N 5,507 3,958 1,549
Age 68.9 (8.7) 69.1 (8.8) 68.4 (8.4) 0.01*
Women 3,215 (58%) 2,322 (59%) 893 (58%) 0.67**
Mean follow-up 9.24 (3.21) 9.31 (3.17) 9.07 (3.32) <0.01†
Incident AD cases 443 (8%) 249 (6%) 194 (13%) <0.01†
Values are numbers (percentages) or means (standard deviation). The p-values are for the difference between APOEε4 carriers 
and non-carriers. AD: Alzheimer’s disease
* sex-adjusted
** age-adjusted
† age and sex-adjusted
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Of the 20 remaining SNPs in GAB2 15 also showed a significant (p<0.05) association 
as well as the imputed SNP rs2373115 (Table2). Table 3 shows that although the p-values 
would not survive multiple-testing correction for 21 SNPs, the probability that these find-
ings are false-discoveries is very small. In the Figure p-values for all SNPs within 250-kbp 
of the GAB2 gene are plotted against their respective genomic position and stratified by 
APOEε4-allele. Among APOEε4-carriers various SNPs that were in high linkage disequilib-
rium (LD) with SNPs within GAB2 had a p-value<0.05. Non-significant SNPs were located 
further away from GAB2 across recombination sites and in other LD-blocks (see Figure). 
In contrast, in non-carriers only one SNP in the whole region located outside GAB2 had a 
p-value<0.05.
Table 4 shows hazard-ratios, adjusted for age, sex and time-to-event. The associations 
among non-carriers hardly changed, but among APOEε4-carriers the associations attenuated 
slightly. Nevertheless, eleven of the 22 SNPs were still significant among APOEε4-carriers, 
whereas several others SNPs were borderline significant. Finally, the interaction term for 
APOEε4*SNP was not significant for any SNP (data not shown).
Table 3. Statistics for the association between polymorphisms in GAB2 and incident Alzheimer’s disease, stratified 
by APOE ε4 status.
A. APOE ε4 carriers
SNP Unadjusted p-value False discovery rate* Adjusted False 
discovery rate**
Corrected empirical 
p-value***
rs11603112 0.0109 0.0290 0.0050 0.0672
rs1893447 0.0134 0.0290 0.0050 0.0787
rs2450129 0.0141 0.0290 0.0050 0.0821
rs2292572 0.0147 0.0290 0.0050 0.0866
rs1318241 0.0162 0.0290 0.0050 0.0918
rs10899469 0.0164 0.0290 0.0050 0.0922
rs7941639 0.0176 0.0290 0.0050 0.0941
rs731600 0.0177 0.0290 0.0050 0.0963
rs10501426 0.0184 0.0290 0.0050 0.0978
rs10899496 0.0184 0.0290 0.0050 0.0978
rs6592772 0.0185 0.0290 0.0050 0.0986
rs2511175 0.0194 0.0290 0.0050 0.1036
rs4945261 0.0194 0.0290 0.0050 0.1036
rs7112234 0.0199 0.0290 0.0050 0.1042
rs7107174 0.0207 0.0290 0.0050 0.1160
rs4944196 0.0257 0.0337 0.0058 0.1374
rs1981405 0.0574 0.0709 0.0121 0.2652
rs2450135 0.1710 0.1976 0.0341 0.6026
rs7927923 0.1788 0.1976 0.0356 0.6276
rs11237451 0.2231 0.2343 0.0440 0.6833
rs11601726 0.7215 0.7215 0.1295 0.9992
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Meta-analysis with published studies showed a pooled random-effects odds ratio for 
rs2373115 among APOEε4-carriers of 1.58 (95%CI 1.17-2.14) with p=3.0*10-3. For 
rs4945261 the meta-analysis showed among APOEε4-carriers a random-effects odds ratio 
of 1.75 (1.21-2.55) with p=3.0*10-3. Among non-carriers the odds ratios were 1.09 (0.97-
1.23) with p=0.16 for rs2373115 and 1.20 (1.01-1.41) with p=0.03 for rs4945261 (see 
Appendix).
DiSCuSSiOn
In this population-based cohort study we found that rs4945261 was associated with AD in 
persons carrying the APOEε4-allele. In non-carriers no significant association was found. 
Furthermore, we also found that several other SNPs within and around GAB2 were associ-
ated with AD in APOEε4-allele carriers but not in non-carriers, though these would not 
survive multiple-testing correction.
B. APOE ε4 non-carriers
SNP Unadjusted p-value False discovery rate* Adjusted False discovery 
rate**
Corrected empirical 
p-value***
rs10899496 0.0824 0.3365 0.0995 0.3366
rs7112234 0.0954 0.3365 0.0995 0.3750
rs10501426 0.1303 0.3365 0.0995 0.4728
rs2292572 0.1337 0.3365 0.0995 0.4817
rs11603112 0.1382 0.3365 0.0995 0.4883
rs2450135 0.1568 0.3365 0.0995 0.5417
rs4944196 0.1916 0.3365 0.0995 0.6258
rs6592772 0.2060 0.3365 0.0995 0.6435
rs1981405 0.2151 0.3365 0.0995 0.6605
rs10899469 0.2370 0.3365 0.0995 0.6921
rs1893447 0.2426 0.3365 0.0995 0.6965
rs7107174 0.2569 0.3365 0.0995 0.7329
rs4945261 0.2574 0.3365 0.0995 0.7330
rs2511175 0.2597 0.3365 0.0995 0.7337
rs731600 0.2664 0.3365 0.0995 0.7416
rs2450129 0.2665 0.3365 0.0995 0.7423
rs1318241 0.2724 0.3365 0.0995 0.7642
rs7941639 0.4175 0.4870 0.1448 0.9150
rs11237451 0.6476 0.7157 0.2080 0.9937
rs11601726 0.8011 0.8412 0.2452 0.9999
rs7927923 0.9743 0.9743 0.2832 1.0000
Statistics are based on the 21 genotyped SNPs in GAB2. SNPs are ordered by the unadjusted p-value
* Using the method described by Benjamini and Hochberg.12
** calculated using the R-package ‘fdrtool’,17 which additionally adjusts for the estimated proportion of true null associations
*** obtained after 10,000 permutations
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To our knowledge this is the first study to longitudinally investigate the association be-
tween GAB2 and AD. The population-based design limits the possibility of selection biases 
often seen in case-control studies. A possible limitation is that in some cases the diagnosis 
of AD might have been misclassified. However, such misclassification is likely to be random 
and would therefore lead to an underestimation of the true effect. Another consideration is 
that apart from rs4945261 the other SNPs were different from previous reports. However, 
additional genotyping is unlikely to change our results given the density of SNPs we studied 
and the low recombination rate in GAB2 (see Figure). Moreover, genotyping different SNPs 
can be regarded as contributing to fine-mapping the GAB2-gene and its association with AD. 
Our associations would not have survived stringent multiple testing correction for 21 SNPs. 
However, given the strong LD between SNPs and the low prior probability of these findings 
being false-positive, standard multiple testing could be considered  overly conservative. 
More importantly, the meta-analysis also points towards a positive association.
Table 4. Association between polymorphisms in GAB2 and Alzheimer’s disease using Cox’-proportional hazards 
models.
SnP Position hazard ratios (95% Ci)
APOEε4 non-carriers APOEε4 carriers
rs2450135 77605643 0.74 (0.50-1.11) 0.76 (0.48-1.20)
rs1318241 77608440 1.16 (0.90-1.51) 1.38 (1.00-1.90)
rs2450129 77618033 1.17 (0.90-1.52) 1.38 (1.00-1.90)
rs731600 77640781 1.17 (0.90-1.51) 1.36 (0.99-1.87)
rs1893447 77650830 1.17 (0.90-1.51) 1.37 (1.00-1.88)
rs2511175 77652729 1.17 (0.90-1.52) 1.36 (0.99-1.87)
rs1981405 77653856 1.22 (0.90-1.64) 1.32 (0.92-1.88)
rs7927923 77657062 0.99 (0.79-1.23) 1.11 (0.86-1.44)
rs4945261 77667908 1.17 (0.90-1.52) 1.36 (0.99-1.87)
rs7107174 77675584 1.17 (0.90-1.53) 1.35 (0.99-1.85)
rs4944196 77686379 1.20 (0.92-1.55) 1.32 (0.97-1.80)
rs6592772 77693211 1.20 (0.92-1.55) 1.37 (0.99-1.88)
rs10899469 77695961 1.18 (0.91-1.54) 1.38 (1.00-1.89)
rs11237451 77703107 1.03 (0.82-1.29) 1.10 (0.85-1.42)
rs2292572 77730512 1.21 (0.93-1.57) 1.38 (1.02-1.88)
rs10501426 77734770 1.21 (0.93-1.57) 1.36 (1.01-1.85)
rs11601726 77745687 0.97 (0.74-1.26) 1.14 (0.84-1.55)
rs11603112 77751139 1.19 (0.92-1.55) 1.41 (1.03-1.92)
rs2373115 77768798 1.23 (0.95-1.61) 1.36 (1.00-1.85)
rs7112234 77780118 1.23 (0.95-1.61) 1.36 (1.01-1.85)
rs7941639 77794607 1.12 (0.86-1.45) 1.44 (1.04-2.00)
rs10899496 77801479 1.24 (0.95-1.61) 1.37 (1.01-1.86)
Hazard ratios are adjusted for age, sex, and time to event.
CI Confidence interval
SNPs in bold were also genotyped by Reiman et al.4 The SNP in italic was imputed.
177
Replication study of GAB2 and Alzheimer’s disease
Thus far, three studies have failed to replicate the initial findings3, 5, 7 and only one confirmed 
the association.6 In line with the initial study, we found that GAB2 alleles were associated 
with AD only among APOEε4-carriers, and not in non-carriers. Pooling our data with previ-
ously published data showed highly significant associations with odds ratios of 1.58 and 
1.75.
GAB2 is a protein involved in various pathways, some of which involve AD-related tau 
processing.13-15 Indeed, Reiman et al. also found that GAB2 expression was associated with 
protection from neurofibrillary tangle formation.13-15 Moreover, GAB2 is expressed together 
with other potential AD-related genes.16 However, the exact mechanism of interaction with 
the APOE-gene is still unknown. Future research should focus on disentangling the exact 
interactive mechanism as well as high-density sequencing of GAB2 to find the possible 
causative variant.
In conclusion, we found GAB2 to be associated with AD. Together with previous data, this 
suggests GAB2 as a novel gene modifying the risk of AD in APOEε4-carriers.
Figure. The association between polymorphisms surrounding the GAB2 gene and Alzheimer’s disease.
P-values are for the allelic χ2-test. Triangles pointing up indicate p-values for APOEε4 carriers. Circles indicate p-values for APOEε4 
non-carriers. Large triangles pointing down indicate p-values for the meta-analysis in APOEε4 carriers. The dot-dashed line indicates 
the threshold for p-value=0.05. Light line indicates the estimated recombination rates (as obtained from HapMap) reflecting the local 
linkage disequilibirum (LD) structure. Known genes (arrows) are aligned along their genomic position.
At the bottom the LD structure is shown as obtained from HapMap (for the CEU-population). Light colors indicate low LD, darker colors 
indicate high LD.
Note that the p-values at the lower and upper end of the figure are similar between APOEε4 carriers and non-carriers, but that they 
diverge in the LD-block encompassing GAB2.
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Appendix to Chapter 4.2
methODS fOr metA-AnAlYSiS
We conducted a meta-analysis using random-effects pooling for rs4945261 and rs2373115 
based on data from previously published studies.1-4 To ensure we did not miss any other 
study we searched PubMed using the key-words GAB2, Alzheimer’s disease, and dementia. 
We also sought through reference lists of previous papers and queried the AlzGene da-
tabase (www.alzgene.org). We did not find any other studies and restricted our current 
meta-analysis to Caucasian populations.
Supplementary figure. Meta-analysis of published studies on the association between poly-
morphisms in GAB2 and Alzheimer’s disease, stratified by the APOE ε4 allele.
From all studies, genotype frequencies were obtained for cases and controls and the 
odds ratios calculated using the allelic χ2-test with one degree-of-freedom. No additional 
adjustments were made. The effect sizes (boxes) with 95% confidence intervals are plotted. 
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The size of the box is proportional to the weight of the study. The diamond is for the 
random-effects meta-analysis. Note that the x-axis is depicted on a logarithmic scale.
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In this thesis I investigated genetic and non-genetic determinants and clinical outcomes 
of structural brain changes on MRI. I did not investigate specific focal markers, but instead 
I adopted a general approach in which the focus was on markers across the whole brain 
and the whole genome. In this section I will review the main findings, discuss general 
methodological considerations, and consider implications of the findings with respect to 
clinical practice and future research.
mAin finDingS
Descriptives and risk factors of structural brain changes
Several neuro-imaging studies have investigated brain tissue volume changes across various 
broad age-ranges.1-5 However, population data on brain volume changes in the elderly were 
scarce. In chapter 2.1.1 we quantified brain tissue volumes in persons aged 60 to 90 and 
found that white matter atrophy rather than grey matter atrophy seemed to drive loss of 
brain volume with increasing age. We also found that classic cardiovascular risk factors 
(blood pressure, hypertension, and smoking), white matter lesions and lacunar infarcts were 
more strongly associated with white matter atrophy than grey matter atrophy. These results 
fit well with pathologic studies showing that grey matter decline in healthy elderly brains is 
minimal.6, 7 Moreover, in recent years a substantial body of literature is emerging indicating 
that white matter atrophy may be more important in aging and neuro-degeneration than 
thus far recognized.8-13 Various neuro-imaging as well as pathologic studies suggest that 
white matter atrophy is reflective of the same pathologic process as white matter lesions 
and lacunar infarcts, namely cerebral small vessel disease.8, 9, 14-21 In turn, cardiovascular 
risk factors are thought to be etiologically linked with cerebral small vessel disease.12, 22-25 
Therefore, our results that cardiovascular risk factors, white matter lesions, and lacunar 
infarcts are strongly associated with white matter atrophy provide further evidence for a 
vascular basis of white matter atrophy. These findings prompted us to further investigate 
brain volume changes, especially white matter atrophy, with regard to novel putative risk 
factors and clinical correlates.
We investigated kidney disease and unrecognized myocardial infarction as putative risk fac-
tors of vascular brain disease. Both are highly prevalent in the general population, and have 
been shown to indicate a poor prognosis for various clinical outcomes.26-33 Another feature 
of these risk factors is that both reflect subclinical vascular disease, in the kidney and heart 
respectively. In line with previous findings,34-36 we found that persons with poorer kidney 
function, as measured by poor glomerular filtration rate, had more brain atrophy, especially 
subcortical white matter atrophy, and more often white matter lesions and cerebral infarcts. 
For unrecognized myocardial infarction we found that men, but not women, with unrec-
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ognized myocardial infarction had a higher risk of stroke, dementia, white matter lesions, 
and lacunar infarcts. Thus, these results showed that subclinical vascular disease in the rest 
of the body is consistently associated with both clinical and subclinical vascular disease in 
the brain. The question remains, what underlies these associations? One hypothesis is that 
poor kidney function and ventricular malfunction lead to arterial hemodynamic changes 
which in turn lead to vascular brain pathology.37-39 Another possibility is that shared risk fac-
tors – such as hypertension, smoking and arteriolosclerosis – explain the interrelationship 
between kidney disease, heart disease and brain disease.38 The final common pathway of 
these mechanisms leading to vascular brain disease could be by affecting the blood supply 
to the brain.40 Indeed, in chapter 2.4 we found that total cerebral blood flow as marker 
of the blood supply to the brain was associated with brain atrophy and that this in turn 
mediated the association between cerebral blood flow and cognition. However, in chapter 
2.5 investigating retinal vessels we found that widening venules rather than narrowing 
arterioles are related to white matter atrophy. Given that venular widening seems to reflect 
inflammation and atherosclerosis, whereas arteriolar narrowing is more reflective of hyper-
tension and arteriolosclerosis,41-43 this points towards other mechanisms also contributing 
to the relation between cardiovascular risk factors and vascular brain disease. Indeed, there 
is accumulating evidence that the pathophysiology of cerebral small vessel disease involves 
not only hemodynamic changes,12 but also inflammation and atherosclerosis.44, 45
Clinical outcomes of structural brain changes
Having studied descriptives and determinants of structural brain changes, we focused on 
clinical outcomes, especially dementia, depression and mortality (part 3). We were particu-
larly interested in possible differences between white matter and grey matter pathology 
and the risk of clinical correlates. We further investigated whether we could discern a 
distinct pattern of atrophy across the various lobes in relation to outcomes.
We found that white matter atrophy was associated with poorer information processing 
speed and executive function, whereas grey matter atrophy was specifically related with 
memory performance. Moreover, we found that grey matter atrophy, but not white matter 
atrophy, was related to the risk of dementia and Alzheimer’s disease (chapter 3.1). Previous 
studies have reported associations of vascular risk factors with cognition, especially infor-
mation processing speed and executive function, and dementia.46-49 Our findings provide 
evidence that vascular factors contribute to cognitive decline and dementia by affecting 
white matter. In contrast, the pathways underlying the association between grey matter at-
rophy and memory and dementia seem less vascular driven and possibly involve Alzheimer 
specific pathology, such as amyloid plaques and neuro-fibrillary tangles.50, 51
On a lobar level, atrophy of the hippocampus and temporal grey matter was most 
strongly associated with dementia, followed by frontal, parietal and occipital grey matter, 
which corresponds to the pattern found in pathological studies.52, 53 Interestingly, this pat-
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tern remained present even after we excluded persons who had subjective or objective 
cognitive problems at baseline suggesting temporal differences, in which brain structures 
are affected already during the pre-clinical phase of the disease process. These temporal 
differences are further demonstrated when we investigated how many years before clinical 
onset the various lobes are predictive of dementia, as depicted in Figure 1. Our results 
emphasize previous findings that dementia has a long pre-clinical phase and that the actual 
moment of diagnosis does not accurately reflect the disease process.54
The vascular depression hypothesis postulates that vascular brain disease is causally re-
lated with depression.55 In line with previous reports,56-60 we found a strong cross-sectional 
association between MRI markers of vascular brain disease and depression; markers most 
strongly associated were parietal and temporal lobe atrophy, deep and frontal white matter 
lesions, and brain infarcts. However, we found no association between any of the MRI 
markers and depression prospectively (chapter 3.2). Our results therefore do not support 
the vascular depression hypothesis, but point towards possible other mechanisms linking 
vascular brain disease with depression, such as a common etiology,61 vascular brain disease 
being related to persistence of depression,57 or even depression leading to vascular brain 
disease.62 This study also showed that repeatedly finding a cross-sectional association should 
Figure 1. Figure depicting the hazard ratios for dementia against the time to event.
For this analysis, the incident dementia cases from the Rotterdam Scan Study (n=46) were divided into tertiles based on follow-up time 
till dementia. The non-demented persons were then grouped according to the obtained cut-off values of follow-up time. Hazard ratios 
were calculated for each tertile using Cox’ proportional hazards models adjusted for age and sex.
* denotes significance at p<0.05
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not automatically become the basis to draw causal inferences unless robust longitudinal 
data are present.
Finally, we investigated how structural brain changes were related to all-cause mortality 
and cardiovascular mortality in chapter 3.3. Because brain changes are related with stroke 
and dementia,19, 54, 63, 64 we also investigated whether the associations with mortality were 
independent from these neurological outcomes. We found that brain atrophy, hippocampal 
atrophy and white matter lesions increased the risk of all-cause mortality. We did not find 
clear differences between grey matter and white matter, although the risk estimates for 
white matter atrophy were slightly stronger. The risk of mortality associated with brain 
atrophy and hippocampal atrophy diminished after censoring persons at onset of demen-
tia. This suggests that it is the dementia process per se, with hippocampal atrophy being 
a marker thereof, rather than a small hippocampus itself that is associated with mortality. 
However, it is still largely unknown what are the causes of increased mortality in dementia 
patients.65, 66 
Although white matter lesions and lacunar infarcts are predictive of dementia and stroke, 
the risk of mortality associated with both remained unchanged after censoring for either 
incident dementia or stroke. Moreover, white matter lesions and lacunar infarcts were 
particularly related to cardiovascular mortality, suggesting that these MRI markers reflect 
generalized vascular disease rather than only vascular disease in the brain. 
Genetic factors underlying brain changes and neurodegenerative diseases
In the genome-wide association study on stroke described in chapter 4.1 we identified a 
novel locus that reached genome-wide significance and several highly suggestive loci. The 
novel locus was consistently associated with stroke across all four discovery cohorts and 
we were able to replicate the association in an independent sample of different ethnicity. 
This study also showed the great potential of genome-wide studies when combined in a 
large internationally organized consortium.
In chapter 4.2 we used data from the Rotterdam Study to confirm the association 
between GAB2 and Alzheimer’s disease, which was found in a previous genome-wide as-
sociation study.67 Consistent with the discovery study, we found that polymorphisms in 
GAB2 were related with Alzheimer’s disease only in carriers of the APOE ε4 allele and 
not in non-carriers. Meta-analysis of all published results for two polymorphisms showed 
the same results. Our study is one of the first positive replication of GAB2 in relation with 
Alzheimer’s disease and opens the way for further studies to investigate the pathways that 
underlie this relationship.
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methODOlOgiCAl COnSiDerAtiOnS relAteD tO StuDieS in thiS 
theSiS
Study design
Both the Rotterdam Study and Rotterdam Scan Study are designed as longitudinal popu-
lation-based cohort studies, which limits the possibility of selection biases regularly seen 
in cross-sectional clinic-based samples. Such biases are often due to non-random sampling, 
case fatality influencing participation, selective attrition leading to loss to follow-up, and 
competing risks. We sought to tackle these selection biases by taking a random sample 
from the general population, ensuring a high response rate, using incident cases where 
possible, and meticulous follow-up of the entire cohort in order to have minimal loss to 
follow-up. Moreover, all data acquisition, processing, and analyzing was conducted blinded 
for other parameters that could possibly introduce differential information biases. Finally, 
because stratification and restriction was not always possible, we used multi-variable mod-
eling to account for confounding biases. Most of the associations we investigated were 
independent from potential confounding factors. The interpretation of these findings is 
extensively discussed in the respective chapters.
Imaging studies
The biggest difficulty in interpreting results from neuro-imaging studies is due to differences 
in data acquisition and phenotype definition between studies. These differences include 
firstly the fact that each study uses different MR-sequences and classification algorithms, 
which have been tuned against different golden standards. This introduces considerable 
inter-study variation and can lead to spurious or blurred effects. For instance, depending on 
sequences used lacunar infarcts can be classified as white matter lesions or as cerebrospinal 
fluid and as such contribute to different volumes.68, 69 We addressed this problem by using a 
generic classification algorithm that is independent from sequences used.70
Secondly, for correction of individual head-size differences, some studies include the 
posterior fossa in defining intra-cranial volume, whereas others only include supra-tentorial 
tissues, which leads to considerable volumetric differences of about 15%.1, 71, 72 Studies 
focusing on determinants with possible differential effects on the two compartments 
will therefore be difficult to interpret, if they consider the two compartments together. To 
elucidate any such confounded associations such studies should also investigate the two 
compartments separately. In our studies we only investigated the supra-tentorial compart-
ment.
Thirdly, segmentation of lobes is different across studies and usually dependent on land-
marks used as boundaries between lobes.1, 73, 74 This, too, will lead to differences in lobar 
volumes across studies.
191
General discussion
Finally, most neuro-imaging studies, including ours, measure brain MRI markers at only 
one time point. Even though by expressing volume as percentage of intra-cranial volume 
we interpreted the data as ‘atrophy’, real atrophy can only be obtained by measuring at 
two time points. Thus far, reliable methods for investigating changes in MRI markers in a 
population-based setting are lacking. However, efforts are underway that could facilitate 
investigating this in future.54, 75, 76
Genetic studies
Most genome-wide studies reported to date have employed a two-stage design: polymor-
phisms reaching genome-wide significance in a discovery stage or being otherwise highly 
suggestive are followed up in a replication stage. Usually, the shortlist of polymorphisms 
for replication is made based on smallest p-values, linkage disequilibrium between the 
polymorphisms, imputed versus directly genotyped polymorphisms, and possibly known 
functionality of the polymorphism. However, no clear set of guidelines exists that facilitates 
similar selection of polymorphisms across various studies.
Moreover, the question remains what is deemed sufficient replication of a locus. Some 
studies have sought to obtain genome-wide significance for a locus only after joint analysis 
of the discovery and replication stages;67, 77 in other studies a locus reaches genome-wide 
significance already in the discovery stage and then a (Bonferroni corrected) p-value of 0.05 
is used for sufficient replication;78, 79 while even other studies provide data for a locus that 
reaches genome-wide significance both in the discovery and replication stage separately.80 
An important consideration is that the role of replication is not only to reach statistically 
significant results (alone or combined with the initial results), but to accumulate evidence 
that builds on the initial discovery.81 As such, it is also important to focus on the risk esti-
mates.81 In the CHARGE consortium we decided a priori not to separate studies into those 
used for discovery or for replication. We considered that in the meta-analysis each study 
would serve as independent replication for the other three. A practical reason for this ap-
proach is that all participating studies had the logistic and financial infra-structure to obtain 
genome-wide data. This is in contrast to two-stage genome-wide association studies where 
only selected polymorphisms need genotyping in the replication phase. An even more 
important reason is that a meta-analysis of genome-wide data from two studies has more 
power for identifying novel loci than dividing these studies into one used for discovery 
and the other for replication.82, 83 Still, we sought to replicate our findings for stroke in an 
ethnically different population. We used p=0.05 as threshold for significant replication but 
also noted that the risk estimates across all studies were strikingly similar.
Another important feature of genome-wide association studies is analyzing large sample 
sizes in order to have sufficient power to find significant associations. Usually, after the 
initial (single or two-staged) phase, a second or even a third phase is undertaken with 
even larger sample sizes to detect loci for which the initial phase was underpowered.84 
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This is often done by simply adding more samples to the initial study population. In a 
genome-wide association study embedded in a cohort study (e.g the studies participat-
ing in the CHARGE consortium), one way to increase the power is to combine prevalent 
and incident cases. However, if prevalent and incident cases are combined in one logistic 
analysis, difficulties may arise regarding shared controls, adjustments for covariates, and 
use of follow-up time. One solution is to run separate analyses for prevalent and incident 
cases and then combine the results in a meta-analysis. Indeed, the results from a simulation 
shown in Figure 2 demonstrate that the odds ratios obtained using a logistic regression for 
the prevalent cases and the hazard ratios using a Cox proportional hazards regression for 
the incident cases are independent; and that therefore the results can be validly combined 
using meta-analysis.
−0.2 −0.1 0 0.1 0.2
−0.2
−0.1
0
0.1
0.2
prevalent OR
inc
ide
nt
 H
R
1
4
7
9
12
15
18
21
24
26
29
32
35
38
40
43
46
Counts
Figure 2. Results of a simulation demonstrating the independence of the odds ratios using prevalent cases and hazard 
ratios using incident cases from the same study.
In this simulation a cohort of 5000 persons is simulated, of whom 1000 have an event before baseline and we know only their baseline 
status and 1000 have an even after baseline and we know their follow-up time. The results show that the odds ratios obtained using 
a logistic regression for the prevalent cases and the hazard ratios using a Cox proportional hazards regression for the incident cases 
are independent (correlation = -0.008). (Simulation results and figure obtained and reproduced after permission from Dr T. Lumley, 
University of Washington, USA)
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CliniCAl imPliCAtiOnS
In order to prevent disease, it is important to first understand its etiology and identify 
risk factors and risk indicators. Although the studies described may not directly influence 
clinical practice in the short term, some important points can be made.
First of all, clinicians should be aware of the amount of subclinical pathology prevalent 
in the general population. This not only relates to the high prevalence of incidental findings 
on neuro-imaging, but also to the high prevalence of subclinical vascular disease and the 
strong interrelationship between vascular disease in extracerebral vessel beds and vascular 
brain disease.
Second, novel modifiable risk factors are of potential interest for research on preven-
tive strategies. Installment of appropriate treatment in men with unrecognized myocardial 
infarction is one such example. Identification and treatment of subclinical kidney disease 
may be another. For both examples however, the feasibility of screening and efficacy of any 
treatment should be investigated first.
A third clinical implication is the use of MRI-markers in the prediction of neurologi-
cal disease, especially dementia and cognitive impairment. Considerable effort has been 
put into investigating the predictive value of MRI-markers, in particular hippocampus, for 
these outcomes.85, 86 This thesis identifies other MRI-markers that might provide additional 
discriminative power for detection of persons at high risk of developing dementia. Future 
research should establish the added value of these MRI-markers, either combined with 
hippocampal volume or separately.
Finally, all these previous points are readily applicable to the identification of novel genes 
underlying neurological disease. Novel genes not only give insights into the etiology of 
disease and identify potential targets for therapies, but can also be used for risk profiling 
and risk stratification in the prediction of disease.
imPliCAtiOnS fOr future reSeArCh
Neuro-imaging
One of the main and consistent findings of our studies is that white matter atrophy is 
important in neuro-degeneration, since it relates with vascular brain disease and cardiovas-
cular risk factors and in turn affects clinical outcomes. Future research should focus on dis-
entangling the exact mechanisms underlying these associations. Diffusion tensor imaging 
(DTI) offers the opportunity to address these issues by investigating the micro-structural 
integrity of the normal appearing white matter.87 DTI parameters are considered an earlier 
marker of neuro-degeneration than structural brain changes. Indeed, initial DTI studies 
have demonstrated that though white matter atrophy and white matter lesion formation 
Chapter 5.1
194
are closely correlated, they appear to be separate processes;88 still, more widespread map-
ping of the normal white matter using DTI is needed to fully comprehend the role of white 
matter pathology in neuro-degenerative processes. It also remains to be seen whether DTI 
parameters are related to risk factors and clinical outcomes in a similar way as volumetric 
parameters of white matter pathology, and if so whether DTI provides information ad-
ditional to those volumetric measures or whether it is merely a ‘proxy’ for those.
Although we focused on brain atrophy taking place across the whole brain, several novel 
focal changes have recently also received considerable interest. Cerebral microbleeds, iron 
depositions, and Virchow-Rubin spaces are all often present in the aging brain.89-94 Even 
though these have been implicated in the etiology of neuro-degenerative diseases, rela-
tively little is known about risk factors and clinical correlates of these focal MRI-markers as 
compared with white matter lesions and brain infarcts. Further research should consider 
studying these markers with respect to determinants and outcomes, and the interrelation-
ship with other generalized and focal MRI-markers.
For all our imaging studies, we focused (solely) on the supra-tentorial compartment of 
the skull. However, based on animal studies it is increasingly being recognized that the 
cerebellum plays a role in neuro-degenerative diseases.94, 95 Investigating the cerebellum on 
a population level can provide further important clues regarding the exact function of this 
thus far underlit structure.
Genetics
The basic premise of genome-wide association studies is that the association is investigated 
free from any hypotheses. Such studies are therefore by definition hypothesis generating. 
Once a genome-wide association study has been conducted, the next steps are to repli-
cate the significant and highly suggestive loci in independent samples. Sequencing and 
functionality studies will contribute in localizing the exact causal variants. Replication not 
only pertains to the initial phenotype, but also to related (endo)phenotypes. In the genome-
wide association analysis presented in this thesis the initial phenotype was stroke and the 
related endophenotypes would be white matter lesions and lacunar infarcts. Based on the 
work described in this thesis we might even consider adding white matter atrophy.
In the CHARGE consortium, one of our main strengths was that we used incident stroke 
cases. However, after considering the potential selection biases and analytical challenges 
(Figure 2), a next step will be to increase our power by adding the prevalent cases from 
each study to the meta-analysis. We also have contacts with studies outside CHARGE to 
perform joint meta-analyses.
Combining genetics and neuro-imaging
Various studies have investigated pre-selected genetic markers underlying MRI markers.96-98 
The advent of genome-wide association studies has meant that instead of a few markers we 
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can now investigate millions of polymorphisms at once, among 
which we want to detect consistent and robust signals. Cur-
rently, efforts are underway to perform genome-wide analyses 
of MRI markers. In the future, similar to genetic research, tech-
nical developments in neuro-imaging will allow investigation 
of millions of voxel-specific data points instead of aggregated 
volumetric data that we use now.99, 100 It is therefore a matter 
of time before genome-wide association analyses are performed 
on such voxel-by-voxel MRI data. Although the conceptual back-
ground of these analyses will not be very novel, it will pose new 
challenges with respect to organizing, structuring, analyzing and 
reporting the large amounts of data. The Table provides rough 
estimates of filesizes of a single dataset pertaining to different 
analyses. A typical dataset, in which 2.2 million polymorphisms 
will be studied against MRI data on a voxel-by-voxel basis (with 
each voxel being 0.2 mm3) is estimated to be 1000Mb in size. 
Current computational infra-structures are underdeveloped to 
handle such datasets in reasonable time. Moreover, it remains to 
be seen how to visualize such analyses and whether currently 
used statistical techniques (e.g. multiple testing corrections) are 
suited for such data-analysis.
COnCluDing remArkS
I have sought to investigate the non-genetic and genetic deter-
minants of structural brain changes and their relationship with 
neurological outcomes. In this chapter I gave an overview of 
the results, discussed methodological issues and based on those 
results gave some recommendations for future research and 
mentioned clinical implications. It is superfluous to mention that 
these recommendations and implications are far from exhaus-
tive; however, they do nicely demonstrate the research questions 
of interest for the coming years, the challenges the investigation 
of these questions will pose, and the potential breakthroughs 
the answers for these questions could become.
Indeed, exciting times are ahead!
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engliSh SummArY
Neuro-imaging and genetics have played an important role in research on etiologic markers 
of neuro-degenerative disease. Various neuro-imaging studies have identified focal structural 
brain changes as in vivo markers of neurodegenerative diseases. It has been suggested that 
generalized brain changes may also be important markers of neurodegenerative diseases. 
Only recently have advances in MRI technology and image processing led to the ability 
to investigate generalized brain changes and their relationship with neurodegenerative 
diseases. Similarly, the search for genetic markers underlying neurodegenerative diseases 
has been limited, because genetic research was restricted to single or few preselected 
markers.
Recently, it has become possible to investigate genetic markers on a large scale across 
the whole genome.
The aim of the studies described in this thesis was to investigate determinants – both 
non-genetic and genetic – and clinical outcomes of structural brain changes on MRI. The 
focus was on markers across the whole brain and whole genome. The studies were embed-
ded within either the Rotterdam Study or the Rotterdam Scan Study, both large prospective 
population-based cohort studies.
In Part 2 descriptives and determinants of structural brain changes were described. In 
chapter 2.1.1 we quantified brain tissue volumes in people aged 60 to 90 years and inves-
tigated how they were related to age, sex, vascular brain disease, and classic cardiovascular 
risk factors. We found that white matter atrophy seemed to drive loss of brain volume 
with increasing age. We also found that vascular brain disease and classic cardiovascular 
risk factors were more associated with white matter atrophy than grey matter atrophy. We 
concluded that white matter atrophy may be more important in neuro-degeneration than 
thus far recognized. In chapter 2.1.2 we report incidental findings in the brain of 2000 
participants from the Rotterdam Scan Study. We found that apart from markers of vascular 
brain changes, the most frequent findings are cerebral aneurysms and benign primary 
tumors. These occurred in 1.8% and 1.6% of all scans, respectively.
Investigating novel determinants of brain atrophy, we first found in chapter 2.2 that 
persons with poorer kidney function had more brain atrophy, especially subcortical white 
matter atrophy, and more often white matter lesions and cerebral infarcts. Next, in chapter 
2.3 we showed that men, but not women, with unrecognized myocardial infarction had a 
higher risk of stroke, dementia, and vascular brain disease. Seeking to elucidate the possible 
mechanism underlying these findings we reported in chapter 2.4 that total cerebral blood 
flow – as marker of arterial hemodynamics of the brain – was related with brain atrophy 
and that this in turn mediated the association between cerebral blood flow and cognition. 
However, the relation between venular diameter and brain atrophy reported in chapter 
2.5 points to other mechanisms also contributing to the association between vascular risk 
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factors and vascular brain disease. A common feature between studies in Part 2 was that 
subclinical vascular disease in the rest of the body and markers thereof were consistently 
associated with both clinical and subclinical vascular disease in the brain.
Part 3 of this thesis was dedicated to the relationship of brain changes with clinical 
outcomes. We started by investigating structural brain changes in relation with cognition, 
dementia, and Alzheimer’s disease in chapter 3.1 and found that white matter atrophy was 
associated with poorer executive function and information processing speed, whereas grey 
matter atrophy was particularly associated with memory performance. Furthermore, we 
showed that grey matter atrophy, but not white matter atrophy, increased the risk of demen-
tia and Alzheimer’s disease. On a lobar level, hippocampal and temporal grey matter atrophy 
was most strongly associated with dementia, followed by frontal, parietal and occipital grey 
matter atrophy. Interestingly, this pattern remained present even after exclusion of persons 
with subjective or objective cognitive problems at baseline. We concluded that atrophy of 
grey matter and atrophy of white matter have distinct effects on cognition and dementia.
Next, in chapter 3.2 we investigated the vascular depression hypothesis. Although we 
found vascular brain disease to be strongly associated with depression cross-sectionally, 
we could not confirm the vascular depression hypothesis in our longitudinal analyses. 
In chapter 3.3 we investigated how structural brain changes were related to all-cause 
mortality and cardiovascular mortality. We found that structural brain changes on MRI are 
predictors of mortality, with the associations with brain atrophy and hippocampal atrophy 
being primarily driven by dementia, whereas those with white matter lesions and lacunar 
infarcts reflecting generalized vascular disease.
In the genome-wide association study on stroke described in chapter 4.1 we identified 
a novel locus that reached genome-wide significance after meta-analysis across four inde-
pendent studies. The study in chapter 4.2 was a positive replication of polymorphisms in 
GAB2 in relation with Alzheimer’s disease. Taken together with previous data, this study 
suggests GAB2 as a novel gene modifying the risk of Alzheimer’s disease in APOEε4 car-
riers. Both genetic studies are a starting point to further investigate the pathways that 
underlie these relationships.
Finally in Part 5, I discuss the main findings, methodological limitation, and clinical im-
plications, and I make recommendations for future research. My main conclusions were 
firstly that white matter atrophy is more important in aging and neuro-degeneration than 
previously thought. Secondly, subclinical vascular disease in the rest of the body is closely 
associated with vascular brain disease. Thirdly, grey matter and white matter atrophy are 
differentially related with cognition, dementia, and to a lesser extent mortality. Finally, 
genome-wide association studies provide a powerful tool to investigate novel genetic mark-
ers underlying neuro-degenerative diseases.
Chapter 5.2
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neDerlAnDSe SAmenVAtting
Neuro-imaging en genetica hebben een belangrijke rol gespeeld in het onderzoek naar 
oorzakelijke markers van neuro-degeneratieve ziekten (zoals beroerte, dementie, ziekte van 
Alzheimer). Verschillende neuro-imaging studies hebben focale structurele hersenveran-
deringen geïdentificeerd die als in vivo markers dienen van neuro-degeneratieve ziekten. 
Echter, er is gesuggereerd dat gegeneraliseerde hersenafwijkingen ook belangrijke markers 
van neuro-degeneratieve ziekten zouden kunnen zijn. Recente ontwikkelingen in MRI tech-
nieken en beeldverwerking hebben ertoe geleid dat het nu mogelijk is gegeneraliseerde 
hersenafwijkingen en de associatie met neuro-degeneratieve ziekten te onderzoeken.
Het onderzoek naar genetische markers van neuro-degeneratieve ziekten was op een 
vergelijkbare manier gelimiteerd, omdat dat onderzoek zich ook beperkte tot een of enkele 
voorgeselecteerde genetische markers. Recentelijk is het mogelijk geworden genetische 
markers over het hele genoom te onderzoeken.
Het doel van dit proefschrift is het onderzoeken van determinanten – zowel niet-genetisch 
als genetisch – en klinische uitkomsten van hersenveranderingen op MRI. De focus was op 
markers over het hele brein en het hele genoom. De studies waren ingebed in de Rot-
terdam Studie (ERGO onderzoek) of de Rotterdam Scan Studie, beide grote prospectieve 
populatieonderzoeken.
In deel 2 worden de normatieve waarden en determinanten van hersenveranderingen be-
schreven. In hoofdstuk 2.1.1 kwantificeerden wij volumina van de grijze stof, witte stof en 
cerebrospinale liquor (hersenvocht) in een populatie van 60 tot 90 jaar en onderzochten wij 
hoe deze gerelateerd waren aan leeftijd, geslacht, vasculaire hersenafwijkingen (wittestofles-
ies en lacunaire herseninfarcten), en klassieke cardiovasculaire risicofactoren. We vonden dat 
wittestofatrofie in plaats van grijzestofatrofie ten grondslag ligt aan breinatrofie op hogere 
leeftijd. Verder vonden we dat vasculaire hersenafwijkingen en klassieke cardiovasculaire 
risicofactoren met name geassocieerd zijn met atrofie van de witte stof in plaats van de grijze 
stof. We concludeerden daarom dat wittestofatrofie mogelijk een belangrijkere rol speelt in 
neuro-degeneratie dan dusver gedacht. In hoofdstuk 2.1.2 rapporteren we toevalsbevindin-
gen op hersenscans van 2000 deelnemers van de Rotterdam Scan Study. Behalve vasculaire 
hersenafwijkingen vonden wij dat aneurysmata en benigne hersentumoren de meest voorko-
mende bevindingen zijn. Deze kwamen respectievelijk in 1.8% en 1.6% van alle scans voor.
Vervolgens onderzochten wij nieuwe determinanten van hersenatrofie. In hoofdstuk 
2.2 vonden we dat mensen met een slechte nierfunctie meer hersenatrofie hebben, met 
name van de subcorticale witte stof, en vaker wittestoflesies en herseninfarcten hebben. 
In hoofdstuk 2.3 tonen we aan dat mannen, maar niet vrouwen, met een niet-herkend 
hartinfarct een hogere risico lopen op beroerte, dementie, en vasculaire hersenafwijkingen. 
Om het mogelijk onderliggende mechnisme van deze associaties te onderzoeken rappor-
teerden we in hoofdstuk 2.4 dat totale bloedstroom naar de hersenen – als marker van 
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arteriële hemodynamica in de hersenen – gerelateerd is met hersenatrofie en dat deze asso-
ciatie vervolgens de mediator is in de relatie tussen totale bloedstroom en cognitie. Echter, 
de associatie tussen retinale venulaire diameters en hersenatrofie die we rapporteren in 
hoofdstuk 2.5 wijst ook naar andere mechanismen die de associatie tussen vasculaire 
risicofactoren en vasculaire hersenziekten mogelijk verklaren. Concluderend kunnen we 
zeggen dat het volgende gemeenschappelijk is in alle hoofdstukken van deel 2: subklini-
sche vasculaire ziekte buiten het brein en markers daarvan zijn consistent geassocieerd 
met zowel klinische als subklinische vasculaire ziekten in het brein.
Deel 3 van het proefschrift was gewijd aan de relatie tussen hersenafwijkingen en 
klinische uitkomsten. Als eerste onderzochten we in hoofdstuk 3.1 hersenafwijkingen in 
relatie tot cognitie, dementie en de ziekte van Alzheimer. We vonden dat wittestofatrofie 
geassocieerd is met slechte scores op cognitieve uitvoeringstaken en snelheidstaken, ter-
wijl grijzestofatrofie met name geassocieerd was met geheugentaken. Verder lieten we zien 
dat grijzestofatrofie in tegenstelling tot wittestofatrofie het risico verhoogt op dementie 
en de ziekte van Alzheimer. Toen we de verschillende hersenkwabben apart onderzochten, 
vonden we dat met name hippocampus atrofie en temporale grijzestofatrofie met dementie 
geassocieerd zijn, gevolgd door grijzestofatrofie in de frontale kwab, pariëtale kwab, en 
occipitale kwab. Het was interessant op te merken, dat dit patroon gehandhaafd bleef als 
we mensen met subjectieve en objectieve cognitieve problemen aan het begin van het 
onderzoek excludeerden. We concludeerden dat atrofie van de grijze stof en atrofie van de 
witte stof verschillende effecten hebben op cognitie en dementie.
In hoofdstuk 3.2 onderzochten we de vasculaire depressie hypothese. Ondanks dat 
we een sterke associatie cross-sectioneel vonden tussen vasculaire hersenafwijkingen en 
depressie, konden we de vasculaire depressie hypothese niet bevestigen in onze longitu-
dinale analyses. In hoofdstuk 3.3 bestudeerden we hoe structurele hersenafwijkingen 
gerelateerd zijn aan mortaliteit en specifiek cardiovasculaire mortaliteit. We vonden dat 
structurele hersenafwijkingen op MRI voorspellers zijn van mortaliteit. De associaties van 
hersenatrofie en hippocampus atrofie met mortaliteit worden gedreven door dementie, 
terwijl de associaties van wittestoflesies en lacunaire infarcten met mortaliteit een reflectie 
zijn van gegeneraliseerde vasculaire aandoeningen.
In de genome-wide associatie studie over beroerte beschreven in hoofdstuk 4.1 hebben 
wij een nieuw regio geïdentificeerd die genome-wide significant was; voor beide genen 
in die regio is het plausibel dat zij oorzakelijk gerelateerd zijn aan beroerte. De studie in 
hoofdstuk 4.2 is een positieve replicatie van polymorphismes in GAB2 in relatie met de 
ziekte van Alzheimer. Samen met voorgaande gepubliceerde data, suggereert deze studie dat 
GAB2 een nieuw gen is dat het risico op de ziekte van Alzheimer modificeert afhankelijk 
van of iemand het APOEε4 allel draagt. Beide genetische studies dienen als startpunt voor 
verder onderzoek naar de exacte mechanismen van deze associaties.
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Ten slotte, in hoofdstuk 5 bediscussieer ik de belangrijkste bevindingen, de methodo-
logische limitaties, and de klinische implicaties van mijn onderzoek en doe ik suggesties 
voor verder onderzoek. Mijn belangrijkste conclusies zijn: ten eerste, wittestofatrofie is 
belangrijker in veroudering en neuro-degeneratie dan tot dusver gedacht. Ten tweede, sub-
klinische vasculaire ziekten buiten het brein zijn sterk geassocieerd met vasculaire ziekte 
in het brein. Ten derde, grijze stof en witte stof zijn verschillend gerelateerd met cognitie, 
dementie, en in mindere mate mortaliteit. Ten slotte, genome-wide associatie studies zijn 
een innovatieve methode om nieuwe genetische markers van neuro-degeneratieve ziekten 
te identificeren.
Chapter 
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Being from a middle class family in Pakistan and studying classic Ayurvedic medicine as a 
hobby, our maternal grandfather always wanted one of his children to become a medical 
doctor. For various reasons, mostly financial, this dream never materialised. However, our 
mother continued to pursue this wish, and eventually three of her children became medi-
cal doctors in the Netherlands.
One December the whole family came together to celebrate the holiday season. The 
weather was cold and wet, and several family members developed a horrible cold and 
cough.
Being strong proponents of evidence based medicine in our daily clinical practice, we 
doctors advised various standard remedies such as not going out into cold and dry air too 
often, stopping smoking, taking cough syrup, etc. Unsurprisingly, none of these helped, so 
we resorted to advising doing nothing and letting nature take its course.
During our childhood, however, our mother had treated us with herbal medicines to 
cure common ailments. With time, and influenced by our studies, we became less and less 
fond of those treatments. Undaunted, our mother now administered such a herbal mixture 
to those of the family who were coughing. We will never know whether it was the natural 
course of the illness (no control group), the placebo effect of the mixture (no blinding), 
motherly love (confounding), or a true healing effect (only a randomised clinical trial could 
prove this), but everyone’s cough disappeared within two to three days.
We would never prescribe this mixture to any of our patients because of lack of clinical 
evidence, but we can’t deny that, after drinking the mixture under strict maternal orders, 
our coughs, too, started to subside.
Epilogue
212
Dankwoord
DAnkwOOrD
Het is al ruim 7 jaar geleden dat ik voor het eerst op de 21e bij de epidemiologie kwam. 
In eerste instantie als MSc-student, daarna als promovendus. De afgelopen vier jaar van 
mijn promotieonderzoek zijn voorbij gevlogen. Waar ik in eerste instantie erg uitkeek naar 
het voortschrijden en afronden van mijn onderzoek, realiseer ik me nu ook dat ik het erg 
jammer vind dat het nu al afgerond is. Dit geeft aan hoe erg ik het naar mijn zin heb gehad! 
De verschillende mensen die deel uitmaken van deze boeiende afdeling hebben daar aan 
bijgedragen en hen wil ik hier bedanken.
Allereerst bedank ik mijn promotor. Beste Monique, we kennen elkaar al ruim 7 jaar en 
ik heb in die periode ontzettend veel van jou geleerd. Dit was niet alleen beperkt tot het 
doen van het onderzoek zelf, maar reikte ook tot andere - even belangrijke - zaken erom 
heen, zoals de optimale presentatie van resultaten, het effectief schrijven van aanvragen, 
de hoofdlijnen niet uit het oog verliezen, samenwerken in internationale consortia etc. 
Daarnaast was je heel motiverend, optimistisch en wist je altijd een duidelijke lijn uit te 
stippelen. Ik keek daarom ook altijd uit naar onze reguliere meetings. Ik hoop van harte dat 
we nog lange tijd deze goede samenwerking voort kunnen zetten!
Ik wil ook de andere leden van de kleine commissie bedanken: prof.dr. Koudstaal, prof.
dr. Van Duijn en prof.dr. DeCarli. Beste Peter, jouw enthousiasme, klinische blik, en altijd 
opgewekte houding maakten het een bijzonder plezier met jou samen te werken. Beste 
Cornelia, mijn transformatie van een leek anderhalf jaar geleden tot een gevorderde op het 
gebied van neuro-genetica heb ik grotendeels te danken aan de gesprekken en besprekin-
gen met jou. Dear Charlie, thank you for being part of my thesis defense committee! It 
is always a great pleasure for me to meet you and being able to discuss and learn about 
neuro-research from you. It’s very inspirational.
Mijn dank gaat ook uit naar de overige leden van de grote commissie; als eerste bedank 
ik prof.dr. Krestin voor het gestelde vertrouwen in mij en ik hoop de hoge verwachtingen 
waar te kunnen maken. Ik zal in ieder geval mijn uiterste best doen! Ten tweede, prof.dr. 
Niessen; beste Wiro, jouw kennis en vernieuwende ideeën kwamen altijd als een verlossing 
wanneer de rest van ons weer eens vast zat met een imaging-probleem.
Op deze plaats bedank ik ook prof.dr. Hofman. Beste Bert, bedankt dat jij mij mijn aller-
eerste kans in de epidemiologie hebt geboden door mij de Master of Science programma te 
laten volgen. Ik ben ontzettend blij dat ik in dit fantastische vakgebied onderzoek heb kun-
nen doen. Verder bedank ik dr. Van der Lugt; beste Aad, over de jaren heen hebben wij heel 
intensief samengewerkt. Jouw enthousiasme voor de radiologie is aanstekelijk gebleken!
Meike, vanaf het begin dat we aan ons onderzoek begonnen klikte het meteen tussen ons. 
Het was ideaal met jou samen te werken; we vulden elkaar perfect aan en ik denk dat we 
samen veel meer uit het onderzoek hebben gehaald dan mogelijk geweest was, indien elk 
213
Dankwoord
van ons apart zou werken. Ik kijk met veel trots terug op deze periode, en ik ben blij dat 
we de komende jaren nog steeds collega’s blijven. Ook de andere leden van de neuro-groep 
ben ik veel dank verschuldigd. Mendel en Jory, jullie waren heel gezellige kamergenoten 
en zorgden altijd voor een speciale dynamiek op de kamer. Mendel, we zouden nog steeds 
de kamer verven! Met Michiel en Sjoerd heb ik talloze interessante discussies gehad over 
onderzoek en alles wat daarbij komt kijken. Ik heb daar veel van geleerd en ik hoop dat 
we deze voort kunnen zetten. Mariëlle, Renske, Elisabeth, Vincent, Ben, Joyce: ik wens jul-
lie veel succes en plezier met jullie onderzoek. Ook de oude ‘garde’ van onderzoekers, 
promovendi en studenten van de neuro-groep wil ik bedanken: Tom, Marieke, Frank Jan, 
Lonneke, Miranda, Kamran, Elizabeth, Christiane, Willemijn, Victor, Tijmetje, en Dymph.
Veel dank ben ik verschuldigd aan de beeldverwerkers en overige leden van de roem-
ruchte ‘imaging meeting’: Henri, Fedde, Renske, Marius, Tom, Rik, Jos, Stefan, Marleen. Bij de 
beeldverwerkers kon ik altijd binnenlopen als ik weer eens een technisch probleem had 
en jullie stonden altijd klaar om mijn probleem aan te horen. Met name bedank ik Henri: 
vanaf het prille begin van mijn onderzoeksproject ben jij erbij betrokken geweest en jouw 
input in dit proefschrift is enorm!
Ook alle andere oude en nieuwe collega’s van de epidemiologie wil ik bij deze dankbe-
tuiging betrekken. I mention here by name Mark, Abbas and Yurii: it was great working with 
you all. I thoroughly enjoyed our discussions and gained essential insights into genetics 
from you.
Over de jaren heen heb ik verschillende congressen bezocht in verschillende landen met 
verschillende reisgenoten. Michiel, Meike, Mariëlle, Mark, Henning, Maaike, Monique, Cor-
nelia: bedankt voor deze onvergetelijke reizen.
Dit onderzoek is natuurlijk tot stand gekomen door vele andere medewerkers die een grote 
of kleine, maar zeker essentiële bijdrage hebben geleverd: de collega’s van de technische 
ondersteuning, de dames op het ERGO-centrum, de medewerkers van het lab, het cluster-
bureau, en het secretariaat. Hen allen bedank ik. Een aantal wil ik hier met naam noemen: 
Lydia, Pauli, Nano, Jeannette, Marti en Esther, hartstikke bedankt voor jullie belangrijke 
input en altijd gezellige manier van werken.
I would also like to thank the numerous co-authors with whom I have worked together 
over the years. Not only those at the Erasmus MC or elsewhere in The Netherlands, but 
also our international collaborators, especially those from the CHARGE-consortium! It’s an 
honor to work together with so many acclaimed researchers.
Michiel en Kamran, bedankt dat jullie mijn paranimfen willen zijn!
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Op deze plek wil ik speciaal ook mijn familie bedanken. Op de allereerste plek mijn broer, 
Kamran. Je hebt altijd veel voor mij betekend, meer nog dan dat je zelf vermoedt. Ik heb 
altijd alle frustraties van het onderzoek bij jou kunnen uiten (of je het wilde aanhoren 
of niet): van de onzekerheden in het begin tot de stress van de deadlines aan het eind. 
De enkele zinnen uit het hele proefschrift die ik hier aan jou kan wijden staan in schril 
contrast met jouw werkelijke waarde voor dit geheel! Verder wens ik jou ook veel succes 
met jouw onderzoek en betrek ik ook Shafak bij deze dankbetuiging. Vervolgens bedank ik 
mijn zus Asmat voor de interesse die ze altijd had in mijn onderzoek en de voortgang ervan, 
met name aan het begin toen we samen met de tram onderweg naar ons werk gingen. 
Ook haar man, Zubair, bedank ik en hun twee kinderen, Javeria Komal en Saad, die altijd 
met hun opgewekte lach thuis mijn kamer binnenstormden om te spelen, ongeacht hoe 
druk ik het had. Jullie beiden zorgden voor de nodige ontspanning en het is een heus feest 
telkens als jullie langskomen. Mijn twee zusjes, Sobia en Shazia: met name het afgelopen 
jaar hebben wij heel vaak met elkaar opgetrokken en het is een werkelijk genoegen jullie 
als zusjes te hebben. I would also like to extend my thanks to my grandmother, and all my 
uncles, aunts, and cousins, whether in The Netherlands, France, Pakistan or elsewhere for 
their continuous support and affection.
Ten slotte, mijn ouders: het is jullie visie, inzet, uithoudingsvermogen, steun, en bovenal 
jullie liefde die niet alleen mij, maar ons allemaal hebben gebracht waar we nu staan. Ik 
hoop nog lang van jullie ouderschap te mogen genieten.
Arfan, Rotterdam 2009
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Chapter 2.1.1 Figure 1. From left to right: HASTE-Odd scan, Proton-density weighted scan, T2 weighted scan, and result after tissue 
classification and removal of non-brain tissues (no manual reclassification performed; blue: cerebrospinal fluid; green: grey matter; 
red: white matter; white: white matter lesion).
Chapter 2.2 Figure 1. HASTE-Odd sequence, in which the boundary (red line) between the deep and lobar brain regions is 
delineated, according to the protocol by Bokde et al.29, 30
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Color Figures
Chapter 3.1 Figure 1. Haste-Odd sequence and the result after segmentation into the various brain lobes using non-
rigid registration. Red: left frontal lobe; white: right frontal lobe; dark green: left parietal lobe; light green: right parietal lobe; dark 
blue: left temporal lobe; light blue: right temporal lobe; yellow: left occipital lobe; purple: central region comprising basal ganglia and 
corpus callosum. The right occipital lobe is not shown on these cross-sections.
